NZ626296B2 - Compositions and methods for antibodies targeting factor p - Google Patents
Compositions and methods for antibodies targeting factor p Download PDFInfo
- Publication number
- NZ626296B2 NZ626296B2 NZ626296A NZ62629612A NZ626296B2 NZ 626296 B2 NZ626296 B2 NZ 626296B2 NZ 626296 A NZ626296 A NZ 626296A NZ 62629612 A NZ62629612 A NZ 62629612A NZ 626296 B2 NZ626296 B2 NZ 626296B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- chain variable
- variable region
- antibody
- light chain
- Prior art date
Links
- 102000004965 antibodies Human genes 0.000 title claims abstract description 683
- 108090001123 antibodies Proteins 0.000 title claims abstract description 683
- 239000000203 mixture Substances 0.000 title claims description 117
- 230000027455 binding Effects 0.000 claims abstract description 326
- 238000009739 binding Methods 0.000 claims abstract description 320
- 239000000427 antigen Substances 0.000 claims abstract description 221
- 108091007172 antigens Proteins 0.000 claims abstract description 218
- 102000038129 antigens Human genes 0.000 claims abstract description 218
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 132
- 150000001413 amino acids Chemical class 0.000 claims description 76
- 230000035693 Fab Effects 0.000 claims description 43
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 29
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 29
- 108091006028 chimera Proteins 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 3
- 102100020197 CFP Human genes 0.000 abstract description 4
- 108010005642 Properdin Proteins 0.000 abstract description 4
- 101700073818 CDR1 Proteins 0.000 description 140
- 102100002977 CDR1 Human genes 0.000 description 140
- 229920000023 polynucleotide Polymers 0.000 description 123
- 239000002157 polynucleotide Substances 0.000 description 123
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 119
- 210000004027 cells Anatomy 0.000 description 112
- 108060001277 CDR2 Proteins 0.000 description 110
- 102100008744 CDR2 Human genes 0.000 description 110
- 101700027814 CDR3 Proteins 0.000 description 110
- 235000001014 amino acid Nutrition 0.000 description 92
- 230000000295 complement Effects 0.000 description 68
- 102000004169 proteins and genes Human genes 0.000 description 65
- 108090000623 proteins and genes Proteins 0.000 description 65
- 235000018102 proteins Nutrition 0.000 description 63
- 230000002401 inhibitory effect Effects 0.000 description 50
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 47
- 150000007523 nucleic acids Chemical class 0.000 description 47
- 230000037361 pathway Effects 0.000 description 47
- 238000004166 bioassay Methods 0.000 description 46
- 206010064930 Age-related macular degeneration Diseases 0.000 description 40
- 208000002780 Macular Degeneration Diseases 0.000 description 40
- 150000002500 ions Chemical class 0.000 description 39
- 230000000694 effects Effects 0.000 description 38
- 102000018358 Immunoglobulins Human genes 0.000 description 36
- 108060003951 Immunoglobulins Proteins 0.000 description 36
- 239000003795 chemical substances by application Substances 0.000 description 36
- 210000002966 Serum Anatomy 0.000 description 35
- 201000010099 disease Diseases 0.000 description 35
- 108020004707 nucleic acids Proteins 0.000 description 34
- 229920001184 polypeptide Polymers 0.000 description 34
- 229920001850 Nucleic acid sequence Polymers 0.000 description 31
- 239000003814 drug Substances 0.000 description 31
- 210000004602 germ cell Anatomy 0.000 description 30
- 238000000034 method Methods 0.000 description 28
- 230000002949 hemolytic Effects 0.000 description 26
- 230000004048 modification Effects 0.000 description 26
- 238000006011 modification reaction Methods 0.000 description 26
- 238000006467 substitution reaction Methods 0.000 description 23
- -1 FR3 Proteins 0.000 description 22
- 229940079593 drugs Drugs 0.000 description 22
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 20
- 230000036809 Fabs Effects 0.000 description 20
- 230000036499 Half live Effects 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 20
- 101710038213 AKR1C4 Proteins 0.000 description 18
- 101710034060 RUNX1T1 Proteins 0.000 description 18
- 230000001225 therapeutic Effects 0.000 description 18
- 101710027851 C1orf56 Proteins 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 210000003743 Erythrocytes Anatomy 0.000 description 16
- 102100016028 OCA2 Human genes 0.000 description 16
- 101700013618 OCA2 Proteins 0.000 description 16
- 101710016786 P/C Proteins 0.000 description 16
- 210000003324 RBC Anatomy 0.000 description 16
- 229920001223 polyethylene glycol Polymers 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000002202 Polyethylene glycol Substances 0.000 description 15
- 229940035295 Ting Drugs 0.000 description 15
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 14
- 229960000060 monoclonal antibodies Drugs 0.000 description 14
- 230000002207 retinal Effects 0.000 description 14
- 235000020945 retinal Nutrition 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 241000282320 Panthera leo Species 0.000 description 12
- 230000003899 glycosylation Effects 0.000 description 12
- 238000006206 glycosylation reaction Methods 0.000 description 12
- 230000001965 increased Effects 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 230000024203 complement activation Effects 0.000 description 11
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 241000894007 species Species 0.000 description 11
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 230000002829 reduced Effects 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 210000003484 anatomy Anatomy 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000002708 enhancing Effects 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 210000004962 mammalian cells Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002703 mutagenesis Methods 0.000 description 9
- 231100000350 mutagenesis Toxicity 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 230000004382 visual function Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 102000016359 Fibronectins Human genes 0.000 description 8
- 108010067306 Fibronectins Proteins 0.000 description 8
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 8
- 210000002540 Macrophages Anatomy 0.000 description 8
- 206010025421 Macule Diseases 0.000 description 8
- 210000001525 Retina Anatomy 0.000 description 8
- 229920000392 Zymosan Polymers 0.000 description 8
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 230000037320 fibronectin Effects 0.000 description 8
- 229940050526 hydroxyethylstarch Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000001404 mediated Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000011604 retinal Substances 0.000 description 8
- 230000003612 virological Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 210000004408 Hybridomas Anatomy 0.000 description 7
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037240 fusion proteins Human genes 0.000 description 7
- 230000002068 genetic Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 230000002934 lysing Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000000051 modifying Effects 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 230000001603 reducing Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000001519 tissues Anatomy 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 6
- 101700007095 C5 Proteins 0.000 description 6
- 108009000280 Complement Activation Proteins 0.000 description 6
- 229940022766 EGTA Drugs 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 6
- 230000000890 antigenic Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000001105 regulatory Effects 0.000 description 6
- 230000004304 visual acuity Effects 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 102100001249 ALB Human genes 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 102100007517 C5 Human genes 0.000 description 5
- 229920001405 Coding region Polymers 0.000 description 5
- 229940088598 Enzyme Drugs 0.000 description 5
- 208000008069 Geographic Atrophy Diseases 0.000 description 5
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 5
- 241000229754 Iva xanthiifolia Species 0.000 description 5
- 102000019298 Lipocalins Human genes 0.000 description 5
- 108050006654 Lipocalins Proteins 0.000 description 5
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 5
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 5
- 201000004569 blindness Diseases 0.000 description 5
- 230000001413 cellular Effects 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 230000001808 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000001186 cumulative Effects 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 101710027066 ALB Proteins 0.000 description 4
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- 102000008102 Ankyrins Human genes 0.000 description 4
- 108010049777 Ankyrins Proteins 0.000 description 4
- 208000006673 Asthma Diseases 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 241001492237 Grapevine virus B Species 0.000 description 4
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 4
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010022114 Injury Diseases 0.000 description 4
- 210000000440 Neutrophils Anatomy 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 230000000996 additive Effects 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000001268 conjugating Effects 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 230000002195 synergetic Effects 0.000 description 4
- 238000003325 tomography Methods 0.000 description 4
- 230000002103 transcriptional Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000004393 visual impairment Effects 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 210000002383 AT1 Anatomy 0.000 description 3
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N Barbital Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 3
- 229960002319 Barbital Drugs 0.000 description 3
- 241000282836 Camelus dromedarius Species 0.000 description 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 3
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102100014838 FCGRT Human genes 0.000 description 3
- 101710003435 FCGRT Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 210000000987 Immune System Anatomy 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 241000282842 Lama glama Species 0.000 description 3
- 210000000265 Leukocytes Anatomy 0.000 description 3
- 206010025135 Lupus erythematosus Diseases 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- 241000255972 Pieris <butterfly> Species 0.000 description 3
- 231100000765 Toxin Toxicity 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 229940050528 albumin Drugs 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 230000001580 bacterial Effects 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003902 lesions Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 230000003278 mimic Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000002285 radioactive Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- 101700027111 3SA0 Proteins 0.000 description 2
- XGUFMAUYGBDFJS-UHFFFAOYSA-N 6'-formyl-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3H-1-benzofuran]-7'-carboxylic acid Chemical compound C1C(C(=CC(C=O)=C2C(O)=O)O)=C2OC21C1(C)CC(O)C(O)C(C)(C)C1CCC2C XGUFMAUYGBDFJS-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 241000432074 Adeno-associated virus Species 0.000 description 2
- 206010001897 Alzheimer's disease Diseases 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 2
- 206010003246 Arthritis Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 206010003885 Azotaemia Diseases 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- 102100007149 BEST1 Human genes 0.000 description 2
- 101700047202 BEST1 Proteins 0.000 description 2
- 208000009964 Basal Laminar Drusen Diseases 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-L CHEBI:8154 Chemical class [O-]P([O-])=O ABLZXFCXXLZCGV-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 208000007556 Cone-Rod Dystrophy Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 2
- 210000002744 Extracellular Matrix Anatomy 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010018987 Haemorrhage Diseases 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 108010029660 Intrinsically Disordered Proteins Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 2
- 230000035633 Metabolized Effects 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000002678 Mucopolysaccharidosis Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 101700037337 PIGA Proteins 0.000 description 2
- 102100012341 PIGA Human genes 0.000 description 2
- 229920002224 Peptide nucleic acid Polymers 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 239000004698 Polyethylene (PE) Substances 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010038847 Retinal deposits Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 102100003386 S100A12 Human genes 0.000 description 2
- 101710023382 S100A12 Proteins 0.000 description 2
- 101700071483 SF1 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- 201000004034 Sorsby's fundus dystrophy Diseases 0.000 description 2
- 206010062766 Stargardt's disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 229920001949 Transfer RNA Polymers 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102400000757 Ubiquitin Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229920002892 amber Polymers 0.000 description 2
- 230000002391 anti-complement Effects 0.000 description 2
- 108010008730 anticomplement Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 101700067609 ctx Proteins 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000004300 dark adaptation Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001815 facial Effects 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 200000000002 platelet activation Diseases 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 201000004681 psoriasis Diseases 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 201000007737 retinal degeneration Diseases 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 230000001340 slower Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000003595 spectral Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 102000002938 thrombospondin family Human genes 0.000 description 2
- 108060008245 thrombospondin family Proteins 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 2
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- ZTHKPSBRWLGUIK-XORBCWOASA-N (2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-6-[[(2R,3S,4R,5R,6R)-3-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)O)[C@H](O)[C@H]1O ZTHKPSBRWLGUIK-XORBCWOASA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- DJBRKGZFUXKLKO-UHFFFAOYSA-M 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound [O-]C(=O)CCSSC1=CC=CC=N1 DJBRKGZFUXKLKO-UHFFFAOYSA-M 0.000 description 1
- VXPSQDAMFATNNG-UHFFFAOYSA-N 3-[2-(2,5-dioxopyrrol-3-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C(=CC=CC=2)C=2C(NC(=O)C=2)=O)=C1 VXPSQDAMFATNNG-UHFFFAOYSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N 5-Dimethylaminonaphthyl-5-sulfonyl chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 101710036216 ATEG_03556 Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 229940022698 Acetylcholinesterase Drugs 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108009000283 Allograft Rejection Proteins 0.000 description 1
- 241000269328 Amphibia Species 0.000 description 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 230000035639 Blood Levels Effects 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 210000003996 CFU-GM Anatomy 0.000 description 1
- 101700008564 CHIC2 Proteins 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-M COP([O-])=O Chemical class COP([O-])=O QCMYYKRYFNMIEC-UHFFFAOYSA-M 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008424 Chemical injury Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 210000000688 Chromosomes, Artificial, Human Anatomy 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 108090000056 Complement Factor B Proteins 0.000 description 1
- 102000003712 Complement Factor B Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 206010070976 Craniocerebral injury Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000008745 EC 6.1.1.- Human genes 0.000 description 1
- 108030004302 EC 6.1.1.- Proteins 0.000 description 1
- 101700045840 ECT Proteins 0.000 description 1
- 101700079760 EFCB Proteins 0.000 description 1
- 101710005090 ERVFC1-1 Proteins 0.000 description 1
- 101710013371 ERVS71-1 Proteins 0.000 description 1
- 206010014128 Echopraxia Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 229940109526 Ery Drugs 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- PHTXVQQRWJXYPP-UHFFFAOYSA-N Ethyltrifluoromethylaminoindane Chemical compound C1=C(C(F)(F)F)C=C2CC(NCC)CC2=C1 PHTXVQQRWJXYPP-UHFFFAOYSA-N 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 101710002377 FLG Proteins 0.000 description 1
- 101700044513 FUT8 Proteins 0.000 description 1
- 102100012684 FUT8 Human genes 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 101700014779 GLB1 Proteins 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108091022077 Glycosyltransferases Proteins 0.000 description 1
- 102000019483 Glycosyltransferases Human genes 0.000 description 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N Griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N Guanosine monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 description 1
- 101710015954 HVA1 Proteins 0.000 description 1
- 208000007475 Hemolytic Anemia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 206010020679 Hypernatraemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 229960004657 Indocyanine Green Drugs 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M Indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101700065814 LEA2 Proteins 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- 102100012758 LRP1 Human genes 0.000 description 1
- 101700005580 LRP1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 206010024602 Lipiduria Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 229940076783 Lucentis Drugs 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N Luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710006307 MVA110L Proteins 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 208000001665 Macular dystrophy, retinal, 1, North Carolina type Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010063185 Macular scar Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 210000003975 Mesenteric Arteries Anatomy 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O Methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N N,N-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 102100009139 NGF Human genes 0.000 description 1
- 229920002957 Naked DNA Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940053128 Nerve Growth Factor Drugs 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000004361 Obstructive Lung Disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 210000003733 Optic Disk Anatomy 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 101700015696 PHL12 Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000006551 Parasitic Disease Diseases 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N Phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 1
- 208000006193 Pulmonary Infarction Diseases 0.000 description 1
- 206010037457 Pulmonary vasculitis Diseases 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108010062724 Ranibizumab Proteins 0.000 description 1
- 229960003876 Ranibizumab Drugs 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 230000036045 Renal clearance Effects 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 206010071391 Retinal fibrosis Diseases 0.000 description 1
- 206010038867 Retinal haemorrhage Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229920001914 Ribonucleotide Polymers 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 241000116133 Siphonodictyon coralliphagum Species 0.000 description 1
- 241001279361 Stachybotrys Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920000978 Start codon Polymers 0.000 description 1
- 206010062958 Subretinal fibrosis Diseases 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 101700003545 TXLR1 Proteins 0.000 description 1
- 101700003161 TXLR2 Proteins 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 208000005765 Traumatic Brain Injury Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 101710042748 UL80 Proteins 0.000 description 1
- 208000009852 Uremia Diseases 0.000 description 1
- 102100015249 VEGFA Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229960003895 Verteporfin Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N Verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 241000282840 Vicugna vicugna Species 0.000 description 1
- 102000006689 Viral Structural Proteins Human genes 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047655 Vitreous haemorrhage Diseases 0.000 description 1
- 229950004094 Xenon (133Xe) Drugs 0.000 description 1
- ASCUXPQGEXGEMJ-GPLGTHOPSA-N [(2R,3S,4S,5R,6S)-3,4,5-triacetyloxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(4-methylanilino)oxan-2-yl]methoxy]oxan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@H]1OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](NC=2C=CC(C)=CC=2)O1 ASCUXPQGEXGEMJ-GPLGTHOPSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000003044 adaptive Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 101710024925 alv Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic Effects 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 125000000089 arabinosyl group Chemical class C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 101700053124 asa1 Proteins 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 150000003937 benzamidines Chemical class 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium(0) Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-Lactamases Human genes 0.000 description 1
- 108020004256 beta-Lactamases Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 230000001851 biosynthetic Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000003435 bronchoconstrictive Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000002612 cardiopulmonary Effects 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000002817 coal dust Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001085 cytostatic Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000000368 destabilizing Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002571 electroretinography Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 230000003352 fibrogenic Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 101700064956 hemo Proteins 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002439 hemostatic Effects 0.000 description 1
- 230000004371 high visual acuity Effects 0.000 description 1
- 101700027420 hly Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003522 irritant Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 101710007041 let-363 Proteins 0.000 description 1
- 101700063973 lgg-1 Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 101700001016 mbhA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000001459 mortal Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000000869 mutational Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 101710036448 neo Proteins 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 101700005116 plc Proteins 0.000 description 1
- 101700016463 pls Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 235000019394 potassium persulphate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 200000000025 progressive disease Diseases 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 230000004233 retinal vasculature Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 101710010431 shlA Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 101700082413 tant Proteins 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000002485 urinary Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
Abstract
The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P (also known as Properdin).
Description
COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P
BACKGROUND OF THE INVENTION
Age related r degeneration (AMD) is a progressive disease and a leading
cause of vision loss and blindness in Americans aged 65 and older. AMD primarily
affects the macula; a part of the retina sible for high visual acuity needed to read
or drive. The majority of AMD patients suffer from an early stage of the e which is
characterized by the presence of extracellular retinal deposits called drusen. Drusen are
extracellular retinal deposits of cell debris, inflammatory mediators, and extracellular
matrix components. The late stages of AMD manifest as a dry or wet form, both are
associated with vision loss. Dry AMD, also known as geographic atrophy, appears on
lmoscopic ation as clearly demarcated regions corresponding to local
areas of retinal pigmented epithelium (RPE) loss. Wet AMD is associated with neo—
vascularization of the choriod, causing a loss of integrity in s membrane and
vessel growth in the retina, where they can often hemorrhage. This leakage causes
permanent damage to retinal cells which die off and create blind spots in the central
vision.
The innate human system is composed of the complement pathway. The
complement pathway serves to defend against ic bacterial infection bridging
innate and adaptive immunity; and disposing of products of immune complexes and
inflammatory injury. The ment is a system of more than 30 proteins involved in
cascade reactions in plasma and cell surfaces. The complement system and its
complement components are involved in various immune processes. For example,
complement C5b-9 complex, also termed the al complex or the ne attack
complex (MAC), plays an important role in cell death by inducing membrane permeability
damages.
There are three known ment activation ys: the classical, lectin, and
alternative pathways. All three ys lead to the cleavage of C3 by C3 convertase
and subsequent cleavage of C5 by the CS convertase, releasing C3a, C5a, and 05b.
Factor P is a key regulator of the alternative complement pathway. it is proposed to
have two major functions in vivo. First, Factor P stabilizes the C3 and 05 convertases by
binding to 03b of the convertase enzyme and thereby prolongs the half life of C3
convertase. Second, Factor P may determine which cells will be lysed by attaching to a
cell surface and functioning as a template on which convertases can form, leading to
activation of the alternative ment pathway and lysis of the cell.
Recent work has demonstrated that complement components C3 and CS are
principal constituents of drusen in patients with AMD. Mulling, R.F. et al. (2000) FASEB
J 14, 835-46 Their presence as well as that of the membrane attack complex (MAC)
C5b-9 and other acute phase reactant proteins in RPE cells overlying drusen has been
speculated to be involved in the process that can trigger complement activation and
formation of MAC. Johnson, L et al. (2001) Exp Eye Res 73, 887-896. Thus, there is
growing evidence that ment components are more than mere mediators of innate
immunity.
Nutritional intervention has been prescribed to inhibit ssion of dry AMD to
wet AMD. At present the only FDA approved treatments for wet AMD include
photodynamic therapy (PDT), an EGF aptamer, such as pegaptanib, and anti-
VEGF antibodies, ranibizumab. These drugs or ies are typically administered to
patients who have already suffered ntial vision loss.
There remains a need to develop an effective ent for AMD, particularly dry
AMD to replace or supplement current ents. Particularly, there is a need for
treatments which can provide early detection, prevention or restoration of vision loss.
SUMMARY OF THE INVENTION
The present invention and the ion of NZ 721643, which was divided from
the present application, relate to an isolated dy, or antigen binding fragment
thereof, that binds to human or cynomolgus Factor P, wherein said antibody binds to the
TSR5 domain (SEQ ID NO: 406). For example, the antibodies, or antigen binding
fragments described herein bind to a region of the TSR5 domain comprising the
sequence of SEQ ID NO: 407, more specifically said antibodies also bind a region of the
Factor P TSR5 domain comprising the amino acid sequence KSlSC (SEQ ID NO: 408).
In certain embodiments, the isolated antibodies, or antigen binding fragments thereof,
bind to a Factor P epitope comprising the amino acid sequence of SEQ ID NO: 407. In
other ments, the isolated antibodies, or antigen binding fragments thereof, bind
to a Factor P epitope sing the amino acid sequence of SEQ ID NO: 408.
In a first aspect, the t invention es an isolated antibody, or antigen
binding fragment, that binds Factor P, said antibody or antigen binding fragment
comprising:
a) heavy chain variable region HCDRt, HCDR2 and HCDR3 as set forth in SEQ
ID NOs: 1, 2, and 3, respectively, and light chain variable region LCDRt, LCDRZ, and
LCDR3 as set forth in SEQ ID NOs: 4, 5, and 6, respectively;
(followed by page 2a)
b) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID
N03: 85, 86, and 87, respectively, and light chain variable region LCDR1, LCDR2, and
LCDR3 as set forth in SEQ ID N03: 88, 89, and 90, respectively;
c) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID
N03: 99, 100, and 101, respectively, and light chain variable region LCDR1, LCDR2, and
LCDR3 as set forth in SEQ ID N05: 102, 103, and 104, respectively;
d) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID
NOs: 113, 114, and 115, respectively, and light chain variable region LCDR1, LCDR2,
and LCDR3 as set forth in SEQ ID N03: 116, 117, and 118, respectively;
1O e) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ
ID N05: 169, 170, and 171, respectively, and light chain variable region LCDR1, LCDR2,
and LCDR3 as set forth in SEQ ID N05: 172, 173, and 174, respectively;
f) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ
ID N03: 183, 184, and 185, respectively, and light chain variable region LCDR1, LCDR2,
and LCDR3 as set forth in SEQ ID N03: 186, 187, and 188, respectively;
9) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ
ID N05: 197, 198, and 199, respectively, and light chain variable region LCDR1, LCDR2,
and LCDR3 as set forth in SEQ ID N03: 200, 201, and 202, respectively;
h) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ
ID N03: 211, 212, and 213, tively, and light chain le region LCDR1, LCDR2,
and LCDR3 as set forth in SEQ ID NOs: 214, 215, and 216, respectively; or
i) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ
ID N03: 225, 226, and 227, respectively, and light chain variable region LCDR1, LCDR2,
and LCDR3 as set forth in SEQ ID N03: 228, 229, and 230, tively.
The isolated dies, or antigen binding fragments, described herein bind
Factor P, with a KD of less than or equal to 1.2 nM. For example, the isolated antibodies
or antigen binding fragments described herein may bind to human or cynomolgus Factor
P with a KD of less than or equal to 1.1 nM, less than or equal to 1nM, less than or equal
to 600pM, less than or equal to 500 pM, less than or equal to 400 pM, less than or equal
to 300 pM, less than or equal to 200 pM, less than or equal to 100 pM, less than or equal
[FOLLOWED BY PAGE 3]
PCT/IBZOlZ/057394
to 75 pM, less than or equal to 50 pM, less than or equal to 40pM, less than or equal to
pM, less than or equal to 20 pM, or less than or equal to 10pM.
The binding affinity of isolated antibodies and antigen binding nts
described herein can be determined by solution equilibrium titration (SET). Methods for
SET are known in the art and are bed in further detail below. Alternatively, binding
y of the isolated antibodies, or fragments, described herein can be determined by
Biacore assay. Methods for Biacore kinetic assays are know in the art and are described
in further detail below.
The isolated antibodies and n binding fragments described herein can be
used to inhibit the alternative complement pathway. For example, an isolated antibody
or antigen binding fragment thereof can inhibit the alternative complement pathway as
e by an in vitro hemolytic assay with an lCSO of less than or equal to 25 nm, less
than or equal to 20 nM, less than or equal to 16nM, less than or equal to 15nM, less
than or equal to 14nM, less than or equal to 13nM, less than or equal to 12nM, less than
or equal to 11nM, less than or equal to 10nM, less than or equal to 9nM, less than or
equal to 8nM, less than or equal to 7nM. More specifically, an isolated antibody or
antigen g fragment thereof as bed herein can inhibit the alternative
complement y in human as measure by an in vitro hemolytic assay with an ICSO
of less than or equal to 16 nm, or less than or equal to 9 nm.
An isolated antibody or antigen binding fragment thereof as described herein can
inhibit the alternative complement pathway as measure by an in vitro 03b deposition
assay with an |C50 of less than or equal to 10 nm, less than or equal to 7nM, less than or
equal to 6 nM, less than or equal to 5nM, less than or equal to 4 nM, less than or equal
to 3 nM, less than or equal to 2 nM, less than or equal to 1 nM, less than or equal to
15nM, less than or equal to 1 nM, less than or equal to 0.5 nM, or less than or equal to
0.1 nM. More ically, an isolated antibody or antigen binding fragment thereof as
bed herein can inhibit the alternative ment pathway in human as measure
by an in vitro C3b deposition assay with an ICSO of less than or equal to 3 nm, or less
than or equal to 2 nM.
An isolated antibody or antigen binding fragment thereof as described herein can
inhibit the alternative complement pathway with an ICSO of less than or equal to 25 nm,
less than or equal to 20 nM, less than or equal to 15 nM, less than or equal to 10 nM,
less than or equal to 9 nM, less than or equal to 8 nM, less than or equal to 7 nM, or less
than or equal to 6 nM, as measure by deposition of the complement membrane attack
complex. More specifically, an isolated antibody or fragment thereof as described herein
can inhibit the alternative complement pathway in human with an ICSO of less than or
equal to 25 nm, or less than or equal to 7.5 nM, as measure by deposition of the
ment membrane attack complex.
An isolated antibody or antigen binding fragment thereof as described herein can
inhibit the ative ment y with an lCSO of less than or equal to 80nM,
less than or equal to 50nM, less than or equal to 45nM, or less than or equal to 35nM, as
measure by generation of 03a.
An isolated antibody or antigen binding fragment thereof as bed herein
may also inhibit the alternative complement pathway with an lCSO of less than or equal to
80nM, less than or equal to 50nM, less than or equal to 45nM, or less than or equal to
35nM, as measure by generation of iCSb.
An isolated antibody or antigen g fragment f as described herein
may also t the ative complement pathway with an ICSO of less than or equal to
80nM, less than or equal to 50nM, less than or equal to 45nM, or less than or equal to
35nM, as measure by generation of C5a.
An isolated antibody or antigen binding fragment thereof as described herein
may also inhibit the alternative complement pathway with an ICSO of less than or equal to
80nM, less than or equal to 50nM, less than or equal to 45nM, or less than or equal to
35nM, as measure by generation of C5b.
An isolated antibody or antigen binding fragment thereof as described herein
may also inhibit the alternative complement pathway by destabilizing and/or blocking the
activity of C3 and/or CS convertase, as measured by a decrease in production of C3a,
03b, iC3b, 05a, and/or C5b.
An isolated antibody or antigen binding fragment thereof as described herein
may also inhibit the generation of 05a with an ICSO of less than or equal to 80nM, less
than or equal to SOnM, less than or equal to 45nM, or less than or equal to 35nM.
The isolated antibodies, or antigen g fragment thereof, may also block
Factor P binding to 03b and/or prevent Factor P binding to the cell surface or to DNA or
oligonucleotides.
Another aspect of the invention includes an isolated antibody, or n binding
fragment thereof, that specifically binds to human, cynomolgus, rat and/or rabbit Factor
P. In a further aspect, the isolated antibody, or antigen binding fragment, competes for
g with an antibody, or antigen binding fragment, described in Table 1.
The isolated antibodies, or antigen binding fragments thereof, as described
herein can be a monoclonal antibodies, a human or zed antibodies, a chimeric
antibodies, single chain antibodies, Fab fragments, Fv fragments, F(ab’)2 fragments, or
ScFv nts, and/or IgG isotypes.
The isolated antibodies, or antigen binding fragments thereof, as described
herein can also include a framework in which an amino acid has been tuted into
the antibody framework from the respective human VH or VL germline sequences.
Another aspect of the invention includes an isolated antibody or antigen binding
fragment thereof having the heavy and light chain sequences of Fabs described in Table
1. For e, the isolated antibody or antigen binding fragment thereof can have the
heavy and light chain sequences of Fab NV8962, NV8963, NVS964, NVS965, ,
, NV8962-G, NV8962-S, NVS962-T, NVS962-Q, NVS962-SB1A, NV8965-Q,
NVS965—S, NVS965—T, NV8804, , NVS806, NV8807, or NV8808.
A further aspect of the invention includes an isolated dy or antigen binding
nt thereof having the heavy and light chain variable domain sequences of Fabs
described in Table 1. For example, the isolated dy or antigen binding fragment
there of can have the heavy and light chain variable domain sequence of Fab NV8962 ,
NVS963, NVS964, NV8965, NV8966, NVSQ67, NV8962—G, NVS962—S, NV8962-T,
NV8962-Q, NV8962-S31A, NVS965—Q, NVS965-S, NV8965—T, NVS804, ,
NVS806, NVS807, or NVS808.
The ion also relates to an isolated antibody or antigen binding fragment
thereof that includes a heavy chain CDR1 selected from the group ting of SEQ lD
NOs 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, 253,
and 267; a heavy chain CDR2 selected from the group consisting of SEQ ID NOs: 2, 16,
, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184, 198, 212, 226, 240, 254, and 268;
and a heavy chain CDR3 selected from the group consisting of SEQ lD NOs: 3, 17, 31,
45, 59, 73, 87, 101, 115, 129, 143, 157, 171, 185, 199, 213, 227, 241, 255, and 269,
wherein the isolated antibody or antigen binding fragment thereof binds to human Factor
P. in another , the isolated antibody or antigen binding fragment thereof further
includes a light chain CDR1 selected from the group ting of SEQ lD NOs: 4, 18,
32, 46, 60, 74, 88, 102, 116, 130, 144, 158, 172, 186,200,214, 228, 242, 256, and 270;
a light chain CDR2 selected from the group consisting of SEQ ID NOs 5, 19, 33, 47, 61,
PCT/IBZOlZ/057394
75,89, 103, 117, 131, 145, 159, 173, 187,201, 215, 229,243,257, and 271; and a light
chain CDR3 selected from the group consisting of SEQ ID NOs 6, 20, 34, 48, 62, 76, 90,
104, 118, 132, 146, 160, 174, 188,202, 216, 230, 244, 258, and 272.
The invention also relates to an isolated dy or antigen binding fragment
thereof that includes a light chain CDR1 ed from the group consisting of SEQ ID
NOs: 4, 18, 32,46, 60, 74, 88, 102, 116, 130, 144, 158, 172, 186, 200, 214, 228, 242,
256, and 270; a light chain CDR2 selected from the group consisting of SEQ ID NOs 5,
19, 33,47, 61, 75, 89, 103, 117, 131, 145, 159, 173, 187, 201,215, 229,243, 257, and
271; and a light chain CDR3 selected from the group ting of SEQ ID NOs 6, 20,
34, 48, 62, 76, 90, 104, 118, 132, 146, 160, 174, 188,202, 216, 230, 244, 258, and 272,
wherein the isolated antibody or antigen binding fragment thereof binds to human Factor
The invention also relates to an ed dy or antigen binding nt thereof
that binds Factor P having HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3,
wherein HCDR1, HCDR2, HCDR3 comprises SEQ ID NOs: 1, 2, 3, and LCDR1,
LCDR2, LCDR3 comprises SEQ ID NOs: 4, 5, 6; or HCDR1, HCDR2, HCDR3 and
LCDR1, LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3 comprises SEQ ID N08 15,
16, 17, and LCDR1, LCDR2, LCDR3 comprises SEQ ID N03: 18, 19, 20; or HCDR1,
HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3
comprises SEQ lD N03 29, 30, 31, and LCDR1, LCDR2, LCDR3 comprises SEQ ID
N08: 32, 33, 34; or HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, wherein
HCDR1, HCDR2, HCDR3 comprises SEQ ID N08 43, 44, 45, and LCDR1, LCDR2,
LCDR3 comprises SEQ ID NOs: 46, 47, 48; or HCDR1, HCDR2, HCDR3 and LCDR1,
LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3 comprises SEQ ID N03 57, 58, 59,
and LCDR1, LCDR2, LCDR3 comprises SEQ ID N05: 60, 61, 62; or HCDR1, HCDR2,
HCDR3 and LCDR1, LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3 comprises
SEQ lD N03 71, 72, 73, and LCDR1, LCDR2, LCDR3 comprises SEQ ID NOs: 74, 75,
76; or HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, wherein HCDR1,
HCDR2, HCDR3 comprises SEQ ID NOs 85, 86, 87, and LCDR1, LCDR2, LCDR3
comprises SEQ ID N03: 88, 89, 90; or HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2,
LCDR3, wherein HCDR1, HCDR2, HCDR3 comprises SEQ lD N03 99, 100, 101, and
LCDR1, LCDR2, LCDR3 comprises SEQ ID N03: 102, 103, 104; or HCDR1, HCDR2,
HCDR3 and LCDR1, LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3 comprises
SEQ ID N03 113, 114, 115, and LCDR1, LCDR2, LCDR3 comprises SEQ ID N08: 116,
117, 118; or HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, wherein HCDR1,
HCDR2, HCDR3 comprises SEQ ID N08 127, 128, 129, and LCDR1, LCDR2, LCDR3
comprises SEQ ID N08: 130, 131, 132; or HCDR1, HCDR2, HCDR3 and LCDR1,
LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3 comprises SEQ ID N05 141, 142,
143, and LCDR1, LCDR2, LCDR3 comprises SEQ ID N03: 144, 145, 146; or HCDR1,
HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3
comprises SEQ ID N08 155, 156, 157, and LCDR1, LCDR2, LCDR3 comprises SEQ ID
N03: 158, 159, 160; or HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, wherein
HCDR1, HCDR2, HCDR3 comprises SEQ ID N05 169, 170, 171, and LCDR1, LCDR2,
LCDR3 comprises SEQ ID N03: 172, 173, 174; or HCDR1, HCDR2, HCDR3 and
LCDR1, LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3 comprises SEQ ID N03
183, 184, 185, and LCDR1, LCDR2, LCDR3 comprises SEQ ID NOs: 186, 187, 188; or
HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, n HCDR1, HCDR2,
HCDR3 comprises SEQ ID NOs 197, 198, 199, and LCDR1, LCDR2, LCDR3 ses
SEQ ID NOs: 200, 201, 202; or HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3,
wherein HCDR1, HCDR2, HCDR3 comprises SEQ ID NOs 211, 212, 213, and LCDR1,
LCDR2, LCDR3 comprises SEQ ID N03: 214, 215, 216; or HCDR1, HCDR2, HCDR3
and LCDR1, LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3 comprises SEQ ID
NOs 225, 226, 227, and LCDR1, LCDR2, LCDR3 comprises SEQ ID NOs: 228, 229,
230; or HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, wherein HCDR1,
HCDR2, HCDR3 comprises SEQ ID NOs 239, 240, 241, and LCDR1, LCDR2, LCDR3
comprises SEQ ID N05: 242, 243, 244; or HCDR1, HCDR2, HCDR3 and LCDR1,
LCDR2, LCDR3, n HCDR1, HCDR2, HCDR3 comprises SEQ ID N03 253, 254,
255, and LCDR1, LCDR2, LCDR3 comprises SEQ ID N08: 256, 257, 258; or HCDR1,
HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, wherein HCDR1, HCDR2, HCDR3
comprises SEQ ID N03 267, 268, 269, and LCDR1, LCDR2, LCDR3 comprises SEQ ID
N03: 270, 271, 272.
In one embodiment of the invention the ed antibody or n binding
fragment thereof includes a heavy chain variable domain sequence selected from the
group consisting of SEQ ID NOs: 7, 21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161, 175,
189, 203, 217, 231, 245, 259 and 273. In another embodiment , the isolated antibody or
antigen binding fragment further comprises a light chain variable domain seqeunce
wherein the heavy chain le domain and light chain variable domain combine to
form and antigen binding site for Factor P. In a r embodiment the isolated antibody
or antigen binding fragment further includes a light chain variable domain sequence
selected from SEQ ID NOs: 8, 22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190,
204, 218, 232, 246, 260, and 274 wherein said isolated dy or antigen binding
fragment thereof binds Factor P.
The invention also relates to an isolated antibody or antigen g fragment
thereof that includes a light chain variable domain sequence selected from the group
consisting of SEQ ID NOs: 8, 22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190,
204, 218, 232, 246, 260, and 274, wherein said isolated antibody or antigen binding
fragment thereof binds to human Factor P. In one embodiment or
, the isolated antibody
antigen g fragment further comprises a heavy chain le domain sequence
wherein the light chain variable domain and heavy chain variable domain combine to
form and antigen binding site for Factor P.
In another embodiment of the invention, the isolated antibody or antigen binding
nt thereof that binds Factor P, may have heavy and light chain variable domains
comprising the sequences of SEQ lD NOs: 7 and 8; 21 and 22; 35 and 36; 49 and 50; 63
and 64; 77 and 78; 91 and 92; 104 and 105; 118 and 119; 132 and 133; 146 and 147;
160 and 161; 174 and 175; 188 and 189; 202 and 203; 216 and 217; 230 and 231; 244
and 245; 258 and 259; or 272 and 273, respectively.
The invention further relates to an isolated antibody or antigen g nt
thereof, that includes a heavy chain variable domain having at least 90% sequence
identity to a sequence selected from the group ting of SEQ ID NOs: 7, 21, 35, 49,
63, 77, 91, 105, 119, 133, 147, 161, 175, 189, 203, 217, 231, 245, 259 and 273, wherein
said antibody binds to Factor P. in one aspect, the isolated antibody or antigen binding
fragment thereof also includes a light chain variable domain having at least 95%
sequence identity to a sequence selected from the group consisting of SEQ ID NOs 8,
22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190, 204, 218, 232, 246, 260, and
274.
In another embodiment the isolated antibody or antigen binding fragment thereof,
may include a light chain variable domain having at least 90% sequence ty to a
sequence selected from the group consisting of SEQ lD NOS 8, 22, 36, 50, 64, 78, 92,
106, 120, 134, 148, 162, 176, 190, 204, 218, 232,246, 260, and 274, wherein said
antibody binds Factor P.
In another embodiment the isolated antibody, or n binding fragment thereof,
that binds to Factor P may have a heavy chain sing the ce of SEQ lD NO:
9, 23, 37, 51, 65, 79, 93, 107, 121, 135, 149, 163, 177, 191, 205, 219, 233, 247, 261 or
275. in a further embodiment, the isolated antibody also es a light chain that can
combine with the heavy chain to form an antigen binding site to human Factor P. in a
further embodiment, the isolated antibody or antigen binding fragment thereof es a
light chain having a sequence comprising SEQ ID NO: 10, 24, 38, 52, 66, 80, 94, 108,
122, 136, 150, 164, 178, 192, 206, 220, 234, 248, 262, or 276.
The invention still further relates to an isolated antibody or antigen binding
nt thereof that includes a heavy chain having at least 90% sequence ty to a
sequence selected from the group consisting of SEQ lD NOs 9, 23, 37, 51, 65, 79, 93,
107, 121, 135, 149, 163, 177, 191,205, 219, 233, 247, 261 and 275, wherein said
antibody binds to Factor P. In one aspect, the isolated antibody or antigen binding
fragment thereof also includes a light chain having at least 95% sequence identity to a
sequence selected from the group consisting of SEQ lD N08 10, 24, 38, 52, 66, 80, 94,
108, 122, 136, 150, 164, 178, 192,206, 220, 234,248, 262, and 276.
The invention still further s to an isolated antibody or antigen g
fragment thereof that includes a light chain having at least 90% sequence identity to a
sequence selected from the group ting of SEQ lD NOs 9, 23, 37, 51, 65, 79, 93,
107, 121, 135, 149, 163, 177, 191, 205, 219, 233, 247,261 and 275, wherein said
antibody binds Factor P.
The ion also relates to compositions comprising the isolated antibody, or
n g fragment thereof, described herein. As well as, antibody compositions in
combination with a pharmaceutically acceptable carrier. Specifically, the invention
further includes pharmaceutical compositions comprising an antibody or antigen binding
fragment thereof of Table 1, such as, for example antibody NVS962, NV8963, NV8964,
NV8965, NVS966, NV8967, NV8962-G, NV8962-S, NV8962-T, NVS962—Q, NVS962—
831A, NVS965—Q, NV8965-S, —T, NV8804, NV8805, NVS806, NV8807, or
NVSBO8. The invention also realtes to pharmaceutical compositions comprising a
combination of two or more of the isolated antibodies or antigen binding fragments
thereof of Table 1.
The invention also relates to an ed nucleic acid comprising a ce
encoding a polypeptide that includes a heavy chain le domain having at least 90%
ce identity to a sequence selected from the group ting of SEQ ID NOs: 7,
21, 35, 49, 63, 77, 91, 105,119,133,147,161, 175, 189, 203, 217, 231, 245, 259 and
273.
The invention also relates to an isolated nucleic acid comprising a sequence
encoding a polypeptide that includes a light chain variable domain having at least 90%
sequence identity to a sequence selected from the group consisting of SEQ ID NOs 8,
22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190, 204, 218, 232, 246, 260, and
274.
The invention also s to a vector that includes one or more of the nucleic
acid molecules described herein.
The invention also relates to an isolated host cell that includes a inant
DNA sequence encoding a heavy chain of the antibody described above, and a second
recombinant DNA sequence encoding a light chain of the antibody described above,
wherein said DNA sequences are operably linked to a promoter and are capable of being
expressed in the host cell. it is plated that the antibody can be a human
monoclonal antibody. it is also contemplated that the host cell is a non—human
mammalian cell.
The invention also s to a method of inhibiting the ment mediated cell
death wherein the method includes the step of contacting a cell with an effective amount
of a composition comprising the isolated antibody or n binding fragments thereof
described herein. It is contemplated that the cell is a human cell. It is further
contemplated that the cell is in a subject. it is still further contemplated that the subject is
human.
The invention still further relates to a method of ting the alternative
complement pathway in a cell wherein the method includes the step of contacting the
cell with an ive amount of a composition comprising the isolated antibody or n
binding fragments thereof described herein. In one aspect, it is contemplated that the
cell is a human cell. It is further contemplated that the cell is in a subject. It is still further
contemplated that the subject is human.
The invention also relates to a method of inhibiting the formation of membrane
attack complex in a cell wherein the method includes the step of contacting the cell with
an ive amount of a ition comprising the ed antibody or antigen binding
fragments thereof described herein. it is contemplated that the cell is a human cell. it is
further contemplated that the cell is in a subject. It is still further contemplated that the
subject is human.
Any of the foregoing isolated antibodies or n binding fragments thereof may
be a monoclonal antibody or antigen binding fragment thereof.
PCT/[32012/057394
In one aspect, the invention provides a a first antibody, or antigen binding
fragment thereof, that binds Factor P, and a second antibody, or antigen binding
fragment thereof, that binds C5, wherein said combination inhibits the alternative
complement pathway. In one aspect the first and second antibodies can be in
combination as a composition.
Such a combination can be used to inhibit ocular inflammation. Ocular
inflammation can be determined by measuring neutrophil accumulation and/or
macrophage recruitment in the retina.
In one aspect, such a combination can be used to inhibit neutrophil accumulation
in the retina, or macrophage recruitment in the .
In one aspect, the antibody in such a combination that binds Factor P, binds a
region of Factor P comprising SEQ ID NO: 408. Alternatively or in combination, such an
antibody binds a region of Factor P comprising SEQ ID NO: 407.
In a further aspect, the combination of antibodies or binding fragments thereof
that bind Factor P and 05 e a first antibody or antigen binding fragment selected
from Table 1 and a second antibody or antigen-binding fragment selected from Table 2.
In one aspect, the first dy, or antigen binding nt thereof binds the same
epitope as is an antibody described in Table 1 and the second dy, or antigen
binding fragment thereof, binds the same e as is an antibody described in Table 2.
In one aspect, the invention provides a first antibody, or antigen binding fragment
thereof that comprises a heavy chain CDR1, 2, 3, and a light chain CDR1, 2, 3, selected
from the group ting of a) a heavy chain variable region HCDR1, HCDR2 and
HCDR3 as set forth in SEQ ID NOs: 1, 2, and 3, respectively, and light chain variable
region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs: 4, 5, and 6,
tively; b) a heavy chain le region HCDR1, HCDR2 and HCDR3 as set forth
in SEQ ID N03: 15, 16, and 17, respectively, and light chain variable region LCDR1,
LCDR2, and LCDR3 as set forth in SEQ ID N08: 18, 19, and 20, respectively; 0) a heavy
chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N08: 29, 30,
and 31, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set
forth in SEQ ID N03: 32, 33, and 34, respectively; d) a heavy chain variable region
HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N08: 43, 44, and 45, respectively,
and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03:
46, 47, and 48, respectively; e) a heavy chain variable region HCDR1, HCDR2 and
HCDR3 as set forth in SEQ ID NOs: 57, 58, and 59, tively, and light chain variable
region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 60, 61, and 62,
respectively; f) a heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in
SEQ ID N08: 71, 72, and 73, respectively, and light chain variable region LCDR1,
LCDR2, and LCDR3 as set forth in SEQ ID N05: 74, 75, and 76, respectively; 9) a heavy
chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N08: 85, 86,
and 87, tively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set
forth in SEQ ID N03: 88, 89, and 90, tively; h) a heavy chain variable region
HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N03: 99, 100, and 101,
respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in
SEQ ID N03: 102, 103, and 104, respectively; i) a heavy chain variable region HCDR1,
HCDR2 and HCDR3 as set forth in SEQ ID N03: 113, 114, and 115, respectively, and
light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 116,
117, and 118, respectively; j) a heavy chain le region HCDR1, HCDR2 and
HCDR3 as set forth in SEQ ID N03: 127, 128, and 129, respectively, and light chain
variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOS: 130, 131, and
132, respectively; k) a heavy chain variable region HCDR1, HCDR2 and HCDR3 as set
forth in SEQ ID N08: 141, 142, and 143, respectively, and light chain variable region
LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 144, 145, and 146,
tively; I) a heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in
SEQ ID N03: 155, 156, and 157, respectively, and light chain variable region LCDR1,
LCDR2, and LCDR3 as set forth in SEQ ID N03: 158, 159, and 160, respectively; m) a
heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N03:
169, 170, and 171, respectively, and light chain variable region LCDR1, LCDR2, and
LCDR3 as set forth in SEQ ID N03: 172, 173, and 174, respectively; n) a heavy chain
le region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N03: 183, 184, and
185, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set
forth in SEQ ID N03: 186, 187, and 188, respectively; 0) a heavy chain variable region
HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N03: 197, 198, and 199,
respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in
SEQ ID N03: 200, 201, and 202, respectively; p) a heavy chain variable region HCDR1,
HCDR2 and HCDR3 as set forth in SEQ ID N08: 211, 212, and 213, respectively, and
light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 214,
215, and 216, respectively; q) a heavy chain variable region HCDR1, HCDR2 and
HCDR3 as set forth in SEQ ID N03: 225, 226, and 227, respectively, and light chain
variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N08: 228, 229, and
230, respectively; r) a heavy chain variable region HCDR1, HCDR2 and HCDR3 as set
forth in SEQ ID N03: 239, 240, and 241, respectively, and light chain variable region
PCT/[82012/057394
LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 242, 243, and 244,
respectively; 5) a heavy chain le region HCDR1, HCDR2 and HCDR3 as set forth
in SEQ ID N08: 253, 254, and 255, respectively, and light chain variable region LCDR1,
LCDR2, and LCDR3 as set forth in SEQ ID NOs: 256, 257, and 258, respectively; and t)
a heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N05:
267, 268, and 269, respectively, and light chain variable region LCDR1, LCDR2, and
LCDR3 as set forth in SEQ ID N08: 270, 271, and 272, respectively, and wherein the
second antibody or antigen binding nt thereof comprises a heavy chain CDR1, 2,
3 and light chain CDR1, 2, 3 selected from the group consisting of: a) a heavy chain
variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs: 410, 411, and
412, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set
forth in SEQ ID N05: 413, 414, and 415, respectively; b) a heavy chain variable region
HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N03: 426, 427, and 428,
respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in
SEQ ID NOs: 429, 430, and 431, respectively; 0) a heavy chain variable region HCDR1,
HCDR2 and HCDR3 as set forth in SEQ ID N08: 442, 443, and 444, respectively, and
light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 445,
446, and 447, respectively; d) a heavy chain variable region HCDR1, HCDR2 and
HCDR3 as set forth in SEQ ID N03: 426, 458, and 428, respectively, and light chain
le region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs: 429, 430, and
459, respectively; and e) a heavy chain variable region HCDR1, HCDR2 and HCDR3 as
set forth in SEQ ID N03: 470, 471, and 472, respectively, and light chain variable region
LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 473, 474 and 475,
respectively.
In one aspect, the invention relates to a first and second dy or antigen
bidning fragement thereof (which may be in combination as a ition) where the
first antibody or n binding fragment thereof includes heavy and light chain variable
regions having amino acid sequences at least 90% identical to SEQ ID NOs: 7 and 8;
SEQ ID N03: 21 and 22; SEQ ID N03: 35 and 36; SEQ ID NOs: 49 and 50; SEQ ID
NOs: 63 and 64; SEQ ID NOs: 77 and 78; SEQ ID NOs: 91 and 92; SEQ ID N03: 105
and 106; SEQ ID N03: 119 and 120; SEQ ID NOs: 133 and 134; SEQ ID NOs: 147 and
148; SEQ ID N03: 161 and 162; SEQ ID N03: 175 and 176; SEQ ID N08: 189 and 190;
SEQ ID N08: 203 and 204; SEQ ID NOs: 217 and 218; SEQ ID N08: 231 and 232; SEQ
ID N03: 245 and 246; SEQ ID N03: 259 and 260; or SEQ ID N08: 273 and 274,
respectively, and wherein the second antibody or antigen binding nt thereof
includes heavy and light chain variable regions having amino acid sequences at least
PCT/IBZOIZ/057394
90% identical to SEQ ID N03: 416 and 417; SEQ ID N03: 432 and 433; SEQ ID N08:
448 and 449; SEQ ID N08: 460 and 461; or SEQ ID N08: 476 and 477, respectively.
In one aspect, the invention s to a first and second dy or antigen
bidning fragement thereof (which may be in combination as a ition) where the
first antibody or antigen binding fragment thereof includes heavy and light chain variable
s having amino acid sequences selected from SEQ ID NOs: 7 and 8; SEQ ID N03:
21 and 22; SEQ ID N03: 35 and 36; SEQ ID N08: 49 and 50; SEQ ID N08: 63 and 64;
SEQ ID N05: 77 and 78; SEQ ID N08: 91 and 92; SEQ ID N08: 105 and 106; SEQ ID
N03: 119 and 120; SEQ ID N03: 133 and 134; SEQ ID NOS: 147 and 148; SEQ ID N05:
161 and 162; SEQ ID N05: 175 and 176; SEQ ID NOs: 189 and 190; SEQ ID N03: 203
and 204; SEQ ID N03: 217 and 218; SEQ ID N08: 231 and 232; SEQ ID NOs: 245 and
246; SEQ ID N03: 259 and 260; or SEQ ID N03: 273 and 274, respectively, and wherein
the second antibody or antigen binding fragment thereof includes heavy and light chain
variable s having amino acid sequences selected from SEQ ID N03: 416 and 417;
SEQ ID N05: 432 and 433; SEQ ID N03: 448 and 449; SEQ ID N08: 460 and 461; or
SEQ ID N03: 476 and 477, respectively.
In a further aspect, the invention includes a first and second dy or antigen
binding fragment thereof (which may be in combination as a composition) in which (a)
the first antibody, or antigen binding fragment thereo includes a heavy chain variable
region comprising SEQ ID NO: 7, 21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161, 175,
189, 203, 217, 231, 245, 259, or 273 and further includes a light chain variable region,
wherein said heavy chain variable region and said light chain variable region combine to
form an n binding site to Factor P and (b) wherein the second antibody or antigen
binding fragment thereof es a heavy chain variable region comprising SEQ ID NO:
416, 432, 448, 460 or 476 and further includes a light chain variable region, wherein said
heavy chain le region and said light chain variable region combine to form an
antigen binding site to 05. In a further aspect, the first antibody or antigen binding
nt thereof includes the light chain variable region sequence of SEQ ID NO: 8, 22,
36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190, 204, 218, 232, 246, 260, or 274,
and the second dy or antigen binding fragment thereof includes the light chain
variable region sequence of SEQ ID NO: 417, 433, 449, 461 or 477.
In a further aspect, the invention includes a first and second antibody or antigen
g fragment thereof (which may be in combination as a composition) in which (a)
the first antibody or antigen bidning fragment thereof incldues a light chain variable
domain comprising SEQ ID NO: 8, 22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176,
190, 204, 218, 232, 246, 260, or 274 and further includes a heavy chain variable domain,
wherein the light chain variable domain and the heavy chain le domain combine to
form an antigen binding site to Factor P and (b) wherein the second antibody or antigen
binding fragment thereof includes a light chain variable region comprises a light chain
variable domain es SEQ ID NO: 417, 433, 449, 461 or 477 and further comprises a
heavy chain variable domain, wherein the light chain variable domain and the heavy
chain variable domain combine to form an antigen g site to C5.
In one , the invention includes a first and second antibody or antigen
binding fragment thereof (which may be in ation as a composition) in which (a)
the first antibody, or antigen binding fragment thereof includes a heavy chain of SEQ ID
NO: 9, 23, 37, 51, 65, 79, 93, 107, 121,135, 149,163, 177, 191, 205, 219, 233, 247, 261
or 275 and further includes a light chain, wherein the heavy chain and the light chain
combine to form an antigen binding site to Factor P and (b) wherein the second antibody
or antigen binding fragment thereof includes a heavy chain of SEQ ID NO: 418, 434,
450, 462, or 478 and further includes a light chain, wherein the heavy chain and the light
chain combine to form an antigen binding site to 05. In a r aspect, the first
antibody or antigen binding fragment f includes a light chain of SEQ ID NO: 10, 24,
38, 52, 66, 80, 94, 108, 122, 136, 150, 164, 178, 192, 206, 220, 234, 248, 262 or 276,
and n the second antibody or antigen binding fragment thereof includes a light
chain of SEQ ID NO: 419, 435, 451, 463, or 479.
In one aspect, the invention includes a first and second antibody or antigen
binding fragment thereof (which may be in combination as a composition) in which (a)
the first dy, or antigen binding fragment f includes a light chain of SEQ ID
NO: 10, 24, 38, 52, 66, 80, 94, 108, 122, 136, 150, 164, 178, 192, 206, 220, 234, 248,
262 or 276 and further includes a heavy chain, wherein the light chain and the heavy
chain combine to form an antigen binding site to Factor P and (b) wherein the second
antibody or antigen binding fragment thereof includes a light chain of SEQ ID NO: 419,
435, 451, 463, or 479 and r includes a heavy chain, wherein the light chain and the
heavy chain combine to form an antigen binding site to C5.
In one aspect, the ion includes a first and second antibody or antigen
g fragment thereof (which may be in ation as a composition) wherein the
first antibody, or antigen binding fragment thereof includes a heavy chain with an amino
acid sequence having at least 90% sequence identity to SEQ ID NO: 9, 23, 37, 51, 65,
79, 93, 107, 121, 135, 149, 163, 177, 191, 205, 219,233,247, 261 or 275 and further
includes a light chain with an amino acid sequence having at least 90% sequence
identity to SEQ ID NO: 10, 24, 38, 52, 66, 80, 94, 108, 122, 136, 150, 164, 178, 192,
206, 220, 234, 248, 262 or 276 and wherein the second antibody or antigen binding
fragement f es a heavy chain with an amino acid sequence having at least
90% sequence identity to SEQ lD NO: 418, 434, 450, 462, or 478 and further includes a
light chain with an amino acid sequence having at least 90% sequence identity to SEQ
ID NO: 419, 435, 451, 463, or 479.
In a further aspect, the invention includes a first and second antibody or antigen
binding fragment thereof (which may be in combination as a ition) wherein the
first antibody, or antigen binding fragment thereof includes a heavy chain with an amino
acid sequence ted from SEQ lD NO: 9, 23, 37, 51, 65, 79, 93, 107, 121, 135, 149,
163, 177, 191, 205, 219,233, 247, 261 or 275 and further includes a light chain with an
amino acid sequence selected from SEQ ID NO: 10, 24, 38, 52, 66, 80, 94, 108, 122,
136, 150, 164, 178, 192, 206, 220, 234, 248, 262 or 276 and wherein the second
dy or antigen binding fragement thereof includes a heavy chain with an amino acid
sequence ed from SEQ lD NO: 418, 434, 450, 462, or 478 and further includes a
light chain with an amino acid sequence selected from SEQ ID NO: 419, 435, 451, 463,
or 479.
in a further aspect, the invention includes a first and second antibody or antigen
binding fragment thereof (which may be in combination as a composition) n the
first dy, or n binding fragment thereof includes a heavy chain and a light
chain with an amino acid sequence having at least 90% ce identity, respectively,
to SEQ ID NO: 9 and 10,23 and 24, 37 and 38, 51 and 52, 65 and 66,79 and 80, 93 and
94,107 and108, 121 and 122, 135 and 136, 149 and150, 163 and 164, 177 and 178,
191 and 192, 205 and 206, 219 and 220, 233 and 234, 247 and 248, 261 and 262, or
275 and 276; and wherein the second antibody or antigen binding fragment thereof
includes a heavy chain and a light chain with an amino acid sequence having at least
90% sequence ty, respectively, to SEQ lD N03: 418 and 419, 434 and 435; 450
and 451; 462 and 463; or 478 and 479.
in a still further aspect, the invention includes a first and second antibody or
antigen binding fragment thereof (which may be in combination as a composition)
wherein the first antibody, or antigen binding fragment thereof includes a heavy chain
and a light chain with an amino acid sequence, respectively, selected from SEQ lD NO: 9
and 10, 23 and 24, 37 and 38, 51 and 52,65 and 66,79 and 80, 93 and 94, 107 and
108, 121 and 122, 135 and 136, 149 and 150, 163 and 164, 177 and 178, 191 and 192,
205 and 206, 219 and 220, 233 and 234, 247 and 248, 261 and 262, or 275 and 276;
and wherein the second antibody or antigen binding fragment f includes a heavy
chain and a light chain with an amino acid sequence, respectively, selected from SEQ ID
N03: 418 and 419, 434 and 435; 450 and 451; 462 and 463; or 478 and 479.
The invention further relates to an isolated nucleic acid le comprising a
nucleotide ce ng the first and/or second antibody or antigen binding
fragment f as described herein. Such a nucleic acid sequence can be included in
a vector, which may, in turn be included in a host cell which, in one aspect, is e of
expressing such c acid sequence.
The invention further relates to a method of treating age related macular
degeneration in a subject comprising administering to said subject, an effective amount
of a first and second antibody or antigen binding fragment thereof, either singly, or in
combination as a composition. The t may be a human.
The invention further releates to a method of inhibiting the alternative
complement pathway in a subject comprising administering to said subject an effective
amount of a first and second antibody or antigen binding fragment thereof, either singly,
or in combination as a composition. The subject may be a human.
DEFINITIONS
Unless defined othenNise, all technical and scientific terms used herein have the
same meaning as commonly understood by those of ordinary skill in the art to which this
invention pertains.
The term "antibody" as used herein means a whole antibodies and any antigen
binding fragment (1'. e., "antigen-binding portion") or single chains thereof. A whole
dy is a glycoprotein comprising at least two heavy (H) chains and two light (L)
chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy
chain le region (abbreviated herein as VH) and a heavy chain constant region.
The heavy chain constant region Is comprised of three domains, CH1, CH2 and CH3.
Each light chain is comprised of a light chain variable region (abbreviated herein as VL)
and a light chain constant region. The light chain constant region is comprised of one
domain, CL. The VH and VL regions can be further subdivided into regions of
hypervariability, termed complementarity determining regions (CDR), interspersed with
regions that are more conserved, termed framework regions (FR). Each VH and VL is
composed of three CDRs and four FRs ed from amino-terminus to y—
terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable
regions of the heavy and light chains contain a binding domain that interacts with an
n. The constant regions of the antibodies may mediate the binding of the
immunoglobulin to host tissues or s, including various cells of the immune system
(e.g., effector cells) and the first component (Clq) of the cal complement system.
The term "antigen binding portion" or “antigen binding fragment” of an antibody,
as used herein, refers to one or more fragments of an intact antibody that retain the
ability to specifically bind to a given n (e.g., Factor P). Antigen binding functions of
an antibody can be performed by fragments of an intact antibody. Examples of binding
nts encompassed within the term n binding portion or antigen binding
fragment of an antibody include a Fab fragment, a monovalent fragment consisting of the
VL, VH, CL and CH1 domains; a F(ab)2 fragment, a bivalent fragment comprising two
Fab fragments linked by a disulfide bridge at the hinge region; an Fd fragment consisting
of the VH and CH1 domains; an Fv fragment consisting of the VL and VH domains of a
single arm of an dy; a single domain antibody (dAb) nt (Ward et al., 1989
Nature 341:544—546), which consists of a VH domain or a VL domain; and an isolated
mentarity determining region (CDR).
Furthermore, although the two domains of the Fv fragment, VL and VH, are
coded for by separate genes, they can be joined, using recombinant methods, by an
artificial peptide linker that enables them to be made as a single protein chain in which
the VL and VH regions pair to form monovalent molecules (known as single chain Fv
; see, 6.9., Bird etal., 1988 Science 242:423-426; and Huston etal., 1988 Proc.
Natl. Acad. Sci. 85:5879-5883). Such single chain antibodies include one or more
antigen binding ns or nts of an dy. These antibody fragments are
obtained using conventional techniques known to those of skill in the art, and the
fragments are screened for utility in the same manner as are intact antibodies.
Antigen binding fragments can also be incorporated into single domain
antibodies, maxibodies, minibodies, intrabodies, diabodies, triabodies, tetrabodies, v—
NAR and bis-scFv (see, e.g., Hollinger and Hudson, 2005, Nature Biotechnology, 23, 9,
1126-1136). Antigen binding portions of antibodies can be grafted into scaffolds based
on polypeptides such as Fibronectin type lll (Fn3) (see US. Pat. No. 6,703,199, which
bes fibronectin polypeptide dies).
Antigen binding fragments can be incorporated into single chain molecules
comprising a pair of tandem Fv segments (VH-CH1—VH—CH1) which, together with
‘l 9
mentary light chain polypeptides, form a pair of antigen binding regions (Zapata et
al., 1995 Protein Eng. 8(10):1057-1062; and U.S. Pat. No. 5,641,870).
As used herein, the term "affinity" refers to the strength of interaction n
dy and antigen at single antigenic sites. Within each antigenic site, the variable
region of the dy “arm” interacts through weak non-covalent forces with antigen at
numerous sites; the more interactions, the stronger the y. As used herein, the term
"high affinity" for an lgG antibody or fragment thereof (e.g., a Fab fragment) refers to an
antibody having a KD of 10'8 M or less, 10'9 M or less, or ”IO"10 M, or 10'11 M or less, or
‘lO'12 M or less, or 10‘13 M or less for a target antigen. However, high affinity g can
vary for other antibody isotypes. For example, high affinity binding for an lgM isotype
refers to an antibody having a KD of 10'7 M or less, or 10'8 M or less.
The term "amino acid" refers to lly occurring and synthetic amino acids, as
well as amino acid analogs and amino acid mimetics that function in a manner similar to
the naturally occurring amino acids. Naturally occurring amino acids are those encoded
by the genetic code, as well as those amino acids that are later modified, e.g.,
hydroxyproline, y-carboxyglutamate, and O-phosphoserine. Amino acid s refer to
compounds that have the same basic chemical structure as a naturally occurring amino
acid, i.e., an alpha carbon that is bound to a hydrogen, a carboxyl group, an amino
group, and an R group, 9.9., homoserine, cine, methionine ide, methionine
methyl sulfonium. Such analogs have modified R groups (9.9., norleucine) or d
peptide backbones, but retain the same basic chemical structure as a naturally occurring
amino acid. Amino acid mimetics refers to chemical compounds that have a structure
that is different from the general Chemical structure of an amino acid, but that functions in
a manner similar to a lly ing amino acid.
The term “binding specificity” as used herein refers to the ability of an individual
antibody combining site to react with only one antigenic determinant.
The phrase “specifically (or selectively) blnds” to an antibody (e.g., a Factor P-
binding antibody) refers to a binding reaction that is determinative of the presence of a
cognate antigen (e.g., a human Factor P or cynomolgus Factor P) in a heterogeneous
population of proteins and other biologics. The phrases “an antibody recognizing an
antigen” and “an antibody specific for an antigen” are used interchangeably herein with
the term “an antibody which binds specifically to an antigen”.
The term "conditions or disorders associated with macular degeneration" refers to
any of a number of conditions in which the retinal macula rates or becomes
ZOIZ/057394
dysfunctional, e.g., as a consequence of decreased growth of cells of the macula,
sed death or rearrangement of the cells of the macula (e.g., RPE cells), loss of
normal biological function, or a combination of these events. Macular degeneration
s in the loss of ity of the histoarchitecture of the cells and/or extracellular
matrix of the normal macula and/or the loss of function of the cells of the macula.
Examples of macular degeneration-related disorder include AMD, North Carolina
macular dystrophy, Sorsby's fundus dystrophy, Stargardt‘s disease, pattern dystrophy,
Best disease, dominant drusen, and malattia leventinese (radial drusen). The term also
encompasses extramacular changes that occur prior to, or ing dysfunction and/or
degeneration of the . Thus, the term "macular degeneration—related disorder" also
broadly includes any condition which alters or damages the integrity or function of the
macula (e.g., damage to the RPE or s membrane). For example, the term
encompasses retinal detachment, chorioretinal degenerations, retinal degenerations,
photoreceptor degenerations, RPE rations, mucopolysaccharidoses, rod-cone
dystrophies, cone-rod dystrophies and cone degenerations.
The term “complement component’3 H
, complement proteins" or “complement
component proteins” refers to the molecules that are involved in activation of the
complement . The classical pathway components include, e.g., Ciq, Cir, 018,
C4, CZ, C3, C5, CB, CY, C8, 09, and CSb-Q complex (membrane attack complex: MAC).
The alternative pathway components include, e.g., Factor B, Factor D, Factor H, Factor I
and Properdin.
The term “cellular activities regulated by the complement pathway” include cell
damage resulting from the CSb-Q attack x, vascular permeability changes,
contraction and ion of smooth muscle cells, T cell proliferation, immune
adherence, aggregation of dendritic cells, tes, granulocyte and platelet,
phagocytosis, migration and activation of neutrophils (PMN) and macrophages.
Further, activation of the complement pathways s in the increase of
proinflammatory response contributed by the by-products within the complement
pathway. ers associated with activation of the ment pathway include
nephritis, asthma, reperfusion injury, hemodialysis, rheumatoid arthritis, systemic lupus,
psoriasis, le sclerosis, transplantation, Alzheimer’s disease, aHUS, MPGN II, or
any other complement-mediated disease. Disorders associated with macular
degeneration include AMD, North Carolina r phy, Sorsby's fundus
dystrophy, Stargardt's disease, pattern dystrophy, Best disease, dominant drusen, and
malattia leventinese (radial drusen), extramacular changes that occur prior to, or
PCT/IBZOlZ/057394
following dysfunction and/or degeneration of the macula, retinal detachment,
chorioretinal degenerations, retinal degenerations, photoreceptor degenerations, RPE
degenerations, mucopolysaccharidoses, rod-cone dystrophies, cone-rod dystrophies and
cone degenerations.
The term "chimeric antibody" is an antibody molecule in which (a) the constant
, or a portion f, is altered, replaced or exchanged so that the antigen binding
site (variable region) is linked to a constant region of a different or altered class, effector
function and/or species, or an entirely different le which confers new properties to
the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b)
the variable region, or a portion thereof, is altered, replaced or exchanged with a variable
region having a different or altered antigen icity. For example, a mouse antibody
can be modified by replacing its constant region with the constant region from a human
globulin. Due to the replacement with a human constant region, the chimeric
antibody can retain its specificity in izing the antigen while having reduced
antigenicity in human as compared to the original mouse antibody.
The term “Factor P protein” or “Factor P antigen” or “Factor P” are used
interchangeably, and refers to the Factor P protein in different species. For example,
human Factor P has the sequence as set out in Table ‘l: SEQ ID NO: 401. Human
Factor P can be obtained from Complement Tech, Tyler, TX. Cynomolgus Factor P can
be purified from cynomolgus serum (protocol adapted from Nakano etal., (1986) J
Immunoi Methods 90:77-83). es of Factor P protein from other species are
provided in Table 1, SEQ lD N03: 402, 403, 404 or 405, as well as Factor P protein
binding domains and fragments (e.g.: SEQ lD N03: 406, 407 or 408). Factor P is also
know in the art as “Properdin”.
The term "conservatively modified variant" applies to both amino acid and nucleic
acid sequences. With respect to ular nucleic acid sequences, conservatively
modified variants refers to those nucleic acids which encode identical or ially
identical amino acid sequences, or where the nucleic acid does not encode an amino
acid sequence, to essentially identical sequences. Because of the degeneracy of the
c code, a large number of functionally identical nucleic acids encode any given
protein. For ce, the codons GCA, GCC, GCG and GCU all encode the amino acid
alanine. Thus, at every position where an alanine is specified by a codon, the codon can
be altered to any of the corresponding codons described without ng the d
polypeptide. Such nucleic acid variations are "silent variations," which are one species
of conservatively modified ions. Every nucleic acid sequence herein which
PCT/IBZOIZ/057394
encodes a polypeptide also describes every possible silent variation of the nucleic acid.
One of skill will recognize that each codon in a nucleic acid (except AUG, which is
ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for
tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each
silent variation of a nucleic acid that encodes a polypeptide is implicit in each described
sequence.
For polypeptide sequences, “conservatively modified variants” include individual
substitutions, deletions or additions to a polypeptide sequence which result in the
substitution of an amino acid with a chemically similar amino acid. Conservative
substitution tables providing functionally similar amino acids are well known in the art.
Such conservatively modified variants are in addition to and do not exclude polymorphic
variants, pecies homologs, and alleles of the invention. The ing eight groups
contain amino acids that are conservative substitutions for one another: 1) Alanine (A),
Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) gine (N), Glutamine (Q);
4) ne (R), Lysine (K); 5) Isoleucine (l), Leucine (L), Methionine (M), Valine (V); 6)
Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), ine (T); and 8)
Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)). In some
embodiments, the term "conservative sequence modifications" are used to refer to amino
acid modifications that do not significantly affect or alter the binding characteristics of the
antibody ning the amino acid sequence.
The term “epitope” means a protein determinant capable of specific binding to an
antibody. Epitopes usually consist of ally active e groupings of les
such as amino acids or sugar side chains and usually have specific three dimensional
structural characteristics, as well as specific charge characteristics. Conformational and
nonconformational es are distinguished in that the binding to the former but not the
latter is lost in the presence of denaturing solvents.
The term "human antibody", as used herein, is intended to include antibodies
having variable regions in which both the ork and CDR regions are derived from
sequences of human origin. Furthermore, if the dy contains a nt region, the
constant region also is derived from such human sequences, e.g., human germline
sequences, or mutated ns of human germline sequences. The human antibodies
of the invention may include amino acid residues not encoded by human sequences
(e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic
mutation in vivo).
The term ”human monoclonal antibody" refers to antibodies displaying a single
binding specificity which have variable regions in which both the framework and CDR
regions are derived from human sequences. in one embodiment, the human monoclonal
antibodies are produced by a hybridoma which includes a B cell obtained from a
transgenic nonhuman animal, e.g., a transgenic mouse, having a genome comprising a
human heavy chain transgene and a light chain transgene fused to an immortalized cell.
A "humanized" antibody is an antibody that retains the vity of a non-human
antibody while being less immunogenic in humans. This can be achieved, for ce,
by retaining the non—human CDR regions and replacing the remaining parts of the
antibody with their human counterparts (i.e., the constant region as well as the
framework ns of the variable region). See, e.g., Morrison et al., Proc. Natl. Acad.
Sci. USA, 81:6851—6855, 1984; Morrison and Oi, Adv. lmmunol., 44:65-92, 1988;
Verhoeyen et al., e, 239:1534-1536, 1988; Padlan, Molec. lmmun., 28:489-498,
1991; and Padlan, Molec. lmmun., 31 :169-217, 1994. Other examples of human
engineering logy include, but are not limited to Xoma technology disclosed in US
,766,886.
The terms “identical" or percent “identity,” in the context of two or more nucleic
acids or polypeptide sequences, refer to two or more sequences or subsequences that
are the same. Two sequences are "substantially cal" if two sequences have a
specified percentage of amino acid es or nucleotides that are the same (i.e., 60%
ty, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity over a
specified region, or, when not specified, over the entire sequence), when compared and
aligned for maximum correspondence over a comparison window, or designated region
as measured using one of the following sequence comparison algorithms or by manual
alignment and visual inspection. Optionally, the identity exists over a region that is at
least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region
that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in
length.
For sequence comparison, typically one sequence acts as a reference sequence,
to which test sequences are compared. When using a sequence comparison algorithm,
test and reference sequences are entered into a computer, subsequence coordinates are
designated, if necessary, and sequence algorithm m parameters are designated.
Default m parameters can be used, or alternative parameters can be designated.
The ce comparison thm then ates the percent ce identities for
WO 93762 2012/057394
the test sequences relative to the reference sequence, based on the program
parameters.
A “comparison window”, as used herein, includes reference to a segment of any
one of the number of contiguous positions selected from the group consisting of from 20
to 600, usually about 50 to about 200, more y about 100 to about 150 in which a
sequence may be compared to a reference sequence of the same number of contiguous
ons after the two sequences are optimally aligned. Methods of alignment of
sequences for ison are well known in the art. Optimal alignment of sequences for
comparison can be conducted, e.g., by the local homology algorithm of Smith and
Waterman (1970) Adv. Appl. Math. 224820, by the homology alignment algorithm of
Needleman and Wunsch, J. Mol. Biol. 482443, 1970, by the search for similarity method
of Pearson and Lipman, Proc. Natl. Acad. Sci. USA 852444, 1988, by computerized
implementations of these algorithms (GAP, BESTFlT, FASTA, and TFASTA in the
Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr.,
Madison, WI), or by manual alignment and visual inspection (see, 9.9., Brent et al.,
Current Protocols in Molecular y, John Wiley & Sons, Inc. (Ringbou ed., 2003)).
Two examples of algorithms that are suitable for determining percent sequence
identity and sequence rity are the BLAST and BLAST 2.0 algorithms, which are
described in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1977; and ul et al., J.
Mol. Biol. 215:403-410, 1990, respectively. re for performing BLAST analyses is
publicly available through the al Center for Biotechnology Information. This
algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying
short words of length W in the query sequence, which either match or satisfy some
positive—valued threshold score T when aligned with a word of the same length in a
database sequence. T is referred to as the neighborhood word score threshold (Altschul
et al., supra). These initial neighborhood word hits act as seeds for initiating searches to
find longer HSPs containing them. The word hits are extended in both directions along
each ce for as far as the cumulative alignment score can be increased.
Cumulative scores are calculated using, for nucleotide sequences, the parameters M
(reward score for a pair of matching es; always > 0) and N (penalty score for
mismatching es; always < 0). For amino acid sequences, a g matrix is used
to calculate the cumulative score. Extension of the word hits in each direction are halted
when: the cumulative alignment score falls off by the quantity X from its maximum
achieved value; the cumulative score goes to zero or below, due to the accumulation of
one or more negative-scoring residue alignments; or the end of either ce is
reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and
PCT/[82012/057394
speed of the alignment. The BLASTN program (for nucleotide sequences) uses as
defaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=-4 and a comparison
of both strands. For amino acid sequences, the BLASTP program uses as defaults a
ngth of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see
Henikoff and ff, Proc. Natl. Acad. Sci. USA 15, 1989) alignments (B) of 50,
expectation (E) of 10, M=5, N=-4, and a ison of both strands.
The BLAST algorithm also performs a statistical analysis of the similarity between
two sequences (see, e.g., Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5787,
1993). One measure of similarity provided by the BLAST algorithm is the smallest sum
probability (P(N)), which provides an indication of the probability by which a match
between two nucleotide or amino acid ces would occur by chance. For example,
a nucleic acid is considered similar to a reference sequence if the smallest sum
ility in a comparison of the test nucleic acid to the reference nucleic acid is less
than about 0.2, more preferably less than about 0.01, and most ably less than
about 0.001.
The percent identity between two amino acid sequences can also be determined
using the algorithm of E. Meyers and W. Miller (Comput. Appl. Blosci., 4:11-17, 1988)
which has been incorporated into the ALIGN program (version 2.0), using a PAM120
weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the
percent ty between two amino acid sequences can be determined using the
Needleman and Wunsch (J. Mol, Biol. 48:444-453, 1970) algorithm which has been
incorporated into the GAP program in the G06 software package (available on the world
wide web at gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap
weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
Other than percentage of sequence identity noted above, r indication that
two nucleic acid sequences or polypeptides are ntially identical is that the
polypeptide encoded by the first nucleic acid is immunologically cross reactive with the
antibodies raised against the polypeptide encoded by the second nucleic acid, as
described below. Thus, a polypeptide is lly substantially identical to a second
polypeptide, for example, where the two es differ only by conservative
substitutions. r tion that two nucleic acid sequences are substantially
identical is that the two molecules or their complements hybridize to each other under
stringent conditions, as described below. Yet another indication that two nucleic acid
sequences are substantially identical is that the same primers can be used to amplify the
sequence.
WO 93762 PCT/IBZOlZ/057394
The term “inhibit (or inhibits) the alternative complement pathway” refers to the
ability of Factor P antibodies to interfere with tion of the alternative complement
y. Specifically, “inhibit" refers to a statistically significant decrease (i.e., ) in
alternative complement activation as measured by one or more assays as described
herein, including MAC ion, hemolytic assay, or 03b deposition assay in a cell or
subject ing contact with an actor P dy or fragment f as described
herein relative to a control. As used herein, “inhibit (or inhibits) the alternative
complement pathway” can also refer to a clinically relevant improvement in visual
function or retinal anatomy following ent with an anti—Factor P antibody described
herein in a patient diagnosed with age related macular degeneration as described below.
The term "isolated antibody“ refers to an antibody that is substantially free of
other antibodies having different antigenic specificities (e.g., an isolated antibody that
specifically binds Factor P is substantially free of antibodies that specifically bind
antigens other than Factor P). An isolated antibody that specifically binds Factor P may,
however, have cross-reactivity to other antigens. Moreover, an ed antibody may be
substantially free of other cellular material and/or chemicals.
The term "isotype" refers to the antibody class (e.g., lgM, lgE, lgG such as lgG1
or lgG4) that is provided by the heavy chain constant region genes. lsotype also
includes modified versions of one of these classes, where modifications have been made
to alter the Fc function, for example, to enhance or reduce effector functions or binding to
Fc receptors.
The term "Kassoc" or "Ka", as used herein, is intended to refer to the association
rate of a particular antibody-antigen interaction, whereas the term "Kdis" or "Kd," as used
herein, is intended to refer to the dissociation rate of a particular antibody—antigen
interaction. The term "KD", as used herein, is intended to refer to the dissociation
constant, which is obtained from the ratio of Kd to Ka (i.e. Kd/Ka) and is sed as a
molar concentration (M). KD values for antibodies can be determined using methods well
established in the art. Methods for determining the KB of an antibody include measuring
surface plasmon resonance using a biosensor system such as a Biacore® system, or
ing affinity in solution by solution brium titration (SET).
The terms "monoclonal antibody" or "monoclonal antibody ition" as used
herein refer to a ation of antibody molecules of single molecular composition. A
monoclonal antibody composition displays a single binding specificity and affinity for a
particular epitope.
ZOIZ/057394
The term "nucleic acid" is used herein interchangeably with the term
“polynucleotide” and refers to deoxyribonucleotides or cleotides and rs
thereof in either single— or double—stranded form. The term encompasses nucleic acids
containing known nucleotide analogs or modified backbone residues or linkages, which
are synthetic, naturally occurring, and non—naturally occurring, which have similar binding
properties as the reference nucleic acid, and which are metabolized in a manner r
to the reference nucleotides. Examples of such analogs include, without limitation,
phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl
phosphonates, 2-O-methyl ribonucleotides, peptide—nucleic acids (PNAs).
Unless ise indicated, a ular nucleic acid ce also implicitly
encompasses conservatively modified variants thereof (e.g., degenerate codon
substitutions) and mentary sequences, as well as the sequence explicitly
indicated. Specifically, as detailed below, rate codon tutions may be
achieved by generating sequences in which the third position of one or more selected (or
all) codons is substituted with mixed-base and/or deoxyinosine residues r et al.,
Nucleic Acid Res. 1925081, 1991; Ohtsuka eta/., J. Biol. Chem. 260:2605-2608, 1985;
and Rossolini eta/., Mol. Cell. Probes 8:91-98, 1994).
The term "operably " refers to a functional relationship between two or more
polynucleotide (e.g., DNA) segments. Typically, the term refers to the functional
relationship of a transcriptional regulatory ce to a transcribed sequence. For
example, a promoter or enhancer sequence is operably linked to a coding sequence if it
stimulates or modulates the transcription of the coding sequence in an appropriate host
cell or other expression system. Generally, promoter transcriptional regulatory
sequences that are operably linked to a transcribed sequence are physically contiguous
to the transcribed sequence, i.e., they are cis—acting. However, some transcriptional
regulatory sequences, such as enhancers, need not be physically contiguous or located
in close proximity to the coding sequences whose transcription they enhance.
As used herein, the term, "optimized" means that a nucleotide sequence has
been altered to encode an amino acid sequence using codons that are preferred in the
tion cell or organism, generally a eukaryotic cell, for e, a cell of Pichia, a
Chinese Hamster Ovary cell (CHO) or a human cell. The optimized nucleotide sequence
is engineered to retain completely or as much as possible the amino acid sequence
originally encoded by the starting nucleotide sequence, which is also known as the
"parental" sequence. The zed sequences herein have been engineered to have
codons that are preferred in mammalian cells. However, optimized expression of these
PCT/{82012/057394
sequences in other eukaryotic cells or prokaryotic cells is also envisioned herein. The
amino acid sequences encoded by optimized nucleotide sequences are also referred to
as optimized.
The terms eptide“ and "protein" are used interchangeably herein to refer to
a polymer of amino acid residues. The terms apply to amino acid polymers in which one
or more amino acid residue is an artificial chemical mimetic of a corresponding naturally
occurring amino acid, as well as to naturally occurring amino acid rs and non-
naturally occurring amino acid polymer. Unless ise indicated, a particular
polypeptide sequence also implicitly encompasses conservatively modified variants
thereof.
The term "recombinant human antibody", as used herein, includes all human
antibodies that are prepared, expressed, created or isolated by inant means,
such as antibodies isolated from an animal (e.g., a mouse) that is transgenic or
transchromosomal for human globulin genes or a hybridoma prepared therefrom,
antibodies isolated from a host cell ormed to express the human antibody, e.g.,
from a transfectoma, antibodies ed from a recombinant, combinatorial human
antibody library, and antibodies prepared, expressed, created or isolated by any other
means that involve splicing of all or a portion of a human immunoglobulin gene,
sequences to other DNA sequences. Such recombinant human antibodies have variable
regions in which the ork and CDR regions are derived from human germline
immunoglobulin sequences. in certain embodiments, however, such recombinant human
dies can be ted to in vitro mutagenesis (or, when an animal transgenic for
human lg sequences is used, in vivo c mutagenesis) and thus the amino acid
sequences of the VH and VL s of the recombinant antibodies are sequences that,
while derived from and related to human germline VH and VL sequences, may not
naturally exist within the human antibody germline repertoire in vivo.
The term “recombinant host cell” (or simply “host cell”) refers to a cell into which a
recombinant expression vector has been introduced. It should be understood that such
terms are intended to refer not only to the particular subject cell but to the y of
such a cell. Because certain modifications may occur in succeeding generations due to
either mutation or environmental influences, such progeny may not, in fact, be identical
to the parent cell, but are still included within the scope of the term “host cell” as used
herein.
2012/057394
The term “subject" includes human and non-human animals. Non-human
animals e all vertebrates (e.g.: mammals and non-mammals) such as, non-human
primates (e.g.: cynomolgus monkey), sheep, dog, cow, chickens, amphibians, and
reptiles. Except when noted, the terms “patient” or “subject” are used herein
interchangeably. As used herein, the terms “cyno” or “cynomolgus” refer to the
cynomolgus monkey (Macaca fascicularis).
As used herein, the term “treating" or "treatment" of any e or disorder (i.e.,
AMD) refers in one embodiment, to ameliorating the disease or disorder (i.e., g or
arresting or reducing the development of the disease or at least one of the clinical
symptoms thereof). In another embodiment "treating" or "treatment" refers to alleviating
or ameliorating at least one physical parameter including those which may not be
discernible by the patient. In yet r embodiment, "treating" or "treatment" refers to
modulating the disease or disorder, either physically, (e.g., stabilization of a nible
symptom), physiologically, (e.g., stabilization of a physical parameter), or both. in yet
another embodiment, "treating" or "treatment" refers to preventing or delaying the onset
or development or ssion of the disease or disorder. “Prevention” as it relates to
AMD means any action that prevents or slows a ing in visual function, retinal
anatomy, and/or an AMD disease parameter, as described below, in a patient at rist for
said worsening. More specifically, “treatment” of AMD means any action that s in
the improvement or preservation of visual function and/or reginal anatomy. Methods for
assessing treatment and/or prevention of disease are known in the art and bed
hereinbelow.
The term “vector” is intended to refer to a polynucleotide molecule capable of
transporting another polynucleotide to which it has been linked. One type of vector is a
“plasmid”, which refers to a ar double stranded DNA loop into which additional DNA
segments may be ligated. Another type of vector is a viral vector, such as an adeno-
ated viral vector (AAV, or AAV2), wherein additional DNA segments may be
ligated into the viral genome. Certain vectors are capable of autonomous replication in a
host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of
replication and episomal mammalian s). Other vectors (e.g., non-episomal
mammalian vectors) can be ated into the genome of a host cell upon introduction
into the host cell, and thereby are replicated along with the host genome. Moreover,
certain vectors are e of ing the expression of genes to which they are
operatively linked. Such vectors are referred to herein as “recombinant expression
vectors” (or simply, ssion vectors”). In general, expression vectors of utility in
recombinant DNA techniques are often in the form of plasmids. in the present
PCT/IBZOlZ/057394
specification, “plasmid” and “vector” may be used interchangeably as the plasmid is the
most commonly used form of vector. However, the invention is intended to include such
other forms of expression vectors, such as viral vectors (e.g., replication defective
retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent
functions.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 Depicts the Factor P binding site. Firgure 1A illustrates the relative position
TSR5 domain of Factor P and the TSR5 sequence fragments: A, B, C and D. Figure 1B
shows the human TSR5 sequence aligned with the mouse sequence. Brackets te
the sequence fragments of TSR5. Figure 10 illustrates the antibodies bind to region B of
TSR5.
Figure 2 shows the results of a hemolytic assay trating inhibition of the
alternative ment y in 20% human serum.
Figure 3 shows an isobologram generated using the data from the tic assay
depicted in Figure 2.
Figure 4 shows the % inhibition of macrophage infiltrates in a mouse poly-IC model,
comparing the inhibition of anti-FactorP and anti-CS antibodies singly and in
combination.
Figure 5 shows an isobologram generated using the data from the poly—IC results
depicted in Figure 4.
DETAILED DESCRIPTION
The present invention is based, in part, on the ery of antibody molecules
that specifically bind to both human and cynomolgus Factor P. The invention s to
both full IgG format antibodies as well as n binding fragments thereof, such as Fab
fragments (e.g., see antibodies NVSQSS—S, NVSQGZ-S, NVS804 and NV8807 ).
Accordingly, the present ion provides antibodies that specifically bind to
Factor P (e.g., human Factor P, cynomolgus Factor P, rat Factor P, rabbit Factor P),
pharmaceutical compositions, production methods, and methods of use of such
dies and compositions.
PCT/IBZOlZ/057394
Factor P Antibodies & Antigen Binding Fragments
The present ion provides antibodies that specifically bind to Factor P. In
some embodiments, the present invention provides antibodies that specifically bind to
human, cynomolgus, rat and/or rabbit Factor P. Antibodies of the ion e, but
are not limited to, the human monoclonal antibodies and Fabs, isolated as described in
the es.
The present invention provides antibodies that specifically bind a Factor P n (e.g.,
human and/or cynmolgus Factor P), wherein the antibodies comprise a VH domain
having an amino acid sequence of SEQ lD NO: 7, 21, 35, 49, 63, 77, 91, 105, 119, 133,
147, 161, 175, 189, 203, 217, 231, 245, 259 or 273. The t invention also provides
antibodies that specifically bind to a Factor P protein, wherein the antibodies comprise a
VH CDR having an amino acid sequence of any one of the VH CDRs listed in Table 1,
infra. In particular, the invention provides antibodies that specifically bind to a Factor P
protein (e.g., human and/or cynomolgus Factor P), wherein the antibodies comprise (or
alternatively, consist of) one, two, three, or more VH CDRs having an amino acid
sequence of any of the VH CDRs listed in Table 1, infra.
The t invention provides antibodies that specifically bind to a Factor P
protein, said antibodies comprising a VL domain having an amino acid sequence of SEQ
ID NO: 8, 22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190, 204, 218, 232, 246,
260, or 274. The present invention also provides antibodies that cally bind to a
Factor P protein (e.g., human and/or cynomolgus Factor P), said dies comprising a
VL CDR having an amino acid sequence of any one of the VL CDRs listed in Table 1,
infra. In ular, the invention provides antibodies that specifically bind to a Factor P
protein (e.g., human and/or cynomolgus Factor P), said antibodies comprising (or
alternatively, consisting of) one, two, three or more VL CDRs having an amino acid
sequence of any of the VL CDRs listed in Table 1, infra.
Other antibodies of the invention include amino acids that have been mutated, yet
have at least 60, 70, 80, 85, 90 or 95 percent identity in the CDR regions with the CDR
regions depicted in the sequences described in Table 1. In some embodiments, it
includes mutant amino acid sequences wherein no more than 1, 2, 3, 4 or 5 amino acids
have been mutated in the CDR regions when compared with the CDR regions ed
in the sequence described in Table 1.
The present invention also provides nucleic acid sequences that encode VH, VL,
the full length heavy chain, and the full length light chain of the antibodies that
PCT/lBZOlZ/057394
specifically bind to a Factor P protein (e.g., human and/or cynomolgus Factor P). Such
nucleic acid sequences can be optimized for expression in mammalian cells (for
example, Table 1 shows the optimized nucleic acid sequences for the heavy chain and
htofanfibodbs<fitheinvenfionl
Table 1 Examples of Factor P dies, Fabs and Factor P Proteins
AMINO ACID SEQUENCE IDENTIFIER (SEQ.ID.NO:)AND SEQUENCE
SEQUENCE OR
POLYNUCLEOTIDE
(PN)
NV8962
CDRHl 1/281
SYAIS (Kabat)/ GGTFNSY (Chothia)
CDRHZ 2/282
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
“283
HGGYSFDS (Kabat)/ HGGYSFDS (Chothia)
“284
SKYVD (Kabat)/ DNLGSKY (Chothia)
“285
SDNNRPS (Kabat)/ SDN (Chothia)
“286
QTYTSGNNYL (Kabat)/ YTSGNNYL (Chothia)
VH 7
SGAEVKKPGSSVKVSCKASGGTFNSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSS
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVL
HEAVY CHAIN 9
SGAEVKKPGSSVKVSCKASGGTFNSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 10
PPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
KADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 11
SEQ.ID.NO:7 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAACAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
W0 2013(093762
—GTGACCGTGAGCTCA
PN ENCODING 12
SEQ.ID.NO:8 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN NG l3
SEQ.ID.NO:9 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAACAGCTAC
AGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING l4
SEQ.ID.NO:10 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
AGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
GGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
NV8963
CDRHl 15/287
SYAIS (Kabat)/ GGTFSSY (Chothia)
CDRH2 16/288
PINPYYGDAIYAQKFQG (Kabat)/ NPYYGD (Chothia)
CDRH3 17/289
YYSDYMDY (Kabat)/ YYSDYMDY (Chothia)
CDRLl 18/290
IGAGYDVH (Kabat)/ SSSNIGAGYD (Chothia)
CDRL2 19/291
DNSHRPS (Kabat)/ DNS (Chothia)
CDRL3 20/292
ASYDESAHS (Kabat)/ YDESAHS (Chothia)
VH 21
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GPINPYYGDAIYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
WO 93762
—ARYYSDYMDYWGQGTLVTVSS
QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKL
LIHDNSHRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASYDES
GGTKLTVL ,
HEAVY CHAIN 23
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GPINPYYGDAIYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARYYSDYMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 24
QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKL
LIHDNSHRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASYDES
AHSVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFY
PGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSH
RSYSCQVTHEGSTVEKTVAPTECS
PN ENCODING 25
SEQ.ID.NO:21 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTTAGCAGCTAC
AGCTGGGTGCGCCAGGCTCCAGGACAGGGCCTGGAATGGATG
GGCCCCATCAACCCCTACTACGGCGACGCCATCTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGC
GCCCGGTACTACAGCGACTACATGGACTACTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 26
SEQ.ID.NO:22 CAGTCAGTGCTGACCCAGCCTCCCTCTGTGTCTGGCGCCCCTGGCCAG
AGAGTGACCATCAGCTGCACCGGCTCCAGCAGCAACATCGGAGCTGGA
TACGACGTGCACTGGTATCAGCAGCTGCCCGGCACAGCCCCTAAGCTG
CTGATCCACGACAACAGCCACAGACCCAGCGGCGTGCCCGATAGATTC
AGCGGCAGCAAGAGCGGCACCAGCGCCAGCCTGGCCATCACCGGCCTG
CAGAGCGAGGACGAGGCCGACTACTACTGCGCCAGCTACGACGAGAGC
GCCCACAGCGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 27
SEQ.ID.NO:23 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTTAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCAGGACAGGGCCTGGAATGGATG
GGCCCCATCAACCCCTACTACGGCGACGCCATCTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGC
GCCCGGTACTACAGCGACTACATGGACTACTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
CTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 28
SEQ.ID.NO:24 CAGTCAGTGCTGACCCAGCCTCCCTCTGTGTCTGGCGCCCCTGGCCAG
AGAGTGACCATCAGCTGCACCGGCTCCAGCAGCAACATCGGAGCTGGA
TACGACGTGCACTGGTATCAGCAGCTGCCCGGCACAGCCCCTAAGCTG
CTGATCCACGACAACAGCCACAGACCCAGCGGCGTGCCCGATAGATTC
AGCGGCAGCAAGAGCGGCACCAGCGCCAGCCTGGCCATCACCGGCCTG
CAGAGCGAGGACGAGGCCGACTACTACTGCGCCAGCTACGACGAGAGC
PCT/IBZOIZ/057394
GCCCACAGCGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAG
CCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAG
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTAC
CCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAG
GCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTAC
GCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCAC
AGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAG
ACAGTGGCCCCTACAGAATGTTCA
CDRHl 29/293
SHYMH (Kabat)/ GYTFTSH (Chothia)
CDRH2 30/294
KINADLGDTNYAQKFQG )/ NADLGD (Chothia)
CDRH3 31/295
DGIEHGGHYYWGYLFDI (Kabat)/ DGIEHGGHYYWGYLFDI
(Chothia)
32/296
SGDSIREYYVH (Kabat)/ DSIREYY (Chothia)
CDRLZ 33/297
DDTNRPS (Kabat)/ DDT (Chothia)
CDRL3 34/298
AAWDFSPAI )/ WDFSPAI (Chothia)
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHYMHWVRQAPGQGLEWM
GKINADLGDTNYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYC
ARDGIEHGGHYYWGYLFDIWGQGTLVTVSS
SYELTQPPSVSVAPGQTARISCSGDSIREYYVHWYQQKPGQAPVLVIG
DDTNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCAAWDFSPAI
VFGGGTKLTVL
HEAVY CHAIN 37
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHYMHWVRQAPGQGLEWM
GKINADLGDTNYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYC
ARDGIEHGGHYYWGYLFDIWGQGTLVTVSSASTKGPSVFPLAPSSKST
SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 38
SYELTQPPSVSVAPGQTARISCSGDSIREYYVHWYQQKPGQAPVLVIG
DDTNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCAAWDFSPAI
VFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGA
VTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSY
EGSTVEKTVAPTECS
PN ENCODING 39
SEQ.ID.NO:35 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCTGGCGCC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCAGCCAC
TACATGCACTGGGTGCGCCAGGCTCCAGGACAGGGCCTGGAATGGATG
GGCAAGATCAACGCCGACCTGGGCGACACCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATGACCCGGGACACCAGCATCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGC
GCCAGGGACGGCATCGAGCACGGCGGCCACTACTACTGGGGCTACCTG
TTCGACATCTGGGGCCAGGGCACCCTGGTGACCGTGAGCTCA
PN ENCODING 4O
SEQ.ID.NO:36 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
AGAATCAGCTGCAGCGGCGACAGCATCCGGGAGTACTACGTG
CACTGGTATCAGCAGAAGCCCGGCCAGGCTCCTGTGCTGGTGATCGGC
W0 20131‘093762
ACCAACAGACCCAGCGGCATCCCCGAGAGATTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGATTACTACTGCGCCGCCTGGGACTTCAGCCCTGCCATC
GTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 41
SEQ.ID.NO:37 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCTGGCGCC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCAGCCAC
TACATGCACTGGGTGCGCCAGGCTCCAGGACAGGGCCTGGAATGGATG
GGCAAGATCAACGCCGACCTGGGCGACACCAACTACGCCCAGAAATTC
AGAGTGACCATGACCCGGGACACCAGCATCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGC
GCCAGGGACGGCATCGAGCACGGCGGCCACTACTACTGGGGCTACCTG
TTCGACATCTGGGGCCAGGGCACCCTGGTGACCGTGAGCTCAGCATCC
ACCAAGGGTCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACC
TCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC
GAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTG
CACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGC
AGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATC
GTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT
GAGCCCAAATCTTGT
PN ENCODING 42
SEQ.ID.NO:38 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAGCATCCGGGAGTACTACGTG
CACTGGTATCAGCAGAAGCCCGGCCAGGCTCCTGTGCTGGTGATCGGC
GACGACACCAACAGACCCAGCGGCATCCCCGAGAGATTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGATTACTACTGCGCCGCCTGGGACTTCAGCCCTGCCATC
GTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAGGCT
GCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCC
AACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCC
GTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTG
ACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGC
AGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTAC
AGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCC
GAATGTTCA
NV3966
CDRHl 43/299
NYWIG (Kabat)/ GYSFTNY (Chothia)
CDRH2 44/300
RIDPGESLTNYAPSFQG (Kabat)/ DPGESL (Chothia)
CDRH3 45/301
TGVADVDMPFAH (Kabat)/ TGVADVDMPFAH (Chothia)
CDRLl 46/302
SGDNLGSYYVN (Kabat)/ DNLGSYY (Chothia)
CDRL2 47/303
GDSERPS (Kabat)/ GDS (Chothia)
CDRL3 48/304
GSWDITSF (Kabat)/ WDITSF ia)
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWM
GRIDPGESLTNYAPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYC
ARTGVADVDMPFAHWGQGTLVTVSS
SYVLTQPPSVSVAPGKTARISCSGDNLGSYYVNWYQQKPGQAPVLVIY
ZOlZ/057394
GDSERPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCGSWDITSFV
FGGGTKLTVL
HEAVY CHAIN 51
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWM
GRIDPGESLTNYAPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYC
ARTGVADVDMPFAHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTA
ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 52
PPSVSVAPGKTARISCSGDNLGSYYVNWYQQKPGQAPVLVIY
SGIPERFSGSNSGNTATLTISRAQAGDEADYYCGSWDITSFV
FGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAV
TVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYS
CQVTHEGSTVEKTVAPTECS
PN ENCODING 53
SEQ.ID.NO:49 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAGCCTGGCGAG
AGCCTGAAGATCAGCTGCAAGGGCAGCGGCTACAGCTTCACCAACTAC
TGGATCGGCTGGGTGCGCCAGATGCCTGGCAAGGGCCTGGAATGGATG
GGCAGAATCGACCCCGGCGAGTCCCTGACCAACTACGCCCCCAGCTTC
CAGGGCCAGGTGACAATCAGCGCCGACAAGAGCATCAGCACCGCCTAT
CTGCAGTGGAGCAGCCTGAAGGCCAGCGACACCGCCATGTACTACTGC
GCCAGAACCGGCGTGGCCGACGTGGACATGCCTTTTGCCCACTGGGGC
CAGGGCACCCTGGTGACCGTGAGCTCA
PN NG 54
SEQ.ID.NO:50 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCTACTACGTG
AACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
GGCGACAGCGAGAGGCCTAGCGGCATCCCCGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCTCTAGAGCCCAGGCCGGC
GACGAGGCCGATTACTACTGCGGCTCCTGGGACATCACCAGCTTCGTG
TTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 55
SEQ.ID.NO:51 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAGCCTGGCGAG
AGCCTGAAGATCAGCTGCAAGGGCAGCGGCTACAGCTTCACCAACTAC
TGGATCGGCTGGGTGCGCCAGATGCCTGGCAAGGGCCTGGAATGGATG
GGCAGAATCGACCCCGGCGAGTCCCTGACCAACTACGCCCCCAGCTTC
CAGGGCCAGGTGACAATCAGCGCCGACAAGAGCATCAGCACCGCCTAT
CTGCAGTGGAGCAGCCTGAAGGCCAGCGACACCGCCATGTACTACTGC
ACCGGCGTGGCCGACGTGGACATGCCTTTTGCCCACTGGGGC
CAGGGCACCCTGGTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCG
GCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTG
TCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCT
GTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG
CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCAC
AAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 56
SEQ.ID.NO:52 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCTACTACGTG
AACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
GGCGACAGCGAGAGGCCTAGCGGCATCCCCGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCTCTAGAGCCCAGGCCGGC
GACGAGGCCGATTACTACTGCGGCTCCTGGGACATCACCAGCTTCGTG
TTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAGGCTGCC
CCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAAC
AAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTG
ACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAG
ACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGC
TATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGC
TGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCT
ACAGAATGTTCA
NV8965
CDRHl 57/305
SYAIS (Kabat)/ GGTFNSY (Chothia)
CDRH2 58/306
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
CDRH3 59/307
HGGYSFDS (Kabat)/ HGGYSFDS (Chothia)
CDRLl 60/308
SGDNLGSKYVD (Kabat)/ DNLGSKY (Chothia)
CDRL2 61/309
SDNNRPS (Kabat)/ SDN (Chothia)
CDRL3 62/310
ATYDSSPRTE (Kabat)/ YDSSPRTE (Chothia)
V 63
EVQLVQSGAEVKKPGSSVKVSCKASGGTFNSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSS
SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVL
HEAVY CHAIN 65
EVQLVQSGAEVKKPGSSVKVSCKASGGTFNSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 66
PPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
KADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 67
SEQ.ID.NO:63 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAACAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
CTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN NG 68
SEQ.ID.NO:64 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
AGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
TATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
PCT/IBZOIZ/057394
_—GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 69
SEQ.ID.NO:65 CAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAACAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
CTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 7O
SEQ.ID.NO:66 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
TTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
ACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
TATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
NVS967
c DRHl 71/3:1
SHYMH (Kabat)/ GYTFTSH (Chothia)
CDRH2 72/3;2
NINPVDGGTEYAQKFQG (Kabat)/ NPVDGG (Chothia)
CDRH3 73/3L3
DGIEHGGHYYWGYLFDI (Kabat)/ DGIEHGGHYYWGYLFDI
(Chothia)
CDRLl 74/3:4
SGDSIREYYVH (Kabat)/ DSIREYY (Chothia)
CDRLZ 75/315
DDTNRPS (Kabat)/ DDT (Chothia)
CDRL3 76/316
AAWDFSPAI )/ WDFSPAI (Chothia)
Iiillllllllllll 77 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHYMHWVRQAPGQGLEWM
GNINPVDGGTEYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYC
ARDGIEHGGHYYWGYLFDIWGQGTLVTVSS
vL 78
SYVLTQPPSVSVAPGKTARISCSGDSlREYYVHWYQQKPGQAPVLVIG
DDTNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCAAWDFSPAI
VFGGGTKLTVL
W0 2013I093762 ZOlZ/057394
SGAEVKKPGASVKVSCKASGYTFTSHYMHWVRQAPGQGLEWM
DGGTEYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYC
ARDGIEHGGHYYWGYLFDIWGQGTLVTVSSASTKGPSVFPLAPSSKST
SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 8O
SYVLTQPPSVSVAPGKTARISCSGDSIREYYVHWYQQKPGQAPVLVIG
DDTNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCAAWDFSPAI
VFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGA
VTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSY
SCQVTHEGSTVEKTVAPTECS
PN ENCODING 81
SEQ.ID.NO:77 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCTGGCGCC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCAGCCAC
TACATGCACTGGGTGCGCCAGGCTCCAGGACAGGGCCTGGAATGGATG
GGCAACATCAACCCCGTGGACGGCGGCACCGAGTACGCCCAGAAATTC
CAGGGCAGAGTGACCATGACCCGGGACACCAGCATCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGC
GCCAGGGACGGCATCGAGCACGGCGGCCACTACTACTGGGGCTACCTG
TTCGACATCTGGGGCCAGGGCACCCTGGTGACCGTGAGCTCA
PN ENCODING 82
SEQ.ID.NO:78 TCTTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAGCATCCGGGAGTACTACGTG
CACTGGTATCAGCAGAAGCCCGGCCAGGCTCCTGTGCTGGTGATCGGC
GACGACACCAACAGACCCAGCGGCATCCCCGAGAGATTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCTCTAGAGCCCAGGCCGGC
GACGAGGCCGATTACTACTGCGCCGCCTGGGACTTCAGCCCTGCCATC
GTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN NG 83
SEQ.ID.NO:79 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCTGGCGCC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTCACCAGCCAC
TACATGCACTGGGTGCGCCAGGCTCCAGGACAGGGCCTGGAATGGATG
GGCAACATCAACCCCGTGGACGGCGGCACCGAGTACGCCCAGAAATTC
CAGGGCAGAGTGACCATGACCCGGGACACCAGCATCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGC
GCCAGGGACGGCATCGAGCACGGCGGCCACTACTACTGGGGCTACCTG
TTCGACATCTGGGGCCAGGGCACCCTGGTGACCGTGAGCTCAGCCTCC
ACCAAGGGTCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACC
TCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC
GAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTG
CACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGC
AGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATC
TGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT
GAGCCCAAATCTTGT
PN NG 84
SEQ.ID.NO:8O TCTTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAGCATCCGGGAGTACTACGTG
CACTGGTATCAGCAGAAGCCCGGCCAGGCTCCTGTGCTGGTGATCGGC
GACGACACCAACAGACCCAGCGGCATCCCCGAGAGATTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCTCTAGAGCCCAGGCCGGC
GACGAGGCCGATTACTACTGCGCCGCCTGGGACTTCAGCCCTGCCATC
GTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAGGCT
TCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCC
AACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCC
GTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTG
GAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGC
PCT/132012/057394
AGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTAC
AGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCC
GAATGTTCA
85/317
SYAIS (Kabat)/ GGTFSSY (Chothia)
CDRH2 86/318
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
CDRH3 87/319
HGGYSYFDS (Kabat)/ HGGYYFDS (Chothia)
CDRLl 88/320
SKYVD (Kabat)/ DNLGSKY ia)
CDRL2 89/321
SDNNRPS (Kabat)/ SDN (Chothia)
CDRL3 90/322
QTYTSGNNYL (Kabat)/ YTSGNNYL (Chothia)
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYYFDSWGQGTLVTVSS
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVL
HEAVY CHAIN 93
SGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYYFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 94
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 95
SEQ.ID.NO:91 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
AGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACTACTTCGATAGCTGGGGCCAGGGCACCCTG
GTGAGCTCA
PN ENCODING 96
SEQ.ID.NO:92 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 97
SEQ.ID.NO:93 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
PCT/182012/057394
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
AGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
CACGGCGGCTACTACTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
CTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 98
SEQ. ID.NO:94 GAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
CDRHl 99/323
SYAIS (Kabat)/ GGTFSSY (Chothia)
CDRH2 100/324
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
CDRH3 101/325
HGGYIFDS (Kabat)/ HGGYIFDS (Chothia)
CDRLl 102/326
SGDNLGSKYVD (Kabat)/ DNLGSKY (Chothia)
CDRLZ 103/327
SDNNRPS (Kabat)/ SDN (Chothia)
CDRL3 104/328
QTYTSGNNYL (Kabat)/ YTSGNNYL (Chothia)
VH 105
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYIFDSWGQGTLVTVSS
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVL
HEAVY CHAIN 107
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
FGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYIFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSWTVPS S S
LGTQTY I CNVNHKPSNTKVDKRVEPKS C
W0 2013.1093762
LIGHT CHAIN 108
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 109
SEQ.ID.NO:105 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACATTTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 110
SEQ.ID.NO:106 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
GGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 111
SEQ.ID.NO:107 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACATTTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
CTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
ACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 112
SEQ.ID.NO:108 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
PCT/IBZOIZ/057394
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
steo6 —
CDRHl 113/329
SYAIS (Kabat) / GGTFSSY (Chothia)
CDRH2 114/330
RIIPIFGTANYAQKFQG (Rabat) / IPIFGT (Chothia)
CDRH3 115/331
HGGYVFDS (Kabat) / HGGYVFDS ia)
CDRLl 2
SKYVD (Kabat) / DNLGSKY (Chothia)
CDRL2 117/333
SDNNRPS (Kabat) / SDN (Chothia)
CDRL3 118/334
QTYTSGNNYL (Kabat) / YTSGNNYL (Chothia)
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYVFDSWGQGTLVTVSS
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVL
HEAVY CHAIN 121
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYVFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 122
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
KADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 123
SEQ.ID.NO:119 CAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
ATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACGTCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 124
SEQ.ID.NO:12O AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
TATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 125
SEQ.ID.NO:121 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
W0 20131093762
AAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
AGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACGTCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 126
SEQ.ID.NO:122 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
TTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
””3”
SYAIS (Kabat)/ GGTFSSY (Chothia)
128””
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
129/337
HGGYVFDS (Kabat)/ HGGYIFDS (Chothia)
130/338
SGDNLGSKYVD (Kabat)/ DNLGSKY (Chothia)
SDNNRPS (Kabat)/ SDN (Chothia)
”234‘”
PRTE (Kabat)/ YDSSPRTE (Chothia)
VH 133
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
IFDSWGQGTLVTVSS
lii|||||||||||||||| 134SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIYSDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRTEVFGGGTKLTVL
HEAVY CHAIN 135
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
FGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYIFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
2012/057394
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
ICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 136
SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING I37
SEQ.ID.NO:133 CAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACATTTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 138
SEQ.ID.NO:134 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 139
SEQ.ID.NO:135 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
CACGGCGGCTACATTTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 140
SEQ.ID.NO:136 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
CCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
AAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
SYAIS (Kabat)/ GGTFSSY (Chothia)
GTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
DS )/ HGGYYFDS (Chothia)
SGDNLGSKYVD (Kabat)/ DNLGSKY (Chothia)
C W
SDNNRPS (Kabat)/ SDN (Chothia)
PRTE (Kabat)/ YDSSPRTE (Chothia)
-EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMVH 147
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYYFDSWGQGTLVTVSS
IiiIIIIIIIIIIIII 148SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIYSDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRTEVFGGGTKLTVL
HEAVY CHAIN 149
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYYFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 150
SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 151
SEQ.ID.NO:147 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACTACTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 152
SEQ.ID.NO:148 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 153
.NO:149 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
CTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACTACTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACcCTCCTcCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 154
SEQ.ID.NO:150 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
AGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCc
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
CDRHl 155/347
SYAIS (Kabat)/ GGTFSSY ia)
CDRHZ 156/348
GTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
CDRH3 157/349
HGGYVFDS (Kabat)/ HGGYVFDS (Chothia)
CDRLl :58/350
SGDNLGSKYVD (Kabat)/ DNLGSKY (Chothia)
CDRLZ :59/351
SDNNRPS (Kabat)/ SDN (Chothia)
CDRL3 160/352
ATYDSSPRTE (Kabat)/ TE (Chothia)
VH I61
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYVFDSWGQGTLVTVSS
SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVL
HEAVY CHAIN 163
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYVFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 164
SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
2012/057394
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN NG 165
SEQ.ID.NO:161 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
CACGGCGGCTACGTCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 166
SEQ.ID.NO:162 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
TTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN NG 167
SEQ.ID.NO:163 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACGTCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 168
SEQ.ID.NO:164 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
CCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
NVS962—S
SYAIS (Kabat)/ GGTFSSY (Chothia)
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
HGGYSFDS (Kabat)/ HGGYSFDS (Chothia)
W0 20131093762
”“5”
SKYVD (Kabat)/ DNLGSKY (Chothia)
“33”
SDNNRPS (Kabat)/ SDN (Chothia)
””5”
QTYTSGNNYL )/ YTSGNNYL (Chothia)
-EVOLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMVH 175
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSS
IiiIIIIIIIIIIIIII 176SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIYSDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNYLVFGGGTKLTVL
HEAVY CHAIN 177
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 178
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 179
SEQ.ID.NO:175 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
CACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 180
SEQ.ID.NO:176 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
GGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 181
SEQ.ID.NO:177 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
ACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 182
.NO:178 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
TATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
CDRHl 183/359
SYAIS (Kabat)/ GGTFQSY (Chothia)
CDRHZ 184/360
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
CDRH3 185/361
HGGYSFDS (Kabat)/ HGGYSFDS ia)
CDRLl 186/362
SGDNLGSKYVD (Kabat)/ DNLGSKY (Chothia)
CDRL2 3
SDNNRPS (Kabat)/ SDN (Chothia)
CDRL3 188/364
QTYTSGNNYL (Kabat)/ YTSGNNYL (Chothia)
VH 189
EVQLVQSGAEVKKPGSSVKVSCKASGGTFQSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSS
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVL
HEAVY CHAIN 191
EVQLVQSGAEVKKPGSSVKVSCKASGGTFQSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 192
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING
PCT/IBZOlZ/057394
SEQ.ID.NO:189 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCCAAAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 194
SEQ.ID.NO:19O GAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
TATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 195
SEQ.ID.NO:191 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCCAAAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
CTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 196
SEQ.ID.NO:192 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
NV8962-S31A
SYAIS (Kabat)/ GGTE‘NAY (Chothia)
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
HGGYSFDS (Kabat)/ HGGYSFDS (Chothia)
SKYVD (Kabat)/ DNLGSKY (Chothia)
201/369
SDNNRPS (Kabat)/ SDN (Chothia)
CDRL3 0
NNYL (Kabat)/ YTSGNNYL (Chothia)
liillllllllllll 203EVQLVQSGAEVKKPGSSVKVSCKASGGTFNAYAISWVRQAPGQGLEWMGRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARHGGYSFDSWGQGTLVTVSS
Iiilllllllllllll 204SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIYSDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNYLVFGGGTKLTVL
HEAVY CHAIN 205
EVQLVQSGAEVKKPGSSVKVSCKASGGTFNAYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 206
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 207
SEQ.ID.NO:203 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAACGCCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
CTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 208
SEQ.ID.NO:204 AGCTACGAGCTGACTCAGCCCCCITCTGTGTCTGTGGCCCCTGGCCAG
AGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 209
SEQ.ID.NO:205 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAACGCCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
AGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PCT/IBZOlZ/057394
PN ENCODING 210
SEQ. ID.NO:206 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
CJRHl 211/371
SYAIS (Kabat)/ GGTFGSY (Chothia)
O 3RH2 212/372
RZIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
o 3RH3 3
HGGYSFDS (Kabat)/ HGGYSFDS (Chothia)
r) DRLl 214/374
SGDNLGSKYVD )/ DNLGSKY (Chothia)
O DRLZ 215/375
SDNNRPS (Kabat)/ SDN (Chothia)
0 3RL3 2:6/376
QTYTSGNNYL (Kabat)/ YTSGNNYL (Chothia)
<1:1: 2:7
EVQLVQSGAEVKKPGSSVKVSCKASGGTFGSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSS
<t‘i 218
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVL
HEAVY CHAIN 219
SGAEVKKPGSSVKVSCKASGGTFGSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 220
PPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN NG 221
SEQ. ID.NO:217 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCGGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
W0 20131093762
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 222
SEQ.ID.NO:218 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 223
SEQ.ID.NO:219 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCGGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
CTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
CACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
CTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 224
SEQ.ID.NO:220 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
TATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
CDRHI 225/377
SYAIS (Kabat)/ GGTFTSY (Chothia)
CDRHZ 8
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
CDRH3 227/379
HGGYSFDS (Kabat)/ HGGYSFDS (Chothia)
CDRLl 228/380
SGDNLGSKYVD (Kabat)/ DNLGSKY (Chothia)
CDRL2 229/381
SDNNRPS (Kabat)/ SDN (Chothia)
CDRL3 230/382
NNYL (Kabat))/ YTSGNNYL (Chothia)
PCT/IBZOIZ/057394
EVQLVQSGAEVKKPGSSVKVSCKASGGTFTSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSS
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVL
HEAVY CHAIN 233
EVQLVQSGAEVKKPGSSVKVSCKASGGTFTSYAISWVRQAPGQGLEWM
FGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 234
SYELTQPPSVSVAPGQTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTSGNNY
LVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 235
SEQ.ID.NO:23I CAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCACCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 236
SEQ.ID.NO:232 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 237
SEQ.ID.NO:233 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCACCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
CACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
CTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 238
SEQ.ID.NO:234 AGCTACGAGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCCAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
TATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
PCT/[82012/057394
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAG
GACGAGGCCGACTACTACTGCCAGACCTACACCAGCGGCAACAACTAC
CTGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
CCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
NVS965-T
23938”
SYAIS (Kabat)/ GGTFTSY (Chothia)
GTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
HGGYSEDS (Kabat)/ HGGYSFDS (Chothia)
SGDNLGSKYVD (Kabat)/ DNLGSKY (Chothia)
SDNNRPS (Kabat)/ SDN (Chothia)
“4388/
ATYDSSPRTE (Kabat)/ YDSSPRTE (Chothia)
IIIIIIIIIIH 245
EVQLVQSGAEVKKPGSSVKVSCKASGGTFTSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSS
llilllllllllllllll 246SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIYSDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRTEVFGGGTKLTVL
HEAVY CHAIN 247
EVQLVQSGAEVKKPGSSVKVSCKASGGTFTSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
SFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 248
SYVLTQPPSVSVAPGKTAR:SCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 249
.NO:245 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCACCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 250
SEQ.ID.NO:246 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
W0 20132‘093762
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING 251
SEQ.ID.NO:247 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCACCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
GTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 252
SEQ.ID.NO:248 GTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
NVS965-Q
SYAIS (Kabat)/ GGTFQSY (Chothia)
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT ia)
HGGYSFDS (Kabat)/ HGGYSFDS (Chothia)
SGDNLGSKYVD (Kabat)/ Y (Chothia)
SDNNRPS (Kabat)/ SDN (Chothia)
ATYDSSPRTE (Kabat)/ YDSSPRTE (Chothia)
Iii|||||||||||||| LVQSGAEVKKPGSSVKVSCKASGGTFQSYAISWVRQAPGQGLEWMGRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARHGGYSFDSWGQGTLVTVSS
Iiillllllllllllllll 260SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIYSDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
W0 20132093762
—EVFGGGTKLTVL
HEAVY CHAIN 261
EVQLVQSGAEVKKPGSSVKVSCKASGGTFQSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 262
SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
KADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 263
SEQ.ID.NO:259 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCCAAAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
AGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 264
SEQ.ID.NO:260 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN NG 265
.NO:26I CAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCCAAAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 266
SEQ.ID.NO:262 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
AAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACccTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
CDRHl 267/395
SYAIS (Kabat)/ GGTFSSY ia)
DRHZ 268/396
RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia)
DRH3 269/397
HGGYSFDS (Kabat)/ HGGYSFDS (Chothia)
3RL1 270/398
SGDNLGSKYVD (Kabat)/ DNLGSKY (Chothia)
O 3RL2 271/399
SDNNRPS (Kabat)/ SDN (Chothia)
O 3RL3 272/400
ATYDSSPRTE (Kabat)/ YDSSPRTE (Chothia)
L 273
SGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSS
L“ 274
SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVL
HEAVY CHAIN 275
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
FGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC
LIGHT CHAIN 276
SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
PN ENCODING 277
SEQ . ID.NO:273 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
AGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA
PN ENCODING 278
SEQ. ID.NO:274 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
TTCGGAGGCGGAACAAAGTTAACCGTCCTA
PN ENCODING
WO 2013093762 PCT/IBZOIZ/057394
SEQ.ID.NO:275 CAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
CACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
ACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT
PN ENCODING 280
SEQ.ID.NO:276 GTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
AAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
Human Factor P 40l
NP_OOll38724.l PVLCFTQYEESSGKCKGLLGGGVSVEDCCLNTAFAYQKRSGGLCQPCR
SPRWSLWSTWAPCSVTCSEGSQLRYRRCVGWNGQCSGKVAPGTLEWQL
QACEDQQCCPEMGGWSGWGPWEPCSVTCSKGTRTRRRACNHPAPKCGG
HCPGQAQESEACDTQQVCPTHGAWATWGPWTPCSASCHGGPHEPKETR
SRKCSAPEPSQKPPGKPCPGLAYEQRRCTGLPPCPVAGGWGPWGPVSP
CPVTCGLGQTMEQRTCNHPVPQHGGPFCAGDATRTHICNTAVPCPVDG
EWDSWGEWSPCIRRNMKSISCQEIPGQQSRGRTCRGRKFDGHRCAGQQ
QDIRHCYSIQHCPLKGSWSEWSTWGLCMPPCGPNPTRARQRLCTPLLP
KYPPTVSMVEGQGEKNVTFWGRPLPRCEELQGQKLVVEEKRPCLHVPA
CKDPEEEEL
Chimpanzee 402
Factor P MITEGAQAPCLLLPPLLLLLTLPATGSDPVLCFTQYEESSGKCKGLLG
XP_001136665.1 GGVSVKDCCLNTAYAYQERNGGLCQPCRSPRWSLWSTWAPCSVTCSEG
SQLRYRRCVGWNGQCSERVALGTLEWQLQACEDKQCCPEMGGWSDWGP
WEPCSVTCSKGMRTRRRACNHPAPKCGGHCPGEAQESEACDTQQVCPT
WGPWSPCSGSCHGGPHEPKETRSRTCSAPEPSQKPPGKPCPG
PAYE
PQHGGPSCAGDATRTHICNTAAPCPVDGEWDLWGQWSTCVRRNMKSIS
CEEIPGQQSRWRTCKGRKFDGHRCTGQQQDIRHCYSIQHCPLKGSWSE
WSTWGLCMPPCGPNPTRARQRLCTPLLPKYPPTVSMVEGQGEKNVTFW
GRPLPRCEELQGQKLVVEEKRPCLHVPACKDPEEEKL
Rat Factor P 403
NP_001100227.1 MPVGMQAPQWLLLLLLILPTTGSDPVLCFTQYEEPSGRCKGLLGRDIR
VEDCCLNTAYAFQEHDGGLCQSCRSPQWSAWSSWGPCSVTCSEGSQLR
HRRCVGRGGQCSEKAAPGTLEWQLQACEDQLCCPEMGGWSEWGPWGPC
SVTCSKGTQTRQRLCDNPAPKCGGHCPGEAQQSQACDTQKICPTHGAW
ASWGPWSACSGSCLGGAQEPKETRSRSCSAPAPSHQPPGKPCSGTAYE
HRGCSGLPPCPVAGGWGPWGPSSPCPVTCGLGQTLERRTCDHPVPRHG
GPFCAGDATRKHVCNTAMPCPVNGEWEAWGKWSHCSRVRMKSISCDEI
PGQQSRSRSCGGRKFDGQPCTGKLQDIRHCYDIHNCVLKGSWSQWSTW
GLCTPPCGPNPTRVRQRLCTPLLPKYSPTVSMVEGQGEKNVTFWGIPR
QGQKLVVEEKRPCLHVPSCRDPEEKKP
Rabbit Factor P 404
XP_002719931.1 PPLPLLLLPLLLTLPATGADPVVCFTEYDEPSGKCKGLLGGG
VSVEHCCLNAAYAFQEPGSGLCHACRSPLWSPWSAWAPCSVTCSEGSQ
LRHRRCVGQGGPCSEKAAPGTLQWQLQACEDQPCCPEIGGWSDWGPWR
PCSVTCSKGTKTRQRACDRPAPKCGGRCPGEAQESEACDTKQVCPTHG
LWAAWGPWSPCSGSCHGGPQVPKETRSRTCSAPEPSKQPPGKPCSGPA
YEEQSCAGLPPCPVAGGWGPWGPVSSCSVTCGLGKTLEKRTCDHPVPQ
HGGPFCTGDATRTHICNTAVPCPVNGEWEAWGEWSECSRPGRKSISCE
EVPGQQRRTRVCKGRKFDGQRCAGEYQDIRHCYNIQRCRLKGSWLEWS
SWGLCTPPCGPSPTRTRQRLCTALLPKFPPTISLVEGQGEKNVTFWGK
PWPQCEQLQGQKLVVEEKRPCLHVPACKDPEEKP
Mouse Factor P 405
NP_O32849.2 MPAEMQAPQWLLLLLVILPATGSDPVLCFTQYEESSGRCKGLLGRDIR
VEDCCLNAAYAFQEHDGGLCQACRSPQWSAWSLWGPCSVTCSEGSQLR
HRRCVGRGGQCSENVAPGTLEWQLQACEDQPCCPEMGGWSEWGPWGPC
SVTCSKGTQIRQRVCDNPAPKCGGHCPGEAQQSQACDTQKTCPTHGAW
ASWGPWSPCSGSCLGGAQEPKETRSRSCSAPAPSHQPPGKPCSGPAYE
HKACSGLPPCPVAGGWGPWSPLSPCSVTCGLGQTLEQRTCDHPAPRHG
GPFCAGDATRNQMCNKAVPCPVNGEWEAWGKWSDCSRLRMSINCEGTP
RSCGGRKFNGKPCAGKLQDIRHCYNIHNCIMKGSWSQWSTWS
LCTPPCSPNATRVRQRLCTPLLPKYPPTVSMVEGQGEKNVTFWGTPRP
LCEALQGQKLVVEEKRSCLHVPVCKDPEEKKP
TSRS Domain of 406
SEQ ID NO: 401 VDGEWDSWGEWSPCIRRNMKSISCQEIPGQQSRGRTCRGRKFDGHRCAGQQQD
IRHCYSIQHCP
domain PCIRRNMKSISCQEIPGQQSRGR
binding domain KSISC
TSRS Domain of 409
mouse SEQ ID VNGEWEAWGKWSDCSRLRMSINCEGTPGQQSRSRSCGGRKFNGKPCAGKLQDI
NO: 405 HNCI
Table 2 Examples of C5 Antibodies, Fabs and C5 Proteins
-_CDRH1 410
-_CDRH2 411
-_CDRH3 412
-—CDRL1 413
-_CDRLZ 414
-_CDRL3 415
PCT/IBZOIZ/057394
41 6
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIGPFFGTANYAQKFQG
RVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSS
41 7
PLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGS NSGN
TATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVL
41 8
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIGPFFGTANYAQKFQG
RVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKST
SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVN
HKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKA
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Light chain 41 9
SYELTQPLSVSVALGQTARITCSGDSI PNYYVYWYQQKPGQAPVLVIYDDSNRPSGlPERFSGSNSGN
TATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVLGQF’KAAPSVTLFPPSSEELQANKATLVC
PGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGST
VEKTVAPTECS
PN encoding 420
SEQ ID CAATTGGTTCAGTCTGGCGCGGAAGTGAAAAAACCGGGCAGCAGCGTGAAAGTGAGCT
NO:416 GCAAAGCCTCCGGAGGCACTTTTTCTTCTFATGCCATTTCTTGGGTGCGCCAAGCCCCTGGGCAG
GGTCTCGAGTGGATGGGCGGTATCGGTCCGTITTITGGCACTGCGAATTACGCGCAGAAGTTTCA
GGGCCGGGTGACCATTACCGCGGATGAAAGCACCAGCACCGCGTATATGGAACTGAGCAGCCTG
CGTAGCGAAGATACGGCCGTGTATTATTGCGCGCGTGATACTCCTTA'I'T'ITGATI'ATI'GGGGCCA
AGGCACCCTGGTGACGGTTAGCTCA
PN encoding 421
SEQ ID TCCTATGAACTCACACAGCCCCTGAGCGTGAGCGTGGCCCTGGGCCAGACCGCCCGGATCACCT
NO:417 GCTCCGGCGACAGCATCCCCAACTACTACGTGTACTGGTACCAGCAGAAGCCCGGCCAGGCCCC
CGTGCTGGTGATCTACGACGACAGCAACCGGCCCAGCGGCATCCCCGAGCGG'ITCAGCGGCAG
CAACAGCGGCAACACCGCCACCCTGACCATTTCCAGAGCACAGGCAGGCGACGAGGCCGACTA
CTACTGCCAGAGCTTCGACAGCAGCCTGAACGCCGAGGTGTTCGGCGGAGGGACCAAGTTAACC
GTCCTA
PN encoding 422
SEQ ID GAGGTGCAA'ITGGTI'CAGTCTGGCGCGGAAGTGAAAAAACCGGGCAGCAGCGTGAAAGTGAGCT
NO:418 GCAAAGCCTCCGGAGGCACTTTTTCTTCTTATGCCATTTCTI'GGGTGCGCCAAGCCCCTGGGCAG
GGTCTCGAGTGGATGGGCGGTATCGGTCCGTTTTTTGGCACTGCGAATTACGCGCAGAAGTTTCA
GGGCCGGGTGACCATTACCGCGGATGAAAGCACCAGCACCGCGTATATGGAACTGAGCAGCCTG
CGTAGCGAAGATACGGCCGTGTATTATTGCGCGCGTGATACTCCTTA'H‘ITGATTATTGGGGCCA
CCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG
AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTG
TCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGG
CACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT
GAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCGGGGG
GACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACC
GGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAA
GGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCC
CCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCC
TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA
GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC
AGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGC
ATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
PN encoding 423
SEQ ID TCCTATGAACTCACACAGCCCCTGAGCGTGAGCGTGGCCCTGGGCCAGACCGCCCGGATCACCT
NO:419 GCTCCGGCGACAGCATCCCCAACTACTACGTGTACTGGTACCAGCAGAAGCCCGGCCAGGCCCC
CGTGCTGGTGATCTACGACGACAGCAACCGGCCCAGCGGCATCCCCGAGCGGTTCAGCGGCAG
CAACAGCGGCAACACCGCCACCCTGACCATTTCCAGAGCACAGGCAGGCGACGAGGCCGACTA
CTACTGCCAGAGCTTCGACAGCAGCCTGAACGCCGAGGTGTTCGGCGGAGGGACCAAGTTAACC
GTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTC
AAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGC
CTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAG
CAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGA
AGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAAT
GTTCA
Optimized PN 424
encoding SEQ GAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCCGGTAGCAGCGTCAAGGTGTCC
|DNOA18 TGCAAGGCCAGCGGCGGCACCTTCAGCAGCTACGCCATCAGCTGGGTGCGGCAGGCCCCAGGC
CAGGGCCTGGAGTGGATGGGCGGCATCGGCCCATTCTTCGGCACCGCCAACTACGCCCAGAAG
TTCCAGGGCAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAGCTGTCCA
GCCTGAGAAGCGAGGACACCGCCGTGTACTACTGCGCCAGAGACACCCCCTACTTCGACTACTG
GGGCCAGGGCACCCTGGTGACCGTGAGCAGCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCT
GGCCCCCAGCAGCAAGAGCACCTCCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTA
CTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTT
CGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTCCAGCGTGGTGACAGTGCCCAGCAG
CAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGAC
AAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCCGAA
GCTGCAGGCGGCCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCA
GGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTCA
ACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACA
CCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGA
GTGCAAGGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAAAAGACCATCAGCAAGGCC
AAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCTTCTCGGGAGGAGATGACCAAG
AACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGG
AGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCA
GCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTGTTCAG
CTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCACCC
GGCAAG
Optimized PN 425
encoding SEQ AGCTACGAGCTGACCCAGCCCCTGAGCGTGAGCGTGGCCCTGGGCCAGACCGCCAGGATCACC
ID NO:419 TGCAGCGGCGACAGCATCCCCAACTACTACGTGTACTGGTATCAGCAGAAGCCCGGCCAGGCCC
CCGTGCTGGTGATCTACGACGACAGCAACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGCA
GCAACAGCGGCAACACCGCCACCCTGACCATCAGCAGAGCCCAGGCCGGCGACGAGGCCGACT
ACTACTGCCAGAGCTTCGACAGCTCACTGAACGCCGAGGTGTTCGGCGGAGGGACCAAGCTGAC
CGTGCTGGGCCAGCCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGAGCT
GCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTG
AAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAG
AGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACA
2012/057394
GGTCCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCG
AGTGCAGC
Antibody 8110 Sequence Identifier (SEQ ID NO:) and Sequence or comments
-_CDRH1 426
-_CDRHZ 427
-_CDRH3 428
-_CDRL1 429
-—CDRL2 430
-—CDRL3 431
VH 432
SGAEVKKPGESLKISCKGSGYSFTNYISWVRQMPGKGLEWMGIIDPDDSYTEYSPSFQGQV
TISADKSISTAYLQWSSLKASDTAMYYCARYEYGGFDIWGQGTLVTVSS
SYELTQPPSVSVAPGQTARISCSGDN |GNSWHWYQQKPGQAPVLVIYKDNDRPSGIPERFSGSNSG
NTATLTISGTQAEDEADYYCGTYDIESYVFGGGTKLTVL
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYISWVRQMPGKGLEWMGI |DPDDSYTEYSPSFQGQV
S ISTAYLQWSSLKASDTAMYYCARYEYGGFDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTS
GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNH
KPSNTKVDKRVEPKSCDKTHTCF’PCPAPEAAGGPSVFLFF’PKPKDTLMISRTPEVTCVWDVSHEDPE
VKFNWYVDGVEVH NAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDlAVEWESNGQPENNYKTI'PPVLDSDGSFFLY
SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Light chain 435
SYELTQPPSVSVAPGQTARISCSGDN |GNSYVHWYQQKPGQAPVLVIYKDNDRPSGIPERFSGSNSG
NTATLTISGTQAEDEADYYCGTYDIESWFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLIS
DFYPGAVTVAWKADSSPVKAGVETTTPSKQSN NKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVE
KTVAPTECS
PN encoding 436
SEQ ID GAGGTGCAATTGGTI'CAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT
N02432 GCAAAGGTTCCGGATATTCCTTTACTAATTATATTTC'ITGGGTGCGCCAGATGCCTGGGAAGGGT
CTCGAGTGGATGGGCATTATTGATCCTGATGATTCTI'ATACTGAGTATTCTCCTTC'TTTTCAGGGT
CAGGTCACCATTAGCGCGGATAAAAGCATTAGCACCGCGTATCTTCAATGGAGCAGCCTGAAAGC
GAGCGATACGGCCATGTATTATTGCGCGCGTTATGAGTATGGTGGT'ITTGATATI'TGGGGCCAAG
GCACCCTGGTGACGGTTAGCTCA
PN encoding 437
SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGT
NO:434 GTAGCGGCGATAATATTGGTAATI‘C'ITATGTI'CATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTTCTTGTGATTTATAAGGATAATGATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATI'ATTA‘IT
GCGGTACTI'ATGATATTGAGTC‘ITATGTGTTTGGCGGCGGCACGAAG'I'I'AACCGTCCTA
PN ng 488
SEQ ID GAGGTGCAA'I'TGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT
W0 093762
GCAAAGGTTCCGGATATTCCTTTACTAATTATATTTCTTGGGTGCGCCAGATGCCTGGGAAGGGT
CTCGAGTGGATGGGCATTATTGATCCTGATGATTCTTATACTGAGTATTCTCCTTCTTTTCAGGGT
CAGGTCACCATTAGCGCGGATAAAAGCAITAGCACCGCGTATCTTCAATGGAGCAGCCTGAAAGC
GAGCGATACGGCCATGTATTATTGCGCGCGTTATGAGTATGGTGGTTTTGATATTTGGGGCCAAG
GCACCCTGGTGACGGTIAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACCCTC
CTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCA
CCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGA
ATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCGGGGGGA
CCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGT
CACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC
GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGG
GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGG
TCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCG
ACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTG
ACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGC
CGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCAT
GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
PN encoding 439
SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGT
N02436 GTAGCGGCGATAATATTGGTAATTCTTATGTTCATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTTCTTGTGATTTATAAGGATAATGATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATT
GCGGTACTTATGATATTGAGTCTTATGTGTTTGGCGGCGGCACGAAGTTAACCGTCCTAGGTCAG
CCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGG
CCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGA
TAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTAC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCC
AGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA
Optimized PN 44o
ng SEQ GAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAAAAGCCCGGTGAGAGCCTGAAGATCAGC
iD NO:434 TGCAAGGGCAGCGGCTACAGCTTCACCAACTACATCAGCTGGGTGCGGCAGATGCCCGGCAAG
GGCCTGGAGTGGATGGGCATCATCGACCCCGACGACAGCTACACCGAGTACAGCCCCAGCTTCC
AGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCAGCACCGCCTACCTGCAGTGGAGCAGCC
TGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGATACGAGTACGGCGGCTTCGACATCTG
GGGCCAGGGCACCCTGGTGACCGTCAGCTCAGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCT
GGCCCCCAGCAGCAAGAGCACCTCCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTA
CTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTT
CCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTCCAGCGTGGTGACAGTGCCCAGCAG
CAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGAC
AAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCCGAA
GCTGCAGGCGGCCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCA
GGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTCA
ACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACA
ACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGA
AJACAAGTGCAAGGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAAAAGACCATCAGCAAGGCC
AAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCTTCTCGGGAGGAGATGACCAAG
AACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGG
PCT/IBZOIZ/057394
AGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCA
GCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTGTTCAG
CTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCACCC
GGCAAG
Optimized PN 441
encoding SEQ AGCTACGAGCTGACCCAGCCCCCCAGCGTGAGCGTGGCCCCAGGCCAGACCGCCAGGATCAGC
1D NO:435 TGCAGCGGCGACAACATCGGCAACAGCTACGTGCACTGGTATCAGCAGAAGCCCGGCCAGGCC
CCCGTGCTGGTGATCTACAAGGACAACGACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGC
AGCAACTCCGGCAACACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAGGACGAGGCCGAC
TACTACTGCGGCACCTACGACATCGAGTCATACGTGTI'CGGCGGAGGGACCAAGCTGACCGTGC
TGGGCCAGCCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGAGCTGCAGG
CCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTGGCCTG
GAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGCAA
CAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAGGTC
CTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTG
CAGC
Antibody 8111 Sequence Identifer (SEQ ID NO' l : ) and Sequence or comments
-_CDRH1 442
-_CDRH2 443
B 444
-_CDRL1 445
-—CDRL2 446
-—CDRL3 447
VH 448
EVTLKESGPALVKPTQTLTLTCTFSGFSLSTSGGGVSWIRQPPGKALEWLAN| DDADiKDYSPSLKSRL
TISKDTSKNQWLTMTNMDPVDTATYYCARGPYGFDSWGQGTLVTVSS
V 449
ESALTQPASVSGSPGQSITISCTGTSSDIGTYNYVSWYQQ
SGNTASLTISGLQAEDEADYYCQSYDSQSIVFGGGTKLTVL
Heavy chain 450
EVTLKESGPALVKPTQTLTLTCTFSGFSLSTSGGGVSWIRQPPGKALEWLANIDDADIKDYSPSLKSRL
TISKDTSKNQWLTMTNMDPVDTATYYCARGPYGFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTS
GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNH
VDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSH EDPE
VDGVEVH NAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Light chain 451
ESALTQPASVSGSPGQSiTlSCTGTSSDIGTYNYVSWYQQ
SGNTASLTiSGLQAEDEADYYCQSYDSQSIVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLV
CLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGS
TVEKTVAPTECS
PN encoding 452
SEQ ID GAGGTGACATTGAAAGAAAGCGGCCCGGCCCTGGTGAAACCGACCCAAACCCTGACCCTGACCT
WO 93762
GTACCT'ITTCCGGATTTAGCCTGTCTAC'ITCTGGTGGTGGTGTGTC'ITGGATTCGCCAGCCGCCT
GGGAAAGCCCTCGAGTGGCTGGCTAATA'ITGATGATGCTGATATTAAGGATTATI'CTCCTI'CTCTT
AAGTCTCGTCTGACCATTAGCAAAGATACTTCGAAAAATCAGGTGGTGCTGACTATGACCAACATG
GTGGATACGGCCACCTATTATTGCGCGCGTGGTCCTI'ATGGTFTTGATTCTTGGGGCCA
AGGCACCCTGGTGACGGTTAGCTCA
PN encoding 453
SEQ ID GAAAGCGCACTGACCCAGCCAGCTTCAGTGAGCGGCTCACCAGGTCAGAGCATTACCATCTCGT
N02449 GTACGGGTACTAGCAGCGATATTGGTACTTATAATTATGTGTCTI'GGTACCAGCAGCATCCCGGG
AAGGCGCCGAAACTTATGATTTATGATGATTCTAATCGTCCCTCAGGCGTGAGCAACCGTTTTAGC
GGATCCAAAAGCGGCAACACCGCGAGCCTGACCATTAGCGGCCTGCAAGCGGAAGACGAAGCG
GATI'ATTATTGCCAGTCTTATGATTCTCAGTCTATTGTGTTTGGCGGCGGCACGAAGTTAACCGTC
PN encoding 454
SEQ ID GAGGTGACATTGAAAGAAAGCGGCCCGGCCCTGGTGAAACCGACCCAAACCCTGACCCTGACCT
NO:450 GTACCTTTTCCGGATI'TAGCCTGTCTACTTCTGGTGGTGGTGTGTC‘ITGGATTCGCCAGCCGCCT
GGGAAAGCCCTCGAGTGGCTGGCTAATATTGATGATGCTGATATFAAGGATTATTCTCCTTCTCTI'
AAGTCTCGTCTGACCATTAGCAAAGATACTTCGAAAAATCAGGTGGTGCTGACTATGACCAACATG
GACCCGGTGGATACGGCCACCTATTATTGCGCGCGTGGTCCTTATGGTFTTGATTCTTGGGGCCA
CCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTI'CCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG
TGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTG
TCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGG
CACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT
GAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCGGGGG
GACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACC
GGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAA
GGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCC
CGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCC
TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA
GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTFCCTCTAC
AGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGC
ATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
PN encoding 455
SEQ ID GAAAGCGCACTGACCCAGCCAGCTTCAGTGAGCGGCTCACCAGGTCAGAGCATTACCATCTCGT
NO:451 GTACGGGTACTAGCAGCGATATTGGTACTTATAATTATGTGTCTTGGTACCAGCAGCATCCCGGG
AAGGCGCCGAAACTTATGATTTATGATGATTCTAATCGTCCCTCAGGCGTGAGCAACCGTTTTAGC
GGATCCAAAAGCGGCAACACCGCGAGCCTGACCATTAGCGGCCTGCAAGCGGAAGACGAAGCG
GATTATI'ATI'GCCAGTCTTATGATTCTCAGTCTATI'GTGTTTGGCGGCGGCACGAAGTTAACCGTC
CTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAG
CCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTG
GAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAAC
AACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCT
ACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTC
Optimized PN 456
encoding SEQ GAGGTGACCCTGAAGGAGAGCGGCCCAGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACT
ID NO:448 TGCACC'ITCAGCGGCTTCAGCCTGAGCACCAGCGGAGGGGGCGTGAGCTGGATCAGGCAGCCC
CCAGGTAAGGCCCTGGAGTGGCTGGCCAATATCGACGACGCCGATATCAAGGACTACAGCCCCA
PCT/IBZOIZ/057394
GCCTGAAGAGCAGGCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTGGTGCTGACCATGAC
CAATATGGACCCCGTGGACACCGCCACCTACTACTGCGCCAGAGGCCCCTACGGCTTCGACAGC
TGGGGCCAGGGCACCCTGGTGACCGTCAGCTCAGCTAGCACCAAGGGCCCCAGCGTGTTCCCC
CTGGCCCCCAGCAGCAAGAGCACCTCCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGAC
TACTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCT
TCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTCCAGCGTGGTGACAGTGCCCAGCA
GCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGA
CAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCCGA
AGCTGCAGGCGGCCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGC
AGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTC
AACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTAC
AACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAG
AATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAAAAGACCATCAGCAAGGC
CAAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCTTCTCGGGAGGAGATGACCAA
GAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGG
GAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGC
AGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTGTTCA
GCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCACC
CGGCAAG
OpmnMedPN 457
encoding SEQ GAGAGCGCCCTGACCCAGCCCGCCAGCGTGAGCGGCAGCCCAGGCCAGTCTATCACAATCAGC
ID NO:449 TGCACCGGCACCTCCAGCGATATCGGCACCTACAACTACGTGAGCTGGTATCAGCAGCACCCCG
GCAAGGCCCCCAAGCTGATGATCTACGACGACAGCAACAGGCCCAGCGGCGTGAGCAACAGGTT
CAGCGGCAGCAAGAGCGGCAACACCGCCAGCCTGACAATCAGCGGCCTGCAGGCCGAGGACGA
GGCCGACTACTACTGCCAGAGCTACGACAGCCAGTCAATCGTGTTCGGCGGAGGGACCAAGCTG
ACCGTGCTGGGCCAGCCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGAG
CTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGAC‘ITCTACCCAGGCGCCGTGACCG
TGGCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGC
AGAGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCA
CTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAAC
CGAGTGCAGC
Antibody 8113 Sequence Identifier (SEQ ID NO:) and Sequence or ts
CDRH1 SEQ ID NO:426
CDRHZ 458
IIDPDDSYTRYSPSFQG
CDRH3 SEQ ID NO:428
CDRL1 SEQ ID NO:429
CDRLZ SEQ ID NO:430
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYISWVRQMPGKGLEWMGIIDPDDSYTRYSPSFQGQV
TISADKSISTAYLQWSSLKASDTAMYYCARYEYGGFDIWGQGTLVTVSS
SYELTQPPSVSVAPGQTARISCSGDNIGNSYVHWYQQKPGQAPVLVIYKDNDRPSGIPERFSGSNSG
NTATLTISGTQAEDEADYYCATWGSEDQVFGGGTKLTVL
Heavychan 462
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYISWVRQMPGKGLEWMGHDPDDSYTRYSPSFQGQV
TISADKSISTAYLQWSSLKASDTAMYYCARYEYGGFDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTS
GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNH
PCT/lBZOlZ/057394
KPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLM| SRTPEVTCVWDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPI E KTISKAK
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTFPPVLDSDGSFFLY
SKLTVD KSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK
Light chain 463
SYELTQPPSVSVAPGQTARISCSGDN IGNSYVHWYQQKPGQAPVLVIYKDNDRPSGIPERFSGSNSG
NTATLT|SGTQAEDEADYYCATWGSEDQVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCL
IS DFYPGAVTVAWKADSSPVKAGVETTTPSKQSN NKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTV
EKTVAPTECS
PN encoding 464
SEQ ID GAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATFAGCT
N01460 GCAAAGGTTCCGGATATTCCTTTACTAATTATATFTCTTGGGTGCGCCAGATGCCTGGGAAGGGT
CTCGAGTGGATGGGCATTATCGATCCGGATGATAGCTATACCCGTTATTCTCCGAGCTITCAGGG
ACAGGTGACCATTAGCGCGGATAAAAGCATTAGCACCGCGTATCTTCAATGGAGCAGCCTGAAAG
ATACGGCCATGTATTATTGCGCGCGTTATGAGTATGGTGGTTTTGATATTTGGGGCCAA
GGCACCCTGGTGACGGTTAGCTCA
PN encoding 465
SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGT
N0:461 GTAGCGGCGATAATATTGGTAATI'CTTATGTTCATI'GGTACCAGCAGAAACCCGGGCAGGCGCCA
GTI'CTTGTGATITATAAGGATAATGATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATT
CTTGGGGTI'CTGAGGATCAGGTGTFTGGCGGCGGCACGAAGTTAACCGTCCTA
PN encoding 466
SEQ ID GAGGTGCAATTGGTI'CAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT
NO:462 GCAAAGGTTCCGGATATTCCTTTACTAATTATA‘I'I'TCTTGGGTGCGCCAGATGCCTGGGAAGGGT
CTCGAGTGGATGGGCATTATCGATCCGGATGATAGCTATACCCGTTATTCTCCGAGC‘ITTCAGGG
ACAGGTGACCATTAGCGCGGATAAAAGCATTAGCACCGCGTATC'ITCAATGGAGCAGCCTGAAAG
CGAGCGATACGGCCATGTATI'ATTGCGCGCGTTATGAGTATGGTGGTTITGATAT‘I’I‘GGGGCCAA
GGCACCCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACCCT
AGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG
AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTFCCCGGCTG
TCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTI'GGG
CACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT
GAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCGGGGG
GACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACC
GGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAA
GGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCC
CGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCC
TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA
GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC
AGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGC
ATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
PN ng 467
SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAGCG‘I'I'GCACCAGGTCAGACCGCGCGTATCTCGT
N02483 GTAGCGGCGATAATATI’GGTAA'I'I'CTTATGTTCATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTI'CTTGTGA'ITTATAAGGATAATGATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATT
GCGCTACTTGGGGTTCTGAGGATCAGGTGTTTGGCGGCGGCACGAAGTTAACCGTCCTAGGTCA
PCT/[32012/057394
GCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAG
GCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAG
ATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTA
CAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGC
CAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA
Optimized PN 468
encoding SEQ GAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAAAAGCCCGGTGAGAGCCTGAAGATCAGC
ID NO:462 TGCAAGGGCAGCGGCTACAGCTTCACCAACTACATCAGCTGGGTGCGGCAGATGCCCGGCAAG
GGCCTGGAGTGGATGGGCATCATCGACCCCGACGACAGCTACACCAGGTACAGCCCCAGCTTCC
AGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCAGCACCGCCTACCTGCAGTGGAGCAGCC
TGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGATACGAGTACGGCGGCTTCGACATCTG
GGGCCAGGGCACCCTGGTGACCGTCAGCTCAGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCT
GGCCCCCAGCAGCAAGAGCACCTCCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTA
CTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTT
CCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTCCAGCGTGGTGACAGTGCCCAGCAG
CAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGAC
AAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCCGAA
GCTGCAGGCGGCCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCA
GGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTCA
ACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACA
ACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGA
ATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAAAAGACCATCAGCAAGGCC
AAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCTTCTCGGGAGGAGATGACCAAG
AACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGG
AGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCA
TCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTGTTCAG
CTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCACCC
GGCAAG
Optimized PN 469
encoding SEQ AGCTACGAGCTGACCCAGCCCCCCAGCGTGAGCGTGGCCCCAGGCCAGACCGCCAGGATCAGC
iD NO:463 TGCAGCGGCGACAATATCGGCAACAGCTACGTGCACTGGTATCAGCAGAAGCCCGGCCAGGCCC
CCGTGCTGGTGATCTACAAGGACAACGACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGCA
GCAACTCCGGCAACACCGCCACCCTGACAATCAGCGGCACCCAGGCCGAGGACGAGGCCGACT
ACTACTGCGCCACCTGGGGCTCAGAGGACCAGGTGTTCGGCGGAGGGACCAAGCTGACCGTGC
AGCCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGAGCTGCAGG
CCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTGGCCTG
GAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGCAA
CAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAGGTC
CTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTG
CAGC
_CDRH1 470
-_CDRHZ 471
-_CDRH3 472
-_CDRL1 473
CDRL2 474
KDNNRPS
CDRL3 475
QTWDTGESGV
SGAEVKKPGESLKISCKGSGYSFTSYYIGWVRQMPGKGLEWMGI IDPTDSQTAYSPSFQGQ
VTISADKSISTAYLQWSSLKASDTAMYYCARYMMRGFDHWGQGTLVTVSS
SYELTQPPSVSVAPGQTARISCSGDSLGDYYAYWYQQKPGQAPVLVIYKDNNRPSGIPERFSGSNSG
NTATLTISGTQAEDEADYYCQTWDTGESGVFGGGTKLTVL
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYYIGWVRQMPGKGLEWMGIIDPTDSQTAYSPSFQGQ
KSISTAYLQWSSLKASDTAMYYCARYMMRGFDHWGQGTLVTVSSASTKGPSVFPLAPSSKS
TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NH KPS NTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSH E
DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTI
PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTI'PPVLDSDGS
LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Light chain 479
SYELTQPPSVSVAPGQTARISCSGDSLGDYYAYWYQQKPGQAPVLVIYKDNNRPSGIPERFSGSNSG
NTATLTISGTQAEDEADYYCQTWDTGESGVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLV
CLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGS
TVEKTVAPTECS
PN encoding 480
SEQ ID GAGGTGCAA'I'I'GGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT
NO:476 GCAAAGGTTCCGGATATTCCTTTACTTCTTATTATA'ITGGTTGGGTGCGCCAGATGCCTGGGAAG
GGTCTCGAGTGGATGGGCATTATTGATCCTACTGATI'CTCAGACTGCTI'ATI'CTCCTTCTTTTCAG
GGTCAGGTGACCATTAGCGCGGATAAAAGCATI'AGCACCGCGTATCTI'CAATGGAGCAGCCTGAA
AGCGAGCGATACGGCCATGTATTATTGCGCGCGTTATATGATGCGTGG'ITTI'GATCA'l—I'GGGGCC
AAGGCACCCTGGTGACGGTTAGCTCA
PN encoding 481
SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGT
NO:478 GTAGCGGCGATTCTCTTGGTGATTATTATGCTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTTCTTGTGATTTATAAGGATAATAATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATI'ATT
GCCAGACTTGGGATACTGGTGAGTCTGGTGTGT'ITGGCGGCGGCACGAAGTFAACCGTCCTA
PN encoding 482
SEQ ID GAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT
NO:479 GCAAAGGTTCCGGATATTCCTTTACTTCTTATTATATTGGTTGGGTGCGCCAGATGCCTGGGAAG
GGTCTCGAGTGGATGGGCATTATTGATCCTACTGATI'CTCAGACTGCITATTCTCCTTCTTTTCAG
GGTCAGGTGACCATTAGCGCGGATAAAAGCATTAGCACCGCGTATCTTCAATGGAGCAGCCTGAA
AGCGAGCGATACGGCCATGTAWTATI'GCGCGCGTTATATGATGCGTGGTTTTGATCATTGGGGCC
AAGGCACCCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTI'CCCCCTGGCACC
CTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC
GAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCT
GTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGG
GCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGT
TGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCGGGG
GGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGA
GGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTG
2012/057394
GACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTAC
CGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCA
AGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCC
CCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGC
CTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC
AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTA
GCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
PN encoding 483
SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGT
N02480 GTAGCGGCGATTCTCTTGGTGATTATTATGCTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTTCTTGTGATTTATAAGGATAATAATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATT
GCCAGACTTGGGATACTGGTGAGTCTGGTGTGTTTGGCGGCGGCACGAAGTTAACCGTCCTAGG
TCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAAC
AAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGG
CAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAA
GTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGC
TGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA
OpmnuedPN 484
encoding SEQ GAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAAAAGCCCGGTGAGAGCCTGAAGATCAGC
ID N02479 TGCAAGGGCAGCGGCTACAGCTTCACCAGCTACTACATCGGCTGGGTGCGGCAGATGCCCGGC
AAGGGCCTGGAGTGGATGGGCATCATCGACCCCACCGACAGCCAGACCGCCTACAGCCCCAGC
TTCCAGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCAGCACCGCCTACCTGCAGTGGAGCA
AGGCCAGCGACACCGCCATGTACTACTGCGCCCGGTACATGATGAGGGGCTTCGACCA
CTGGGGTCAGGGCACCCTGGTGACCGTCAGCTCAGCTAGCACCAAGGGCCCCAGCGTGTTCCC
CCTGGCCCCCAGCAGCAAGAGCACCTCCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGA
CTACTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACAC
CTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTCCAGCGTGGTGACAGTGCCCAG
CAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTG
GACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCC
GAAGCTGCAGGCGGCCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCA
GCAGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGT
TCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGT
ACAACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAA
AGAATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAAAAGACCATCAGCAAG
GCCAAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCTTCTCGGGAGGAGATGACC
AAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGT
GCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACG
GCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTGTT
CAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCA
CCCGGCAAG
Optimized PN 485
encoding SEQ AGCTACGAGCTGACCCAGCCCCCCAGCGTGAGCGTGGCCCCAGGCCAGACCGCCAGGATCAGC
ID NO:480 TGCAGCGGCGACAGCCTGGGCGACTACTACGCCTACTGGTATCAGCAGAAGCCCGGCCAGGCC
CCCGTGCTGGTGATCTACAAGGACAACAACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGCA
GCAACAGCGGCAACACCGCCACCCTGACAATCAGCGGCACCCAGGCCGAGGACGAGGCCGACT
ACTACTGCCAGACCTGGGACACCGGCGAGTCAGGCGTGTTCGGCGGAGGGACCAAGCTGACCG
TGCTGGGTCAGCCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGAGCTGC
AGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTGGC
PCT/IBZOIZ/057394
CTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAG
CAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAG
GTCCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGA
GTGCAGC
Other antibodies of the invention include those where the amino acids or nucleic
acids encoding the amino acids have been d, yet have at least 60, 65, 70, 75, 80,
85, 90, or 95 percent ty to the ces described in Table 1. Some
embodiments include mutant amino acid sequences wherein no more than 1, 2, 3, 4 or 5
amino acids have been mutated in the variable regions when ed with the le
regions depicted in the sequence described in Table 1, while retaining substantially the
same antigen binding activity.
Since each of these antibodies can bind to Factor P, the VH, VL, full length light
chain, and full length heavy chain sequences (amino acid sequences and the nucleotide
sequences encoding the amino acid sequences) can be "mixed and matched" to create
other Factor P-binding antibodies of the invention. Such "mixed and matched" Factor P-
binding dies can be tested using the binding assays known in the art (e.g., ELlSAs,
and other assays described in the Example section). When these chains are mixed and
matched, a VH sequence from a particular VH/VL pairing should be replaced with a
structurally similar VH sequence. Likewise a full length heavy chain sequence from a
particular full length heavy chain /full length light chain pairing should be replaced with a
structurally similar full length heavy chain ce. Likewise, a VL sequence from a
particular VH/VL pairing should be replaced with a structurally similar VL sequence.
Likewise a full length light chain sequence from a particular full length heavy chain / full
length light chain pairing should be replaced with a structurally similar full length light
chain sequence. Accordingly, in one aspect, the invention provides an isolated antibody
or antigen binding region thereof having: a heavy chain variable domain comprising an
amino acid sequence selected from the group ting of SEQ ID NOs: 7, 21, 35, 49,
63, 77, 91, 105, 119, 133, 147, 161, 175, 189, 203, 217, 231, 245, 259 and 273, and a
light chain variable domain comprising an amino acid sequence selected from the group
consisting of SEQ lD NOs: 8, 22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190,
204, 218, 232, 246, 260, and 274 wherein the antibody specifically binds to Factor P
(e.g., human and/or cynomolgus Factor P).
In another , the invention provides (i) an isolated antibody having: a full
length heavy chain comprising an amino acid sequence that has been optimized for
expression in a ian cell selected from the group consisting of SEQ ID NOs: 9,
PCT/IBZOIZ/057394
23, 37, 51, 65, 79, 93, 107, 121, 135, 149, 163, 177, 191, 205, 219, 233, 247, 261 and
275, and a full length light chain comprising an amino acid sequence that has been
zed for expression in a mammalian cell selected from the group consisting of SEQ
ID N03: 10, 24, 38, 52, 66, 80, 94, 108, 122, 136, 150, 164, 178, 192, 206, 220, 234,
248, 262 and 276; or (ii) a onal protein comprising an antigen binding portion
The terms “complementarity ining region,” and “CDR,” as used herein refer
to the sequences of amino acids within antibody variable regions which confer antigen
specificity and binding ty. in general, there are three CDRs in each heavy chain
variable region (HCDR1, HCDR2, HCDR3) and three CDRs in each light chain le
region (LCDR1, LCDR2, LCDR3).
The precise amino acid sequence boundaries of a given CDR can be readily
determined using any of a number of well-known schemes, including those bed by
Kabat et al. (1991), “Sequences of ns of immunological interest,” 5th Ed. Public
Health Service, National Institutes of Health, Bethesda, MD (“Kabat" numbering
scheme), Al—Lazikani et al., (1997) JMB 273,927-948 (“Chothia" numbering scheme).
For example, under Kabat, the CDR amino acid residues in the heavy chain
variable domain (VH) are numbered 31—35 (HCDR1), 50—65 (HCDR2), and 95-102
(HCDR3); and the CDR amino acid residues in the light chain variable domain (VL) are
numbered 24—34 (LCDR1), 50—56 (LCDRZ), and 89-97 (LCDR3). Under a the
CDR amino acids in the VH are numbered 26~32 (HCDR1), 52—56 (HCDR2), and 95-102
(HCDR3); and the amino acid residues in VL are numbered 26—32 (LCDR1), 50—52
(LCDRZ), and 91-96 (LCDR3). By combining the CDR definitions of both Kabat and
Chothia, the CDRs consist of amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and
95~102 (HCDR3) in human VH and amino acid residues 24-34 (LCDR1), 50—56 (LCDR2),
and 89-97 (LCDR3) in human VL.
in another , the present invention provides Factor P binding antibodies that
comprise the heavy chain and light chain CDR1s, CDR2s, and CDR3s as described in
Table 1, or combinations thereof. The amino acid sequences of the VH CDR1s of the
antibodies are shown in SEQ lD NOs: 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155,
169, 183, 197, 211, 225, 239, 253, or 267. The amino acid ces of the VH CDR2s
of the antibodies and are shown in SEQ ID NOs: 2, 16, 30, 44, 58, 72, 86, 100, 114, 128,
142, 156, 170, 184, 198, 212, 226, 240, 254, or 268. The amino acid sequences of the
VH CDR3S of the antibodies are shown in SEQ iD NOS: 3, 17, 31, 45, 59, 73, 87, 101,
115, 129, 143, 157, 171, 185, 199, 213, 227, 241, 255, or 269. The amino acid
sequences of the VL CDRts of the antibodies are shown in SEQ ID NOs: 4, 18, 32, 46,
60, 74, 88, 102, 116, 130, 144, 158, 172, 186, 200, 214, 228, 242, 256, or 270. The
amino acid sequences of the VL CDRZS of the antibodies are shown in SEQ ID NOs: 5,
19, 33, 47, 61, 75, 89, 103, 117, 131, 145, 159, 173, 187, 201, 215, 229, 243, 257, or
271. The amino acid sequences of the VL CDR3s of the antibodies are shown in SEQ
ID NOs: 6, 20, 34, 48, 62, 76, 90, 104, 118, 132, 146, 160, 174, 188, 202, 216, 230, 244,
258, or 272. These CDR regions are delineated using the Kabat system.
Alternatively, as defined using the Chothia system (AI-Lazikani et al., (1997) JMB
273,927-948) the amino acid sequences of the VH CDR1s of the antibodies are shown in
SEQ ID NOs: 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341, 347, 353, 359, 365,
371, 377, 383, 389, or 395. The amino acid sequences of the VH CDR2s of the
antibodies and are shown in SEQ ID N08: 282, 288, 294, 300, 306, 312, 318, 324, 330,
336, 342, 348, 354, 360, 366, 372, 378, 384, 390, or 396. The amino acid sequences of
the VH CDR3s of the antibodies are shown in SEQ ID NOs: 283, 289, 295, 301, 307,
313, 319, 325, 331, 337, 343, 349, 355, 361, 367, 373, 379, 385, 391, or 397. The
amino acid sequences of the VL CDR1s of the antibodies are shown in SEQ ID NOs:
284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 362, 368, 374, 380,
386, 392, or 398. The amino acid sequences of the VL CDR2s of the dies are
shown in SEQ ID NOs: 285, 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357,
363, 369, 375, 381, 387, 393, or 399. The amino acid sequences of the VL CDR3s of
the antibodies are shown in SEQ ID N03: 286, 292, 298, 304, 310, 316, 322, 328, 334,
340, 346, 352, 358, 364, 370, 376, 382, 388, 394, or 400.
Given that each of these antibodies can bind to Factor P and that antigen-binding
specificity is provided primarily by the CDR1, 2 and 3 regions, the VH CDR1, 2 and 3
sequences and VL CDR1, 2 and 3 ces can be "mixed and matched" (i.e., CDRs
from different antibodies can be mixed and matched, although each antibody preferably
ns a VH CDR1, 2 and 3 and a VL CDR1, 2 and 3 to create other Factor P binding
g molecules of the invention. Such "mixed and matched" Factor P g
antibodies can be tested using the binding assays known in the art and those bed
in the Examples (e.g., ELISAs, SET, Biacore). When VH CDR sequences are mixed and
matched, the CDR1, CDR2 and/or CDR3 sequence from a particular VH sequence
should be replaced with a urally similar CDR sequence(s). Likewise, when VL CDR
sequences are mixed and matched, the CDR1, CDR2 and/or CDR3 sequence from a
particular VL sequence should be replaced with a structurally similar CDR sequence(s).
It will be readily nt to the ordinarily skilled artisan that novel VH and VL sequences
can be created by tuting one or more VH and/or VL CDR region sequences with
structurally r sequences from the CDR sequences shown herein for monoclonal
antibodies of the present invention. In addition to the foregoing, in one embodiment, the
antigen binding fragments of the antibodies described herein can comprise a VH CDR1,
2, and 3, or a VL CDR 1, 2, and 3, wherein the fragment binds to Factor P as a single
variable domain.
In certain embodiments of the invention, the antibodies or n g
fragments thereof may have the heavy and light chain sequences of the Fabs described
in Table 1. More specifically, the antibody or antigen binding fragment thereof may have
the heavy and light sequence of Fab NVSQ62, NVSQBB, NV8964, NV8965, NV8966,
NV8967, NVS805, , NVS807, NVS808, NVS809, NV8962-S, NVSQSZ-Q,
NVSQ62-S31A, NVSQBZ-G, NVSQ62—T, NVSQGS-S, NV8965—T, or NV8965—Q.
In other ments of the invention the antibody or antigen g fragment in
that specifically binds Factor P ses a heavy chain variable region CDR1, a heavy
chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable
region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3
as defined by Kabat and described in Table 1. In still other embodiments of the invention
the antibody or antigen g nt in that specifically binds Factor P ses a
heavy chain variable region CDR1, a heavy chain variable region CDR2, a heavy chain
variable region CDR3, a light chain variable region CDR1, a light chain variable region
CDR2, and a light chain variable region CDR3 as defined by Chothia and described in
Table 1.
In a specific embodiment, the ion includes an antibody that specifically
binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO:1; a
heavy chain variable region CDR2 of SEQ ID NO: 2; a heavy chain variable region CDR3
of SEQ ID NO: 3; a light chain variable region CDR1 of SEQ ID NO: 4; a light chain
variable region CDR2 of SEQ ID NO: 5; and a light chain variable region CDR3 of SEQ
ID NO: 6. In another specific embodiment, the invention includes an antibody that
specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID
NO: 15; a heavy chain variable region CDR2 of SEQ ID NO: 16; a heavy chain variable
region CDR3 of SEQ ID NO: 17; a light chain variable region CDR1 of SEQ ID NO: 18; a
light chain variable region CDR2 of SEQ ID NO: 19; and a light chain variable region
CDR3 of SEQ ID NO: 20. In another specific embodiment, the invention includes an
antibody that specifically binds to Factor P comprising a heavy chain variable region
CDR1 of SEQ ID NO: 29; a heavy chain variable region CDR2 of SEQ ID NO: 30; a
heavy chain variable region CDR3 of SEQ ID NO: 31; a light chain variable region CDR1
of SEQ ID NO: 32; a light chain variable region CDR2 of SEQ ID NO: 33; and a light
chain le region CDR3 of SEQ ID NO: 34. In another specific embodiment, the
invention includes an antibody that specifically binds to Factor P comprising a heavy
chain variable region CDR1 of SEQ ID NO: 43; a heavy chain variable region CDR2 of
SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 45; a light chain
variable region CDR1 of SEQ ID NO: 46; a light chain variable region CDR2 of SEQ ID
NO: 47; and a light chain variable region CDR3 of SEQ ID NO: 48. In another specific
embodiment, the invention es an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 57; a heavy chain
le region CDR2 of SEQ ID NO: 58; a heavy chain variable region CDR3 of SEQ ID
NO: 59; a light chain variable region CDR1 of SEQ ID NO: 60; a light chain variable
region CDR2 of SEQ ID NO: 61; and a light chain le region CDR3 of SEQ ID NO:
62. In another specific embodiment, the invention es an antibody that specifically
binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 71; a
heavy chain variable region CDR2 of SEQ ID NO: 72; a heavy chain variable region
CDR3 of SEQ ID NO: 73; a light chain variable region CDR1 of SEQ ID NO: 74; a light
chain variable region CDR2 of SEQ ID NO: 75; and a light chain variable region CDR3 of
SEQ ID NO: 76. In another specific ment, the invention includes an antibody that
specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID
NO: 85; a heavy chain variable region CDR2 of SEQ ID NO: 86; a heavy chain variable
region CDR3 of SEQ ID NO: 87; a light chain variable region CDR1 of SEQ ID NO: 88; a
light chain variable region CDR2 of SEQ ID NO: 89; and a light chain le region
CDR3 of SEQ ID NO: 90. In r specific embodiment, the invention includes an
antibody that specifically binds to Factor P comprising a heavy chain variable region
CDR1 of SEQ ID NO: 99; a heavy chain variable region CDR2 of SEQ ID NO: 100; a
heavy chain variable region CDR3 of SEQ ID NO: 101; a light chain variable region
CDR1 of SEQ ID NO: 102; a light chain variable region CDR2 of SEQ ID NO: 103; and a
light chain variable region CDR3 of SEQ ID NO: 104. In another specific embodiment,
the ion includes an antibody that specifically binds to Factor P comprising a heavy
chain variable region CDR1 of SEQ ID NO: 113; a heavy chain variable region CDR2 of
SEQ ID NO: 114; a heavy chain variable region CDR3 of SEQ ID NO: 115; a light chain
variable region CDR1 of SEQ ID NO: 116; a light chain variable region CDR2 of SEQ ID
NO: 117; and a light chain le region CDR3 of SEQ ID NO: 118. In another specific
embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 ofSEQ ID NO: 127; a heavy chain
variable region CDR2 of SEQ ID NO: 128; a heavy chain variable region CDR3 of SEQ
ID NO: 129; a light chain variable region CDR1 of SEQ ID NO: 130; a light chain le
region CDR2 of SEQ ID NO: 131; and a light chain variable region CDR3 of SEQ ID NO:
132. In another specific embodiment, the invention includes an antibody that specifically
binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 141; a
heavy chain variable region CDR2 of SEQ ID NO: 142; a heavy chain variable region
CDR3 of SEQ ID NO: 143; a light chain variable region CDR1 of SEQ ID NO: 144; a light
chain variable region CDR2 of SEQ ID NO: 145; and a light chain le region CDR3
of SEQ ID NO: 146. In another specific embodiment, the invention includes an antibody
that specifically binds to Factor P comprising a heavy chain variable region CDR1 of
SEQ ID NO: 155; a heavy chain variable region CDR2 of SEQ ID NO: 156; a heavy
chain variable region CDR3 of SEQ ID NO: 157; a light chain variable region CDR1 of
SEQ ID NO: 158; a light chain variable region CDR2 of SEQ ID NO: 159; and a light
chain le region CDR3 of SEQ ID NO: 160. In another specific embodiment, the
invention includes an antibody that specifically binds to Factor P comprising a heavy
chain le region CDR1 of SEQ ID NO: 169; a heavy Chain variable region CDR2 of
SEQ ID NO: 170; a heavy chain variable region CDR3 ofSEQ ID NO: 171; a light chain
variable region CDR1 of SEQ ID NO: 172; a light chain variable region CDR2 of SEQ ID
NO: 173; and a light chain variable region CDR3 of SEQ ID NO: 174. In another specific
ment, the ion includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 183; a heavy chain
variable region CDR2 of SEQ ID NO: 184; a heavy chain variable region CDR3 of SEQ
ID NO: 185; a light chain variable region CDR1 of SEQ ID NO: 186; a light chain le
region CDR2 of SEQ ID NO: 187; and a light chain variable region CDR3 of SEQ ID NO:
188. In another specific embodiment, the invention includes an antibody that ically
binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 197; a
heavy chain variable region CDR2 of SEQ ID NO: 198; a heavy chain variable region
CDR3 of SEQ ID NO: 199; a light chain variable region CDR1 of SEQ ID NO: 200; a light
chain variable region CDR2 of SEQ ID NO: 201; and a light chain variable region CDR3
of SEQ ID NO: 202. In another specific embodiment, the invention includes an dy
that specifically binds to Factor P comprising a heavy chain variable region CDR1 of
SEQ ID NO: 211; a heavy chain variable region CDR2 of SEQ ID NO: 212; a heavy
chain variable region CDR3 of SEQ ID NO: 213; a light chain variable region CDR1 of
SEQ ID NO: 214; a light chain variable region CDR2 of SEQ ID NO: 215; and a light
chain variable region CDR3 of SEQ ID NO: 216. In another specific embodiment, the
invention includes an antibody that specifically binds to Factor P comprising a heavy
chain variable region CDR1 of SEQ ID NO: 225; a heavy chain variable region CDR2 of
SEQ ID NO: 226; a heavy chain variable region CDR3 of SEQ ID NO: 227; a light chain
variable region CDR1 of SEQ ID NO: 228; a light chain variable region CDR2 of SEQ ID
NO: 229; and a light chain variable region CDR3 of SEQ ID NO: 230. In another specific
embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 239; a heavy chain
variable region CDR2 of SEQ ID NO: 240; a heavy chain variable region CDR3 of SEQ
ID NO: 241; a light chain variable region CDR1 of SEQ ID NO: 242; a light chain variable
region CDR2 of SEQ ID NO: 243; and a light chain variable region CDR3 of SEQ ID NO:
244. In r specific embodiment, the ion includes an dy that specifically
binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 253; a
heavy chain variable region CDR2 of SEQ ID NO: 254; a heavy chain variable region
CDR3 of SEQ ID NO: 255; a light chain variable region CDR1 of SEQ ID NO: 256; a light
chain variable region CDR2 of SEQ ID NO: 257; and a light chain variable region CDR3
of SEQ ID NO: 258. In another specific embodiment, the invention includes an antibody
that specifically binds to Factor P comprising a heavy chain variable region CDR1 of
SEQ ID NO: 267; a heavy chain variable region CDR2 of SEQ ID NO: 268; a heavy
chain variable region CDR3 of SEQ ID NO: 269; a light chain le region CDR1 of
SEQ ID NO: 270; a light chain variable region CDR2 of SEQ ID NO: 271; and a light
chain le region CDR3 of SEQ ID NO: 271.
In another specific embodiment, the invention includes an antibody that
specifically binds to Factor P sing a heavy chain variable region CDR1 of SEQ ID
NO: 281; a heavy chain variable region CDR2 of SEQ ID NO: 282; a heavy chain
variable region CDR3 of SEQ ID NO: 283; a light chain variable region CDR1 of SEQ ID
NO: 284; a light chain variable region CDR2 ofSEQ ID NO: 285; and a light chain
variable region CDR3 of SEQ ID NO: 286. In another specific embodiment, the invention
includes an antibody that specifically binds to Factor P comprising a heavy chain variable
region CDR1 of SEQ ID NO: 287; a heavy chain variable region CDR2 of SEQ ID NO:
288; a heavy chain variable region CDR3 of SEQ ID NO: 289; a light chain variable
region CDR1 of SEQ ID NO: 290; a light chain variable region CDR2 of SEQ ID NO: 291;
and a light chain variable region CDR3 of SEQ ID NO: 292. In another specific
embodiment, the invention includes an dy that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 293; a heavy chain
variable region CDR2 of SEQ ID NO: 294; a heavy chain variable region CDR3 of SEQ
ID NO: 295; a light chain variable region CDR1 of SEQ ID NO: 296; a light chain variable
region CDR2 of SEQ ID NO: 297; and a light chain variable region CDR3 of SEQ ID NO:
298. In another specific embodiment, the invention es an antibody that specifically
binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 299; a
PCT/IBZOIZIOS7394
heavy chain variable region CDR2 of SEQ ID NO: 300; a heavy chain variable region
CDR3 of SEQ ID NO: 301; a light chain variable region CDR1 of SEQ ID NO: 302; a light
chain variable region CDR2 of SEQ ID NO: 303; and a light chain variable region CDR3
of SEQ ID NO: 304. In another specific embodiment, the invention includes an dy
that specifically binds to Factor P comprising a heavy chain variable region CDR1 of
SEQ ID NO: 305; a heavy chain variable region CDR2 of SEQ ID NO: 306; a heavy
chain variable region CDR3 of SEQ ID NO: 307; a light chain le region CDR1 of
SEQ ID NO: 308; a light chain variable region CDR2 of SEQ ID NO: 309; and a light
chain variable region CDR3 of SEQ ID NO: 310. In another specific embodiment, the
invention includes an antibody that specifically binds to Factor P comprising a heavy
chain variable region CDR1 of SEQ ID NO: 311; a heavy chain variable region CDR2 of
SEQ ID NO: 312; a heavy chain variable region CDR3 of SEQ ID NO: 313; a light chain
variable region CDR1 of SEQ ID NO: 314; a light chain le region CDR2 of SEQ ID
NO: 315; and a light chain variable region CDR3 of SEQ ID NO: 316. In another specific
embodiment, the invention includes an dy that specifically binds to Factor P
comprising a heavy chain le region CDR1 of SEQ ID NO: 317; a heavy chain
variable region CDR2 of SEQ ID NO: 318; a heavy chain variable region CDR3 of SEQ
ID NO: 319; a light chain variable region CDR1 of SEQ ID NO: 320; a light chain variable
region CDR2 of SEQ ID NO: 321; and a light chain variable region CDR3 of SEQ ID NO:
322. In another specific embodiment, the invention includes an antibody that specifically
binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 323; a
heavy chain variable region CDR2 of SEQ ID NO: 324; a heavy chain variable region
CDR3 of SEQ ID NO: 325; a light chain variable region CDR1 of SEQ ID NO: 326; a light
chain variable region CDR2 of SEQ ID NO: 327; and a light chain le region CDR3
of SEQ ID NO: 328. In another specific ment, the invention es an antibody
that specifically binds to Factor P comprising a heavy chain variable region CDR1 of
SEQ ID NO: 329; a heavy chain variable region CDR2 of SEQ ID NO: 330; a heavy
chain variable region CDR3 of SEQ ID NO: 331; a light chain variable region CDR1 of
SEQ ID NO: 332; a light chain variable region CDR2 of SEQ ID NO: 333; and a light
chain variable region CDR3 of SEQ ID NO: 334. In r specific embodiment, the
invention includes an antibody that specifically binds to Factor P comprising a heavy
chain variable region CDR1 of SEQ ID NO: 335; a heavy chain variable region CDR2 of
SEQ ID NO: 336; a heavy chain variable region CDR3 ofSEQ ID NO: 337; a light chain
variable region CDR1 of SEQ ID NO: 338; a light chain variable region CDR2 of SEQ ID
NO: 339; and a light chain variable region CDR3 of SEQ ID NO: 340. In another specific
embodiment, the invention es an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 ofSEQ ID NO: 341; a heavy chain
2012/057394
variable region CDR2 of SEQ ID NO: 342; a heavy chain le region CDR3 of SEQ
ID NO: 343; a light chain variable region CDR1 of SEQ ID NO: 344; a light chain variable
region CDR2 of SEQ ID NO: 345; and a light chain variable region CDR3 of SEQ ID NO:
346. In another specific embodiment, the invention includes an antibody that specifically
binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 347; a
heavy chain variable region CDR2 of SEQ ID NO: 348; a heavy chain variable region
CDR3 of SEQ ID NO: 349; a light chain le region CDR1 of SEQ ID NO: 350; a light
chain variable region CDR2 of SEQ ID NO: 351; and a light chain variable region CDR3
of SEQ ID NO: 352. In another specific embodiment, the ion includes an antibody
that specifically binds to Factor P comprising a heavy chain le region CDR1 of
SEQ ID NO: 353; a heavy chain variable region CDR2 of SEQ ID NO: 354; a heavy
chain variable region CDR3 of SEQ ID NO: 355; a light chain variable region CDR1 of
SEQ ID NO: 356; a light chain variable region CDR2 of SEQ ID NO: 357; and a light
chain variable region CDR3 of SEQ ID NO: 358. In another specific embodiment, the
invention includes an antibody that specifically binds to Factor P comprising a heavy
chain variable region CDR1 of SEQ ID NO: 359; a heavy chain variable region CDR2 of
SEQ ID NO: 360; a heavy chain le region CDR3 of SEQ ID NO: 361; a light chain
variable region CDR1 of SEQ ID NO: 362; a light chain variable region CDR2 of SEQ ID
NO: 363; and a light chain variable region CDR3 of SEQ ID NO: 364. In r specific
embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 365; a heavy chain
variable region CDR2 of SEQ ID NO: 366; a heavy chain variable region CDR3 of SEQ
ID NO: 367; a light chain variable region CDR1 of SEQ ID NO: 368; a light chain variable
region CDR2 of SEQ ID NO: 369; and a light chain variable region CDR3 of SEQ ID NO:
370. In another specific embodiment, the invention includes an antibody that specifically
binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 371; a
heavy chain variable region CDR2 of SEQ ID NO: 372; a heavy chain variable region
CDR3 of SEQ ID NO: 373; a light chain variable region CDR1 of SEQ ID NO: 374; a light
chain variable region CDR2 of SEQ ID NO: 375; and a light chain variable region CDR3
of SEQ ID NO: 376. In another specific embodiment, the invention includes an antibody
that specifically binds to Factor P comprising a heavy chain variable region CDR1 of
SEQ ID NO: 377; a heavy chain variable region CDR2 of SEQ ID NO: 378; a heavy
chain variable region CDR3 of SEQ ID NO: 379; a light chain variable region CDR1 of
SEQ ID NO: 380; a light chain le region CDR2 of SEQ ID NO: 381; and a light
chain variable region CDR3 of SEQ ID NO: 382. In another specific embodiment, the
invention includes an dy that cally binds to Factor P comprising a heavy
chain variable region CDR1 of SEQ ID NO: 383; a heavy chain variable region CDR2 of
PCT/IBZOIZ/057394
SEQ ID NO: 384; a heavy chain variable region CDR3 of SEQ ID NO: 385; a light chain
variable region CDR1 of SEQ ID NO: 386; a light chain variable region CDR2 of SEQ ID
NO: 387; and a light chain variable region CDR3 of SEQ iD NO: 388. In another specific
embodiment, the invention includes an antibody that ically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 389; a heavy chain
variable region CDR2 of SEQ ID NO: 390; a heavy chain variable region CDR3 of SEQ
ID NO: 391; a light chain le region CDR1 of SEQ ID NO: 392; a light chain variable
region CDR2 of SEQ ID NO: 393; and a light chain variable region CDR3 of SEQ ID NO:
394. In another specific embodiment, the invention includes an antibody that ically
binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 395; a
heavy chain variable region CDR2 of SEQ ID NO: 396; a heavy chain le region
CDR3 of SEQ ID NO: 397; a light chain variable region CDR1 of SEQ ID NO: 398; a light
chain variable region CDR2 of SEQ ID NO: 399; and a light chain variable region CDR3
of SEQ ID NO: 400.
In certain embodiments, the invention includes antibodies or n binding
fragments that specifically binds to Factor P as described in Table 1. In a red
embodiment, the antibody, or antigen binding fragment, that binds Factor P is Fab
NVS962, , , NV8965, NV8966, NV8967, NV8804, NV8805, NVSBOG,
, NV8808, NV8809, NVS962-S, NV8962-Q, NVS962-G, NV8962—T, NV8962-
831A, NV8965-T, NVS965—Q, or NVS965-S.
As used herein, a human antibody comprises heavy or light chain variable
s or full length heavy or light chains that are "the product of" or "derived from" a
particular germline sequence if the variable regions or full length chains of the antibody
are obtained from a system that uses human germline immunoglobulin genes. Such
systems include immunizing a transgenic mouse carrying human immunoglobulin genes
with the antigen of st or screening a human immunoglobulin gene library displayed
on phage with the antigen of interest. A human antibody that is "the product of" or
"derived from" a human germline immunoglobulin sequence can be identified as such by
comparing the amino acid ce of the human antibody to the amino acid sequences
of human germline immunoglobulins and selecting the human germline immunoglobulin
sequence that is closest in sequence (i.e., greatest % identity) to the sequence of the
human antibody. A human antibody that is "the product of" or "derived from” a particular
human germline immunoglobulin sequence may contain amino acid differences as
compared to the germline sequence, due to, for example, naturally ing somatic
mutations or intentional introduction of site-directed mutations. However, in the VH or VL
framework regions, a selected human dy typically is at least 90% identical in amino
acids sequence to an amino acid sequence encoded by a human germline
immunoglobulin gene and contains amino acid residues that identify the human antibody
as being human when compared to the germline immunoglobulin amino acid sequences
of other species (e.g., murine germline sequences). In certain cases, a human antibody
may be at least 60%, 70%, 80%, 90%, or at least 95%, or even at least 96%, 97%, 98%,
or 99% identical in amino acid sequence to the amino acid sequence encoded by the
germline immunoglobulin gene. Typically, a recombinant human antibody will display no
more than 10 amino acid differences from the amino acid sequence encoded by the
human germline immunoglobulin gene in the VH or VL framework regions. In certain
cases, the human antibody may display no more than 5, or even no more than 4, 3, 2, or
1 amino acid difference from the amino acid ce d by the germline
globulin gene. Examples of human germline immunoglobulin genes include, but
are not limited to the le domain germline fragments described below, as well as
DP47 and DPK9.
Homologous antibodies
In yet another embodiment, the present invention provides an antibody, or an
n binding fragment thereof, comprising amino acid sequences that are homologous
to the sequences described in Table 1, and the antibody binds to a Factor P n (9.9.,
human and/or cynomolgus Factor P), and retains the desired functional properties of
those antibodies described in Table 1.
For example, the invention es an ed antibody, or a functional antigen
binding fragment thereof, sing a heavy chain variable domain and a light chain
variable , wherein the heavy chain variable domain comprises an amino acid
sequence that is at least 80%, at least 90%, or at least 95% identical to an amino acid
sequence selected from the group ting of SEQ ID NOs: 7, 21, 35, 49, 63, 77, 91,
105, 119, 133, 147, 161, 175, 189, 203, 217, 231, 245, 259 and 273; the light chain
variable domain comprises an amino acid sequence that is at least 80%, at least 90%, or
at least 95% identical to an amino acid sequence selected from the group consisting of
SEQ lD NOs: 8, 22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190, 204, 218,
232, 246, 260, and 274; and the antibody specifically binds to Factor P (e.g., human
and/or cynomolgus Factor P).
in other embodiments, the VH and/or VL amino acid sequences may be 50%,
60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequences set forth
in Table 1. In other embodiments, the VH and/or VL amino acid sequences may be
PCT/182012/057394
identical except for an amino acid substitution in no more than 1,2,3,4 or 5 amino acid
positions. An antibody having VH and VL regions having high (i. e., 80% or greater)
identity to the VH and VL regions of those described in Table 1 can be obtained by
mutagenesis (e.g., site-directed or PCR-mediated mutagenesis) of nucleic acid
molecules encoding SEQ ID NOs: 7, 21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161,
175, 189, 203, 217, 231, 245, 259 or 273 and SEQ ID NOs: 8, 22, 36, 50, 64, 78, 92,
106, 120, 134, 148, 162, 176, 190, 204, 218, 232, 246, 260, or 274, tively,
followed by testing of the d altered antibody for retained function using the
functional assays described herein.
In other embodiments, the full length heavy chain and/or full length light chain
amino acid sequences may be 50% 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99%
identical to the sequences set forth in Table 1. An antibody having a full length heavy
chain and full length light chain having high (i.e., 80% or r) identity to the full length
heavy chains of any of SEQ ID NOs : 9, 23, 37, 51, 65, 79, 93, 107, 121, 135, 149, 163,
177, 191, 205, 219, 233, 247, 261 or 275, and full length light chains of any of SEQ ID
NOs 10, 24, 38, 52, 66, 80, 94, 108, 122, 136, 150, 164, 178, 192, 206, 220, 234, 248,
262, or 276, can be obtained by mutagenesis (e.g., site-directed or FOR-mediated
nesis) of nucleic acid molecules encoding such polypeptides, followed by testing
of the encoded altered antibody for ed function using the functional assays
described herein.
In other ments, the full length heavy chain and/or full length light chain
nucleotide sequences may be 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99%
identical to the sequences set forth in Table 1.
In other ments, the variable regions of heavy chain and/or the variable
regions of light chain nucleotide sequences may be 60%, 70%, 80%, 90%, 95%, 96%,
97%, 98% or 99% identical to the sequences set forth in Table 1.
As used herein, the percent identity between the two sequences is a function of
the number of identical positions shared by the ces (i.e., % identity equals
number of identical positions/total number of positions x 100), taking into account the
number of gaps, and the length of each gap, which need to be introduced for optimal
alignment of the two sequences. The comparison of sequences and determination of
percent identity between two sequences can be accomplished using a mathematical
algorithm, as bed in the non-limiting examples below.
2012/057394
Additionally or alternatively, the protein ces of the present invention can
further be used as a "query sequence" to perform a search against public databases to,
for e, identify related sequences. For example, such searches can be performed
using the BLAST program (version 2.0) of Altschul, et a/., 1990 J.Mol. Biol. 215:403-10.
Antibodies with Conservative Modifications
In certain embodiments, an antibody of the invention has a heavy chain variable
region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region
comprising CDR1, CDR2, and CDR3 sequences, wherein one or more of these CDR
sequences have specified amino acid sequences based on the antibodies described
herein or conservative modifications thereof, and wherein the dies retain the
desired functional properties of the Factor P-binding antibodies of the invention.
Accordingly, the invention provides an ed antibody, or a antigen binding fragment
f, consisting of a heavy chain variable region comprising CDR1, CDR2, and CDR3
sequences and a light chain variable region comprising CDR1, CDR2, and CDR3
sequences, wherein: the heavy chain variable region CDR1 amino acid ces are
selected from the group consisting of SEQ iD NOs: 1, 15, 29, 43, 57, 71, 85, 99, 113,
127, 141, 155, 169, 183, 197, 211, 225, 239, 253, and 267, and conservative
modifications thereof; the heavy chain variable region CDR2 amino acid sequences are
ed from the group consisting ofSEQ lD NOs: 2, 16, 30, 44, 58, 72, 86, 100, 114,
128, 142, 156, 170, 184, 198, 212, 226, 240, 254, and 268, and conservative
modifications thereof; the heavy chain variable region CDR3 amino acid sequences are
selected from the group consisting ofSEQ iD NOs: 3, 17, 31, 45, 59, 73, 87, 101, 115,
129, 143, 157, 171, 185, 199, 213, 227, 241, 255, and 269, and vative
modifications thereof; the light chain variable regions CDR1 amino acid sequences are
selected from the group consisting of SEQ ID NOs: 4, 18, 32, 46, 60, 74, 88, 102, 116,
130, 144, 158, 172, 186, 200, 214, 228, 242, 256, and 270, and conservative
modifications thereof; the light chain variable regions CDR2 amino acid sequences are
selected from the group consisting of SEQ lD NOs: 5, 19, 33, 47, 61, 75, 89, 103, 117,
131, 145, 159, 173, 187, 201, 215, 229, 243, 257, and 271, and conservative
modifications f; the light chain le regions of CDR3 amino acid sequences are
selected from the group consisting of SEQ ID NOS: 6, 20, 34, 48, 62, 76, 90, 104, 118,
132, 146, 160, 174, 188, 202, 216, 230, 244, 258, and 272, and conservative
modifications thereof; and the antibody or antigen binding fragment thereof specificaiiy
binds to Factor P.
WO 93762 PCT/132012/057394
in other ments, the antibody of the invention is optimized for expression in
a mammalian cell has a full length heavy chain sequence and a full length light chain
sequence, wherein one or more of these sequences have ied amino acid
ces based on the antibodies described herein or conservative modifications
thereof, and wherein the antibodies retain the desired functional properties of the Factor
P binding antibodies of the invention. Accordingly, the invention provides an isolated
antibody optimized for expression in a mammalian cell consisting of a full length heavy
chain and a full length light chain wherein the full length heavy chain has amino acid
sequences ed from the group of SEQ ID NOs: 9, 23, 37, 51, 65, 79, 93, 107, 121,
135, 149, 163, 177, 191, 205, 219, 233, 247, 261 and 275, and conservative
modifications thereof; and the full length light chain has amino acid sequences selected
from the group of SEQ lD NOs: 10, 24, 38, 52, 66, 80, 94, 108, 122, 136, 150, 164, 178,
192, 206, 220, 234, 248, 262, and 276, and vative modifications thereof; and the
antibody ically binds to Factor P (e.g., human and/or cynomolgus Factor P).
Antibodies That Bind to the Same Epitope
The present invention provides antibodies that bind to the same epitope as the
Factor P binding antibodies described in Table 1. Additional dies can therefore be
fied based on their ability to compete (e.g., to competitively inhibit the binding of, in
a statistically significant manner) with other antibodies of the invention in Factor P
binding assays (such as those described in the Examples). The ability of a test antibody
to inhibit the binding of antibodies of the present invention to a Factor P n
demonstrates that the test antibody can compete with that antibody for binding to Factor
P; such an antibody may, according to non-limiting theory, bind to the same or a related
(9.9., a structurally similar or spatially proximal) epitope on the Factor P protein as the
antibody with which it es. in a certain embodiment, the antibody that binds to the
same epitope on Factor P as the dies of the present invention is a human
monoclonal antibody. Such human monoclonal dies can be prepared and isolated
as described herein. As used herein, an antibody “competes" for binding when the
competing antibody inhibits Factor P binding of an antibody or n binding fragment
of the invention by more than 50%, in the presence of an equimolar concentration of
competing antibody.
In other embodiments the antibodies or antigen binding fragments of the
invention bind the Thrombospondin type 5 repeat (TSR 5) domain of Factor P (SEQ ID
NO: 406). In other embodiments the antibodies or antigen binding fragments of the
WO 93762 PCT/IBZOIZ/057394
invention bind a region of the Factor P TSR5 domain comprising SEQ ID NO: 407. Still
in other embodiments the region comprises SEQ ID NO: 408.
In other embodiments of the ion the isolated antibodies or antigen binding
fragments bind an epitope comprising SEQ ID NO: 407, and in other embodiments the
epitope comprises SEQ ID NO: 408. In other embodiments of the invention, the
antibodies or antigen binding fragments bind a peptide according to SEQ ID NO: 407 and
in still other embodiments the Factor P epitope includes SEQ ID NO: 408.
Engineered and Modified dies
An antibody of the Invention r can be prepared using an antibody having
one or more of the VH and/or VL sequences shown herein as starting material to
engineer a modified antibody, which modified antibody may have altered properties from
the starting antibody. An antibody can be engineered by modifying one or more residues
within one or both variable regions (i. e., VH and/or VL), for example within one or more
CDR regions and/or within one or more framework regions. Additionally or alternatively,
an antibody can be ered by modifying residues within the constant region(s), for
example to alter the effector function(s) of the antibody.
One type of variable region engineering that can be med is CDR grafting.
Antibodies interact with target antigens predominantly through amino acid residues that
are located in the six heavy and light chain complementarity determining regions .
For this reason, the amino acid sequences within CDRs are more diverse n
individual antibodies than sequences outside of CDRs. Because CDR ces are
responsible for most antibody-antigen interactions, it is le to express recombinant
antibodies that mimic the properties of specific naturally occurring antibodies by
constructing expression vectors that include CDR sequences from the specific naturally
ing antibody d onto framework sequences from a different antibody with
different properties (see, 9.9., Riechmann, L. et al., 1998 Nature 332:323-327; Jones, P.
etal., 1986 Nature 321:522—525; Queen, C. etal., 1989 Proc. Natl. Acad., U.S.A.
29—10033; US. Patent No. 5,225,539 to Winter, and US. Patent Nos. 5,530,101;
,585,089; 5,693,762 and 6,180,370 to Queen at al.)
Accordingly, another embodiment of the invention pertains to an isolated
antibody, or an antigen binding fragment thereof, comprising a heavy chain variable
region comprising CDR1 ces having an amino acid sequence selected from the
group ting of SEQ ID NOs: 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169,
183, 197, 211, 225, 239, 253, and 267; CDR2 sequences having an amino acid
PCT/[32012/057394
sequence selected from the group consisting of SEQ ID NOs: 2, 16, 30, 44, 58, 72, 86,
100, 114, 128, 142, 156, 170, 184, 198, 212, 226, 240, 254, and 268; CDR3 ces
having an amino acid ce selected from the group consisting of SEQ ID NOs: 3,
17, 31, 45, 59, 73, 87, 101, 115, 129, 143, 157, 171, 185, 199, 213, 227, 241, 255, and
269, respectively; and a light chain variable region having CDR1 sequences having an
amino acid ce selected from the group consisting of SEQ ID NOs: 4, 18, 32, 46,
60, 74, 88, 102, 116, 130, 144, 158, 172, 186, 200, 214, 228, 242, 256, and 270; CDR2
ces having an amino acid sequence selected from the group consisting of SEQ
ID NOs25, 19, 33, 47, 61, 75, 89, 103, 117, 131, 145, 159, 173, 187, 201, 215, 229, 243,
257, and 271; and CDR3 sequences consisting of an amino acid sequence selected from
the group consisting of SEQ ID NOs: 6, 20, 34, 48, 62, 76, 90, 104, 118, 132, 146, 160,
174, 188, 202, 216, 230, 244, 258, and 272, respectively. Thus, such antibodies contain
the VH and VL CDR sequences of monoclonal antibodies, yet may contain different
framework sequences from these antibodies.
Alternatively, another embodiment of the invention pertains to an isolated
antibody, or an n binding fragment thereof, comprising a heavy chain variable
region comprising CDR1 ces having an amino acid sequence selected from the
group consisting of SEQ ID N03: 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341,
347, 353, 359, 365, 371, 377, 383, 389, and 395; CDR2 sequences having an amino
acid sequence selected from the group consisting of SEQ ID N03: 282, 288, 294, 300,
306, 312, 318, 324, 330, 336, 342, 348, 354, 360, 366, 372, 378, 384, 390, and 396;
CDR3 ces having an amino acid sequence selected from the group consisting of
SEQ ID N03: 283, 289, 295, 301, 307, 313, 319, 325, 331, 337, 343, 349, 355, 361, 367,
373, 379, 385, 391, and 397, respectively; and a light chain le region having CDR1
sequences having an amino acid sequence selected from the group consisting of SEQ
ID NOs: 284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 362, 368, 374,
380, 386, 392, and 398; CDR2 sequences having an amino acid sequence selected from
the group consisting of SEQ ID NOs: 285, 291, 297, 303, 309, 315, 321, 327, 333, 339,
345, 351, 357, 363, 369, 375, 381, 387, 393, and 399; and CDR3 sequences consisting
of an amino acid ce selected from the group consisting of SEQ ID NOs: 286, 292,
298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394,
and 400, respectively. Thus, such antibodies contain the VH and VL CDR sequences of
monoclonal antibodies, yet may contain different framework sequences from these
antibodies.
Such framework sequences can be obtained from public DNA databases or
published references that include germline antibody gene sequences. For example,
germline DNA sequences for human heavy and light chain variable region genes can be
found in the “VBase” human germline sequence database (available on the world wide
web at mrc- cpe.cam.ac.uk/vbase), as well as in Kabat, E. A., et al., 1991 Sequences of
Proteins of Immunological interest, Fifth Edition, U.S. Department of Health and Human
Services, NIH Publication No. 91-3242; Tomlinson, l. M., eta/., 1992 J. Mol. Biol.
227:776-798; and Cox, J. P. L. et al., 1994 Eur. J lmmunol. 24:827—836; the contents of
each of which are expressly incorporated herein by reference.
An example of framework sequences for use in the antibodies of the invention are
those that are urally similar to the framework sequences used by selected
antibodies of the invention, e.g., consensus sequences and/or framework sequences
used by monoclonal antibodies of the invention. The VH CDR1, 2 and 3 sequences, and
the VL CDR1, 2 and 3 sequences, can be grafted onto framework regions that have the
identical sequence as that found in the germline immunoglobulin gene from which the
framework sequence derive, or the CDR sequences can be grafted onto framework
regions that contain one or more mutations as compared to the germline sequences. For
example, it has been found that in n instances it is cial to mutate residues
within the framework regions to maintain or enhance the antigen binding ability of the
antibody (see 6.9., US. Patent Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 to
Queen et al). Frameworks that can be utilized as scaffolds on which to build the
dies and antigen binding fragments described herein e, but are not limited to
VH1A, VH1 B, VH3, Vk1, Vl2, and Vk2. onal frameworks are known in the art and
may be found, for example, in the vBase data base on the world wide web at vbase.mrc~
m.ac.uk/index.ph p?&MMN_position=1 :1 .
Accordingly, an embodiment of the invention relates to isolated Factor P binding
antibodies, or antigen g fragments thereof, comprising a heavy chain variable
region comprising an amino acid sequence selected from the group consisting of SEQ lD
NOs: 7, 21, 35, 49, 63, 77, 91, 105, 119,133,147,161,175, 189, 203, 217, 231, 245,
259 and 273, or an amino acid sequence having one, two, three, four or five amino acid
tutions, deletions or additions in the framework region of such sequences, and
further comprising a light chain variable region having an amino acid sequence selected
from the group consisting ofSEQ ID NOs: 8, 22, 36, 50, 64, 78, 92, 106, 120, 134, 148,
162, 176, 190, 204, 218, 232, 246, 260, and 274, or an amino acid sequence having one,
two, three, four or five amino acid tutions, deletions or additions in the framework
region of such sequences.
PCT/IBZOIZ/057394
r type of variable region ation is to mutate amino acid residues
within the VH and/or VL CDR1, CDR2 and/or CDR3 regions to thereby improve one or
more binding properties (e.g., ty) of the antibody of interest, known as “affinity
maturation." Site-directed nesis or PCR-mediated mutagenesis can be performed
to introduce the mutation(s) and the effect on antibody binding, or other functional
property of st, can be evaluated in in vitro or in vivo assays as described herein and
provided in the Examples. Conservative modifications (as sed above) can be
introduced. The ons may be amino acid substitutions, additions or deletions.
Moreover, typically no more than one, two, three, four or five residues within a CDR
region are altered.
Accordingly, in another embodiment, the invention provides isolated Factor P-
binding antibodies, or antigen binding fragments f, consisting of a heavy chain
variable region having a VH CDR1 region consisting of an amino acid sequence selected
from the group having SEQ lD NOs: 1, 15,29, 43, 57, 71, 85,99, 113, 127, 141, 155,
169, 183, 197, 211, 225, 239, 253, and 267 or an amino acid sequence having one, two,
three, four or five amino acid substitutions, deletions or ons as compared to SEQ lD
NOs: 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239,
253, or 267; a Vl-l CDR2 region having an amino acid sequence selected from the group
consisting of SEQ ID NOs: 2, 16, 30, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184,
198, 212, 226, 240, 254, and 268 or an amino acid sequence having one, two, three, four
or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs: 2,
16, 30,44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184, 198, 212,226, 240, 254, or
268; a VH CDR3 region having an amino acid sequence selected from the group
consisting of SEQ ID NOs: 3, 17, 31, 45, 59, 73, 87, 101, 115, 129, 143, 157, 171, 185,
199, 213, 227, 241, 255, and 269, or an amino acid sequence having one, two, three,
four or five amino acid substitutions, deletions or additions as compared to SEQ lD NOs:
3, 17, 31,45, 59, 73, 87, 101, 115, 129, 143, 157, 171, 185, 199,213,227, 241, 255, or
269; a VL CDR1 region having an amino acid sequence selected from the group
consisting of SEQ ID NOs: 4, 18, 32, 46, 60, 74, 88, 102, 116, 130, 144, 158, 172, 186,
200, 214, 228, 242, 256, and 270, or an amino acid sequence having one, two, three,
four or five amino acid substitutions, deletions or ons as compared to SEQ ID NOs:
4, 18, 32, 46, 60, 74, 88, 102, 116, 130, 144, 158, 172, 186, 200, 214, 228,242, 256, or
270; a VL CDR2 region having an amino acid sequence selected from the group
consisting of SEQ ID NOs: 5, 19, 33, 47, 61, 75, 89, 103, 117, 131, 145, 159, 173, 187,
201, 215, 229, 243, 257, and 271, or an amino acid sequence having one, two, three,
four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs:
PCT/IBZOIZ/057394
, 19, 33, 47, 61, 75, 89, 103, 117, 131, 145, 159, 173, 187, 201, 215, 229, 243, 257, or
271; and a VL CDR3 region having an amino acid ce selected from the group
ting of SEQ ID NOS: 6, 20, 34, 48, 62, 76, 90, 104, 118, 132, 146, 160, 174, 188,
202, 216, 230, 244, 258, and 272, or an amino acid sequence having one, two, three,
four or five amino acid substitutions, deletions or additions as compared to SEQ ID NOs:
6, 20, 34,48, 62, 76,90, 104, 118, 132, 146, 160, 174, 188, 202, 216,230,244, 258, or
272.
Accordingly, in another embodiment, the invention provides isolated Factor P—
binding antibodies, or antigen binding fragments thereof, consisting of a heavy chain
variable region having a VH CDR1 region consisting of an amino acid sequence selected
from the group having SEQ ID N03: 281, 287, 9, 305, 311, 317, 323, 329, 335,
341, 347, 353, 359, 365, 371, 377, 383, 389, and 395 or an amino acid sequence having
one, two, three, four or five amino acid substitutions, deletions or additions as compared
to SEQ ID N08: 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341, 347, 353, 359,
365, 371, 377, 383, 389, or 395; a VH CDR2 region having an amino acid ce
selected from the group consisting of SEQ ID N03: 282, 288, 294, 300, 306, 312, 318,
324, 330, 336, 342, 348, 354, 360, 366, 372, 378, 384, 390, and 396 or an amino acid
sequence having one, two, three, four or five amino acid substitutions, deletions or
additions as compared to SEQ ID N03: 282, 288, 294, 300, 306, 312, 318, 324, 330,
336, 342, 348, 354, 360, 366, 372, 378, 384, 390, or 396; a VH CDR3 region having an
amino acid sequence selected from the group consisting of SEQ ID NOs: 283, 289, 295,
301, 307, 313, 319, 325, 331, 337, 343, 349, 355, 361, 367, 373, 379, 385, 391, and
397, or an amino acid sequence having one, two, three, four or five amino acid
substitutions, ons or additions as compared to SEQ ID N03: 283, 289, 295, 301,
307, 313, 319, 325, 331, 337, 343, 349, 355, 361, 367, 373, 379, 385, 391, or 397; a VL
CDR1 region having an amino acid sequence selected from the group consisting of SEQ
ID N08: 284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 362, 368, 374,
380, 386, 392, and 398, or an amino acid sequence having one, two, three, four or five
amino acid substitutions, deletions or ons as compared to SEQ ID N03: 284, 290,
296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 362, 368, 374, 380, 386, 392, or
398; a VL CDR2 region having an amino acid sequence selected from the group
consisting of SEQ ID N03: 285, 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351,
357, 363, 369, 375, 381, 387, 393, and 399, or an amino acid sequence having one, two,
three, four or five amino acid substitutions, deletions or additions as compared to SEQ ID
N03: 285, 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375,
381, 387, 393, or 399; and a VL CDR3 region having an amino acid sequence selected
from the group consisting of SEQ lD N03: 286, 292, 298, 304, 310, 316, 322, 328, 334,
340, 346, 352, 358, 364, 370, 376, 382, 388, 394, and 400, or an amino acid sequence
having one, two, three, four or five amino acid substitutions, deletions or additions as
compared to SEQ ID N08: 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352,
358, 364, 370, 376, 382, 388, 394, or 400.
Grafting Antigen-binding Domains Into Alternative Frameworks or Scaffolds
A wide variety of antibody/ globulin frameworks or scaffolds can be
employed so long as the resulting polypeptide includes at least one binding region which
specifically binds to Factor P. Such frameworks or scaffolds include the 5 main idiotypes
of human immunoglobulins, or fragments thereof, and include immunoglobulins of other
animal s, preferably having humanized aspects. Single heavy-chain antibodies
such as those identified in camelids are of particular interest in this regard. Novel
frameworks, scaffolds and fragments continue to be discovered and developed by those
skilled in the art.
In one aspect, the invention pertains to generating non-immunoglobulin based
dies using non- immunoglobulin scaffolds onto which CDRs of the ion can be
grafted. Known or future non-immunoglobulin frameworks and scaffolds may be
employed, as long as they comprise a binding region specific for the target Factor P
protein. Known non-immunoglobulin orks or scaffolds include, but are not limited
to, fibronectin (Compound Therapeutics, Inc., Waltham, MA), ankyrin (Molecular
Partners AG, Zurich, rland), domain antibodies (Domantis, Ltd., Cambridge, MA,
and Ablynx nv, Zwijnaarde, Belgium), lipocalin (Pieris Proteolab AG, Freising, Germany),
small modular immuno-pharmaceuticals (Trubion Pharmaceuticals lnc., Seattle, WA),
maxybodies (Avidia, lnc., Mountain View, CA), n A (Affibody AG, Sweden), and
affilin -crystallin or ubiquitin) (Scil Proteins GmbH, Halle, Germany).
The fibronectin scaffolds are based on fibronectin type lll domain (e.g., the tenth
module of the fibronectin type ill (10 Fn3 domain». The fibronectin type III domain has 7
or 8 beta strands which are distributed between two beta sheets, which themselves pack
against each other to form the core of the protein, and further containing loops
(analogous to CDRs) which connect the beta strands to each other and are solvent
exposed. There are at least three such loops at each edge of the beta sheet sandwich,
where the edge is the ry of the n perpendicular to the direction of the beta
strands (see US 6,818,418). These fibronectin-based lds are not an
immunoglobulin, although the l fold is closely related to that of the smallest
PCT/[32012/057394
functional dy fragment, the variable region of the heavy chain, which comprises the
entire antigen ition unit in camel and llama lgG. Because of this ure, the
non-immunoglobulin antibody mimics antigen binding properties that are r in nature
and affinity to those of antibodies. These scaffolds can be used in a loop randomization
and shuffling strategy in vitro that is similar to the process of ty maturation of
antibodies in vivo. These ectin-based les can be used as scaffolds where
the loop regions of the molecule can be replaced with CDRs of the invention using
standard cloning techniques.
The ankyrin technology is based on using ns with ankyrin derived repeat
modules as scaffolds for bearing variable regions which can be used for binding to
different targets. The ankyrin repeat module is a 33 amino acid polypeptide consisting of
two anti-parallel o-helices and a B-turn. Binding of the variable regions is mostly
optimized by using ribosome y.
Avimers are d from l A—domain containing protein such as LRP—1.
These domains are used by nature for protein—protein interactions and in human over
250 ns are structurally based on A—domains. Avimers consist of a number of
different “A—domain" monomers (2-10) linked via amino acid linkers. Avimers can be
created that can bind to the target antigen using the methodology described in, for
example, U.S. PatentApplication Publication Nos. 20040175756; 53973;
20050048512; and 20060008844.
Affibody affinity ligands are small, simple ns composed of a three—helix
bundle based on the scaffold of one of the lgG-binding domains of Protein A. Protein A
is a surface protein from the bacterium Staphylococcus aureus. This scaffold domain
consists of 58 amino acids, 13 of which are randomized to generate affibody libraries
with a large number of ligand variants (See e.g., US 5,831,012). Affibody molecules
mimic antibodies, they have a molecular weight of 6 kDa, compared to the molecular
weight of antibodies, which is 150 kDa. in spite of its small size, the binding site of
affibody molecules is similar to that of an antibody.
Anticalins are products developed by the y Pieris ProteoLab AG. They
are derived from lipocalins, a widespread group of small and robust proteins that are
usually involved in the physiological transport or storage of chemically sensitive or
insoluble compounds. Several natural lipocalins occur in human tissues or body liquids.
The protein architecture is reminiscent of immunoglobulins, with hypervariable loops on
top of a rigid framework. r, in contrast with antibodies or their recombinant
fragments, lipocalins are composed of a single ptide chain with 160 to 180 amino
acid es, being just marginally bigger than a single immunoglobulin domain. The
set of four loops, which makes up the binding pocket, shows nced structural
plasticity and tolerates a variety of side chains. The g site can thus be reshaped in
a proprietary process in order to recognize prescribed target molecules of different shape
with high affinity and specificity. One protein of lipocalin family, the bilin—binding protein
(BBP) of Pieris cae has been used to develop anticalins by mutagenizing the set of
four loops. One example of a patent application describing anticalins is in PCT
Publication No. WO 199916873.
Affilin molecules are small non-immunoglobulin proteins which are designed for
specific affinities towards proteins and small molecules. New affilin molecules can be
very quickly ed from two libraries, each of which is based on a different human
derived scaffold protein. Affilin molecules do not show any structural homology to
immunoglobulin ns. Currently, two affilin scaffolds are ed, one of which is
gamma crystalline, a human structural eye lens protein and the other is "ubiquitin"
superfamily proteins. Both human scaffolds are very small, show high temperature
stability and are almost resistant to pH changes and denaturing agents. This high
stability is mainly due to the expanded beta sheet structure of the proteins. Examples of
gamma crystalline derived proteins are described in W0200104‘l44 and examples of
"ubiquitin—like" proteins are bed in W02004106368.
Protein epitope mimetics (PEM) are medium~sized, cyclic, peptide-like molecules
(MW ) mimicking airpin secondary structures of proteins, the major
secondary structure involved in protein-protein interactions.
The present invention provides fully human antibodies that specifically bind to a
Factor P protein. Compared to the chimeric or humanized antibodies, the human Factor
P—binding antibodies of the invention have r reduced antigenicity when
administered to human subjects.
Camelid antibodies
Antibody proteins ed from members of the camel and dromedary (Camelus
bactrianus and Calelus dromaderius) family including new world members such as llama
s (Lama paccos, Lama glama and Lama vicugna) have been characterized with
respect to size, structural complexity and antigenicity for human subjects. Certain lgG
antibodies from this family of s as found in nature lack light chains, and are thus
structurally distinct from the typical four chain quaternary structure having two heavy and
two light chains, for dies from other animals. See PCT/EP93/02214 (WO 94/04678
published 3 March 1994).
A region of the camelid dy which is the small single variable domain
identified as VHH can be obtained by genetic engineering to yield a small protein having
high affinity for a target, resulting in a low molecular weight antibody-derived protein
known as a “camelid nanobody”. See U.S. patent number 5,759,808 issued June 2,
1998; see also Stijlemans, B. etal., 2004 J Biol Chem 279: 1256-1261; Dumoulin, M. et
al., 2003 Nature 424: 783—788; Pleschberger, M. et al. 2003 Bioconjugate Chem 14: 440—
448; —Retamozo, V. et al. 2002 lnt J Cancer 89: 456-62; and Lauwereys, M. eta].
1998 EMBO J 17: 3512-3520. Engineered libraries of camelid antibodies and antibody
fragments are commercially available, for example, from Ablynx, Ghent, Belgium. As
with other dies of non-human , an amino acid ce of a camelid
antibody can be altered recombinantly to obtain a sequence that more closely resembles
a human sequence, i.e., the nanobody can be “humanized”. Thus the natural low
antigenicity of camelid antibodies to humans can be further reduced.
The camelid nanobody has a molecular weight approximately one-tenth that of a
human lgG molecule, and the n has a physical diameter of only a few nanometers.
One consequence of the small size is the ability of d nanobodies to bind to
antigenic sites that are functionally invisible to larger antibody proteins, i.e., camelid
nanobodies are useful as reagents detect antigens that are otherwise cryptic using
classical immunological ques, and as possible eutic agents. Thus yet
another consequence of small size is that a camelid nanobody can inhibit as a result of
binding to a specific site in a groove or narrow cleft of a target protein, and hence can
serve in a capacity that more closely resembles the function of a cal low molecular
weight drug than that of a classical antibody.
The low molecular weight and compact size further result in camelid nanobodies
being extremely thermostable, stable to extreme pH and to proteolytic digestion, and
poorly antigenic. Another consequence is that camelid nanobodies readily move from
the circulatory system into tissues, and even cross the blood-brain r and can treat
disorders that affect nen/ous tissue. Nanobodies can further facilitated drug transport
across the blood brain barrier. See US. patent application 20040161738 published
August 19, 2004. These features combined with the low antigenicity to humans te
great eutic ial. Further, these molecules can be fully expressed in
prokaryotic cells such as E. coli and are expressed as fusion proteins with
bacteriophage and are functional.
WO 93762 ZOIZ/057394
Accordingly, a feature of the present ion is a camelid antibody or nanobody
having high y for Factor P. In certain embodiments herein, the camelid antibody or
nanobody is naturally produced in the camelid animal, i.e., is produced by the camelid
following immunization with Factor P or a peptide fragment thereof, using techniques
described herein for other antibodies. Alternatively, the Factor P—binding camelid
nanobody is ered, i.e., produced by selection for example from a library of phage
displaying appropriately mutagenized camelid nanobody proteins using panning
procedures with Factor P as a target as bed in the examples herein. Engineered
nanobodies can further be customized by genetic engineering to have a half life in a
recipient subject of from 45 minutes to two weeks. in a specific embodiment, the camelid
antibody or nanobody is obtained by grafting the CDRs sequences of the heavy or light
chain of the human dies of the invention into nanobody or single domain antibody
framework sequences, as bed for example in PCT/EP93/02214.
Bispecific Molecules and Multivalent Antibodies
In another aspect, the present ion features bispecific or multispecific
les comprising a Factor P-binding dy, or a fragment thereof, of the
invention. An antibody of the invention, or antigen—binding regions thereof, can be
derivatized or linked to r functional molecule, e.g., another peptide or n (9.9.,
r antibody or ligand for a receptor) to generate a bispecific molecule that binds to
at least two different binding sites or target molecules. The antibody of the invention may
in fact be derivatized or linked to more than one other functional molecule to te
multi-specific molecules that bind to more than two ent binding sites and/or target
molecules; such multi-specific molecules are also intended to be encompassed by the
term "bispecific molecule" as used herein. To create a bispecific molecule of the
invention, an antibody of the invention can be functionally linked (e.g., by chemical
coupling, genetic fusion, noncovalent association or otherwise) to one or more other
binding molecules, such as another antibody, antibody fragment, peptide or binding
mimetic, such that a bispecific molecule results.
Accordingly, the present invention includes bispecific molecules comprising at
least one first binding specificity for Factor P and a second binding specificity for a
second target epitope. For example, the second target epitope is another epitope of
Factor P different from the first target epitope.
Additionally, for the invention in which the ific molecule is multi-specific, the
molecule can further include a third binding specificity, in on to the first and second
target epitope.
in one embodiment, the bispecific molecules of the ion comprise as a
binding city at least one antibody, or an antibody fragment thereof, ing, e.g.,
a Fab, Fab', 2, Fv, or a single chain Fv. The antibody may also be a light chain or
heavy chain dimer, or any minimal fragment f such as a Fv or a single chain
construct as described in Ladner et al. US Patent No. 4,946,778.
Diabodies are bivalent, ific molecules in which VH and VL domains are
expressed on a single polypeptide chain, connected by a linker that is too short to allow
for pairing between the two domains on the same chain. The VH and VL domains pair
with complementary domains of another chain, thereby creating two antigen binding sites
(see e.g., Holliger etaL, 1993 Proc. Natl. Acad. Sci. USA 90:6444—6448; Poljak etal.,
1994 Structure 2:1121-1123). Diabodies can be produced by expressing two
polypeptide chains with either the structure VHA-VLB and A (VH-VL
configuration), or VLA~VHB and VLB-VHA (VL—VH uration) within the same cell.
Most of them can be expressed in soluble form in bacteria. Single chain diabodies
(scDb) are produced by connecting the two diabody—forming polypeptide chains with
linker of approximately 15 amino acid es (see Holliger and Winter, 1997 Cancer
lmmunol. |mmunother., 45(3-4):128—30; Wu et a/., 1996 lmmunotechnology, 2(1):.21-36).
scDb can be expressed in bacteria in soluble, active ric form (see Holliger and
Winter, 1997 Cancer Immunol. |mmunother., : 128-30; Wu eta!., 1996
lmmunotechnology, 2(1):21-36; Pluckthun and Pack, 1997 lmmunotechnology, 3(2): 83—
105; Ridgway etal., 1996 Protein Eng, 17—21). A diabody can be fused to Fc to
generate a “di—diabody” (see Lu et al., 2004 J. Biol. Chem., 279(4):2856-65).
Other antibodies which can be employed in the bispecific molecules of the
invention are murine, chimeric and humanized monoclonal antibodies.
Bispecific molecules can be prepared by conjugating the constituent binding
specificities, using methods known in the art. For example, each binding specificity of
the bispecific molecule can be generated separately and then ated to one another.
When the binding specificities are proteins or peptides, a variety of coupling or cross—
linking agents can be used for covalent conjugation. Examples of cross-linking agents
include protein A, carbodiimide, N-succinimidyl—S-acetyl-thioacetate (SATA), 5,5'-
dithiobis(2—nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N—succinimidyl—
PCT/[32012/057394
3-(2—pyridyldithio)propionate , and sulfosuccinimidyl 4—(N-maleimidomethyl)
cyclohaxane-l-carboxylate (sulfo-SMCC) (see 9.9., Karpovsky et al., 1984 J. Exp. Med.
86; Liu, MA et a/., 1985 Proc. Natl. Acad. Sci. USA 8). Other methods
include those described in Paulus, 1985 Behring Ins. Mitt. No. 78,118—132; Brennan et
al., 1985 Science 229281-83), and Glennie et al., 1987 J. Immunol. 139: 2367—2375).
ating agents are SATA and sulfo-SMCC, both available from Pierce Chemical Co.
(Rockford, lL).
When the binding specificities are antibodies, they can be conjugated by
sulfhydryl bonding of the C-terminus hinge regions of the two heavy chains. In a
particularly embodiment, the hinge region is modified to contain an odd number of
sulfhydryl residues, for example one, prior to conjugation.
Alternatively, both binding specificities can be encoded in the same vector and
expressed and assembled in the same host cell. This method is particularly useful
where the bispecific le is a mAb X mAb, mAb X Fab, Fab x F(ab‘)2 or ligand x Fab
fusion protein. A bispecific molecule of the invention can be a single chain le
comprising one single chain antibody and a binding determinant, or a single chain
bispecific molecule comprising two g inants. Bispecific molecules may
se at least two single chain molecules. Methods for ing bispecific molecules
are described for example in US. Patent Number 5,260,203; US. Patent Number
,455,030; U.S. Patent Number 4,881,175; U.S. Patent Number 5,132,405; US. Patent
Number 5,091,513; US. Patent Number 5,476,786; U.S. Patent Number 5,013,653; U.S.
Patent Number 5,258,498; and US. Patent Number 5,482,858.
Binding of the bispecific molecules to their specific targets can be confirmed by,
for e, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (REA),
FACS analysis, bioassay (e.g., growth inhibition), or Western Blot assay. Each of these
assays generally detects the presence of protein—antibody complexes of particular
interest by ing a labeled reagent (e.g., an antibody) specific for the complex of
interest.
In another aspect, the present invention provides multivalent compounds
comprising at least two identical or different antigen-binding portions of the antibodies of
the invention binding to Factor P. The antigen-binding portions can be linked together
via protein fusion or covalent or non covalent linkage. Alternatively, s of linkage
have been described for the bispecfic molecules. Tetravalent compounds can be
obtained for example by cross—linking dies of the antibodies of the invention with
1 00
an antibody that binds to the nt regions of the antibodies of the invention, for
example the F0 or hinge region.
Trimerizing domain are described for example in Borean patent EP 1 012 28081.
Pentamerizing modules are bed for e in PCT/EP97/05897.
Antibodies with Extended Half Life
The t invention provides for antibodies that specifically bind to Factor P
protein which have an extended half—life in vivo.
Many factors may affect a protein’s half life in vivo. For examples, kidney
filtration, metabolism in the liver, degradation by proteolytlc enzymes ases), and
immunogenic responses (e.g., protein neutralization by antibodies and uptake by
macrophages and dentritic cells). A variety of strategies can be used to extend the half
life of the antibodies of the present invention. For example, by chemical linkage to
polyethyleneglycol (PEG), reCODE PEG, antibody ld, polysialic acid (PSA),
hydroxyethyl starch (HES), n-binding ligands, and carbohydrate shields; by
genetic fusion to proteins g to serum proteins, such as albumin, lgG, FcRn, and
transferring; by coupling (genetically or chemically) to other binding es that bind to
serum proteins, such as nanoboies, Fabs, DARPins, avimers, affibodies, and anticalins;
by genetic fusion to rPEG, n, domain of albumin, albumin-binding proteins, and
F0; or by incorporation into nancarriers, slow release formulations, or medical devices.
To prolong the serum circulation of antibodies in vivo, inert polymer molecules
such as high molecular weight PEG can be attached to the antibodies or a fragment
thereof with or without a multifunctional linker either through site-specific conjugation of
the PEG to the N- or C-terminus of the antibodies or via epsilon-amino groups present on
lysine residues. To pegylate an antibody, the antibody, or fragment thereof, typically is
reacted with polyethylene glycol (PEG), such as a reactive ester or aldehyde derivative
of PEG, under conditions in which one or more PEG groups become attached to the
antibody or antibody fragment. The pegylation can be carried out by an acylation
reaction or an alkylation reaction with a reactive PEG molecule (or an analogous ve
water-soluble polymer). As used herein, the term "polyethylene " is intended to
encompass any of the forms of PEG that have been used to derivatize other proteins,
such as mono (Ct-C10) - or aryloxy—polyethylene glycol or polyethylene glycol-
maleimide. In certain ments, the antibody to be pegylated is an aglycosylated
antibody. Linear or ed polymer derivatization that results in minimal loss of
ical activity will be used. The degree of conjugation can be closely monitored by
1 01
SDS—PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to
the antibodies. Unreacted PEG can be separated from antibody-PEG conjugates by
size-exclusion or by ion-exchange chromatography. PEG-derivatized antibodies can be
tested for binding activity as well as for in vivo efficacy using methods well-known to
those of skill in the art, for e, by immunoassays described . Methods for
pegylating proteins are known in the art and can be applied to the antibodies of the
ion. See for example, EP 0 154 316 by Nishimura et al. and EP 0 401 384 by
lshikawa et al.
Other modified pegylation technologies include reconstituting ally
onal directed engineering technology E PEG), which incorporates
chemically specified side chains into biosynthetic ns via a reconstituted system that
es tRNA synthetase and tRNA. This technology enables incorporation of more
than 30 new amino acids into biosynthetic proteins in E.coli, yeast, and mammalian cells.
The tRNA incorporates a nonnative amino acid any place an amber codon is positioned,
converting the amber from a stop codon to one that s oration of the
chemically specified amino acid.
Recombinant pegylation technology (rPEG) can also be used for serum halflife
extension. This technology involves genetically fusing a 300-600 amino acid
unstructured protein tail to an existing pharmaceutical protein. Because the apparent
molecular weight of such an unstructured protein chain is about 15-fold larger than its
actual molecular weight, the serum halflife of the protein is greatly increased. In contrast
to ional PEGyIation, which requires chemical conjugation and repurification, the
manufacturing process is greatly simplified and the product is homogeneous.
Polysialytion is another technology, which uses the natural polymer polysialic acid
(PSA) to prolong the active life and improve the stability of therapeutic peptides and
proteins. PSA is a polymer of siaiic acid (a sugar). When used for n and
therapeutic peptide drug delivery, polysialic acid es a protective microenvironment
on conjugation. This increases the active life of the therapeutic protein in the circulation
and prevents it from being recognized by the immune system. The PSA r is
naturally found in the human body. It was adopted by certain bacteria which d
over millions of years to coat their walls with it. These naturally polysialylated bacteria
were then able, by virtue of molecular mimicry, to foil the body’s defense system. PSA,
nature's te stealth technology, can be easily produced from such bacteria in large
quantities and with predetermined physical characteristics. Bacterial PSA is completely
1 02
non-immunogenic, even when coupled to proteins, as it is chemically identical to PSA in
the human body.
r technology includes the use of hydroxyethyl starch (“HES”) derivatives
linked to antibodies. HES is a modified natural poiymer derived from waxy maize starch
and can be metabolized by the body’s s. HES ons are usually administered
to substitute deficient blood volume and to improve the rheological ties of the
blood. Hesylation of an antibody enables the prolongation of the ation half-life by
increasing the stability of the molecule, as welt as by ng renal clearance, resulting
in an increased biological activity. By varying different parameters, such as the
molecular weight of HES, a wide range of HES dy conjugates can be customized.
Antibodies having an sed half-life in vivo can also be generated introducing
one or more amino acid modifications (i.e., substitutions, insertions or deletions) into an
IgG constant domain, or FcRn binding fragment f (preferably a F0 or hinge Fc
domain fragment). See, e.g., International Publication No. WO 98/23289; international
Publication No. WO 31; and US. Patent No. 6,277,375.
Further, antibodies can be conjugated to albumin (e.g., human serum albumin;
HSA) in order to make the antibody or antibody fragment more stable in vivo or have a
longer half life in vivo. The techniques are well—known in the art, see, e.g., International
Publication Nos. WO 93/15199, WO 93/15200, and WO 01/77137; and European Patent
No. EP 413,622. In addition, in the context of a bispecific antibody as described above,
the specificities of the dy can be designed such that one binding domain of the
antibody binds to Factor P while a second binding domain of the antibody binds to serum
albumin, ably HSA.
The strategies for increasing half life is especially useful in nanobodies,
fibronectin-based binders, and other antibodies or proteins for which increased in vivo
half life is desired.
Antibody Conjugates
The present invention provides antibodies or fragments thereof that specifically
bind to a Factor P protein recombinantly fused or chemically conjugated (including both
covalent and non-covalent conjugations) to a heterologous protein or polypeptide (or
fragment thereof, preferably to a polypeptide of at least 10, at least 20, at least 30, at
least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 amino
acids) to generate fusion proteins. in particular, the invention es fusion proteins
PCT/IBZOIZ/057394
1 03
comprising an antigen-binding nt of an antibody described herein (6.9., a Fab
fragment, Fd fragment, Fv fragment, F(ab)2 nt, a VH domain, a VH CDR, a VL
domain or a VL CDR) and a heteroiogous protein, polypeptide, or peptide. Methods for
fusing or conjugating proteins, polypeptides, or peptides to an antibody or an antibody
fragment are known in the art. See, e.g., US. Patent Nos. 5,336,603, 5,622,929,
,359,046, 5,349,053, 5,447,851, and 5,112,946; European Patent Nos. EP 307,434 and
EP 367,166; international Publication Nos. WO 96/04388 and WO 91/06570; Ashkenazi
et a/., 1991, Proc. Natl. Acad. Sci. USA 88: 10535-10539; Zheng et al., 1995, J.
immunoi. 154:5590-5600; and Vii etal., 1992, Proc. Natl. Acad. Sci. USA 89:11337—
11341.
Additional fusion proteins may be ted through the techniques of gene-
shuffiing, motif—shuffling, exon-shuffiing, and/or codon—shuffling (collectively ed to as
“DNA shuffling”). DNA shuffling may be employed to alter the ties of antibodies of
the invention or fragments thereof (e.g., dies or fragments thereof with higher
affinities and lower dissociation rates). See, generally, US. Patent Nos. 5,605,793,
,811,238, 5,830,721, 5,834,252, and 5,837,458; Patten eta/., 1997, Curr. Opinion
Biotechnol. 8:724—33; Harayama, 1998, Trends Biotechnol. 16(2):?6—82; Hansson, eta/.,
1999, J. Moi. Biol. 287:265-76; and Lorenzo and , 1998, Biotechniques 24(2):308-
313 (each of these patents and publications are hereby orated by reference in its
entirety). Antibodies or fragments thereof, or the encoded antibodies or fragments
thereof, may be altered by being subjected to random mutagenesis by prone PCR,
random nucleotide insertion or other methods prior to recombination. A polynucleotide
encoding an antibody or fragment thereof that specifically binds to a Factor P protein
may be ined with one or more ents, motifs, sections, parts, domains,
fragments, etc. of one or more heteroiogous molecules.
Moreover, the antibodies or fragments f can be fused to marker
sequences, such as a peptide to facilitate purification. in preferred embodiments, the
marker amino acid sequence is a hexa—histidine peptide, such as the tag provided in a
pQE vector (QIAGEN, inc., 9259 Eton , Chatsworth, CA, 91311), among others,
many of which are commercially available. As described in Gentz et at, 1989, Proc.
Natl. Acad. Sci. USA 86:821-824, for instance, hexa-histidine provides for convenient
purification of the fusion n. Other peptide tags useful for purification include, but
are not limited to, the hemaggiutinin (“HA”) tag, which corresponds to an epitope derived
from the influenza hemaggiutinin n (Wilson et a/., 1984, Cell 372767), and the “flag"
tag.
1 04
In other embodiments, antibodies of the present invention or fragments f
conjugated to a diagnostic or detectable agent. Such dies can be useful for
monitoring or sing the onset, development, progression and/or severity of a
disease or disorder as part of a clinical testing procedure, such as determining the
efficacy of a particular therapy. Such diagnosis and detection can accomplished by
coupling the antibody to detectable substances including, but not limited to, various
enzymes, such as, but not limited to, horseradish peroxidase, alkaline phosphatase,
beta-galactosidase, or acetylcholinesterase; prosthetic groups, such as, but not limited
to, streptavidinlbiotin and avidin/biotin; fluorescent materials, such as, but not limited to,
umbelliferone, fluorescein, scein isothiocynate, rhodamine, dichlorotriazinylamine
fluorescein, dansyl chloride or phycoerythrin; luminescent materials, such as, but not
limited to, luminol; bioluminescent materials, such as but not limited to, luciferase,
luciferin, and aequorin; radioactive materials, such as, but not limited to, iodine (131i,
125i, 123i, and 12“,), carbon (14C), sulfur (358), tritium (3H), indium (115In, 113m,
112ln, and 111ln,), technetium (99Tc), thallium (201Ti), gallium (6863, 676a), palladium
), molybdenum (99Mo), xenon (133Xe), fluorine (18F), 1538m, 177Lu, 159C5d,
149Pm, 140La, 175Yb, 166Ho, 90Y, 4780, 186Re, 188Re,142 Pr, 105Rh, 97Ru, 686e,
5700, 65Zn, 858r, 32P, 15SGd, 169Yb, 51Cr, 54Mn, 7589, 113Sn, and 117Tin; and
positron emitting metals using various on emission tomographies, and
noradioactive gnetic metal ions.
The present invention further encompasses uses of antibodies or fragments
thereof conjugated to a therapeutic moiety. An antibody or fragment thereof may be
conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or dal
agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters. A cytotoxin or
cytotoxic agent includes any agent that is detrimental to cells.
Further, an antibody or fragment thereof may be ated to a therapeutic
moiety or drug moiety that modifies a given biological response. Therapeutic moieties or
drug moieties are not to be construed as limited to classical al therapeutic .
For example, the drug moiety may be a protein, peptide, or polypeptide possessing a
d biological activity. Such proteins may include, for e, a toxin such as abrin,
ricin A, pseudomonas exotoxin, cholera toxin, or diphtheria toxin; a protein such as tumor
is , rferon, B-interferon, nerve growth factor, platelet derived growth
factor, tissue plasminogen activator, an apoptotic agent, an anti-angiogenic agent; or, a
biological response modifier such as, for example, a lymphokine.
WO 93762
1 05
Moreover, an antibody can be conjugated to therapeutic moieties such as a
radioactive metal ion, such as alph-emiters such as 213Bi or macrocyclic chelators
useful for conjugating radiometal ions, including but not limited to, 131ln, 131LU, 131Y,
131 Ho, 131Sm, to polypeptides. In certain ments, the macrocyclic or is
—tetraazacyclododecane—N,N’,N”,N”’-tetraacetic acid (DOTA) which can be
attached to the antibody via a linker molecule. Such linker molecules are commonly
known in the art and described in o et al., 1998, Clin Cancer Res. 2483-90;
Peterson et al., 1999, Bioconjug. Chem. 10(4):553-7; and Zimmerman etal., 1999, Nucl.
Med. Biol. 26(8):943-50, each orated by reference in their entireties.
Techniques for conjugating therapeutic moieties to antibodies are well known,
see, e.g., Arnon et al., “Monoclonal Antibodies For lmmunotargeting Of Drugs In Cancer
Therapy”, in Monoclonal Antibodies And Cancer y, Reisfeld et al. , pp. 243-
56 (Alan R. Liss, Inc. 1985); Hellstrom etal., “Antibodies For Drug Delivery”, in
Controlled Drug ry (2nd Ed), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker,
Inc. 1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A
Review”, in Monoclonal dies 84: Biological And Clinical Applications, Pinchera et
al. (eds), pp. 475-506 (1985); “Analysis, Results, And Future Prospective Of The
Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, in Monoclonal
Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds), pp. 303-16
(Academic Press 1985), and Thorpe et al., 1982, Immunol. Rev. 621119—58.
Antibodies may also be attached to solid supports, which are particularly useful
for assays or purification of the target antigen. Such solid supports include, but
are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride
or polypropylene.
Methods of Producing Antibodies of the Invention
Nucleic Acids Encoding the Antibodies
The invention provides substantially purified nucleic acid molecules which encode
polypeptides comprising segments or domains of the Factor P -binding dy chains
described above. Some of the nucleic acids of the invention comprise the nucleotide
sequence encoding the heavy chain variable region shown in SEQ ID NO: 7, 21, 35, 49,
63, 77, 91, 105, 119, 133, 147, 161, 175, 189, 203, 217, 231, 245, 259 or 273, and/or the
nucleotide sequence encoding the light chain variable region shown in SEQ ID NO: 8,
22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190, 204, 218, 232, 246, 260, or
274. In a specific embodiment, the nucleic acid molecules are those identified in Table
PCT/IBZOIZ/057394
1 06
1. Some other nucleic acid molecules of the invention comprise nucleotide sequences
that are substantially cal (e.g., at least 65, 80%, 95%, or 99%) to the nucleotide
sequences of those identified in Table 1. When sed from riate sion
vectors, polypeptides encoded by these polynucleotides are capable of exhibiting Factor
P antigen binding capacity.
Also provided in the invention are polynucleotides which encode at least one
CDR region and usually all three CDR regions from the heavy or light chain of the Factor
P-binding antibody set forth above. Some other cleotides encode all or
substantially all of the variable region sequence of the heavy chain and/or the light chain
of the Factor P-binding antibody set forth above. Because of the degeneracy of the
code, a variety of nucleic acid sequences will encode each of the immunoglobulin amino
acid sequences.
The nucleic acid molecules of the invention can encode both a variable region
and a constant region of the dy. Some of nucleic acid sequences of the invention
comprise nucleotides encoding a mature heavy chain sequence that is substantially
identical (e.g., at least 80%, 90%, or 99%) to the mature heavy chain sequence set forth
in SEQ lD NO: 9, 23, 37, 51, 65, 79, 93, 107, 121, 135, 149, 163, 177, 191, 205, 219,
233, 247, 261 or 275. Some other nucleic acid sequences comprising tide
encoding a mature light chain sequence that is substantially identical (e.g., at least 80%,
90%, or 99%) to the mature light chain sequence set forth in SEQ ID NO: 10, 24, 38, 52,
66, 80, 94, 108, 122, 136, 150, 164, 178, 192, 206, 220, 234, 248, 262, or 276.
The polynucleotide sequences can be produced by de novo solid-phase DNA
synthesis or by PCR mutagenesis of an existing sequence (e.g., sequences as described
in the Examples below) encoding a Factor P—binding antibody or its binding fragment.
Direct chemical synthesis of nucleic acids can be accomplished by s known in the
art, such as the phosphotriester method of Narang et al., 1979, Meth. Enzymol. 68:90;
the phosphodiester method of Brown et al., Meth. Enzymol. 682109, 1979; the
diethylphosphoramidite method of Beaucage et al., Tetra. Lett., 22:1859, 1981; and the
solid support method of US. Patent No. 4,458,066. Introducing mutations to a
polynucleotide sequence by PCR can be performed as described in, e.g., PCR
Technology: Principles and Applications for DNA Amplification, H.A. Erlich (Ed.),
Freeman Press, NY, NY, 1992; PCR Protocols: A Guide to Methods and Applications,
Innis etal. (Ed), Academic Press, San Diego, CA, 1990; Mattila eta!., Nucleic Acids
Res. , 1991; and Eckert et al., PCR Methods and Applications 1:17, 1991.
PCT/IBZOIZ/057394
1 07
Also provided in the invention are expression vectors and host cells for ing
the Factor P-binding antibodies described above. Various expression vectors can be
employed to express the poiynucleotides encoding the Factor ing antibody chains
or binding fragments. Both viral-based and nonviral expression vectors can be used to
e the antibodies in a ian host cell. Nonviral s and systems include
plasmids, episomal vectors, typically with an sion cassette for expressing a protein
or RNA, and human artificial chromosomes (see, e.g., Harrington eta/., Nat Genet
:345, 1997). For example, nonviral vectors useful for expression of the Factor P-
g polynucleotides and polypeptides in mammalian (e.g., human) cells include
pThioHis A, B & C, pcDNA3.1/His, pEBVHis A, B & C, (lnvitrogen, San Diego, CA),
MPSV vectors, and numerous other vectors known in the art for expressing other
proteins. Useful viral vectors include vectors based on retroviruses, adenoviruses,
adenoassociated viruses, herpes viruses, vectors based on SV40, papilloma virus, HBP
Epstein Barr virus, vaccinia virus vectors and Semliki Forest virus (SFV). See, Brent et
a/., supra; Smith, Annu. Rev. Microbiol. , 1995; and Rosenfeid et al., Cell 68:143,
1992.
The choice of expression vector depends on the intended host cells in which the
vector is to be expressed. Typically, the expression vectors contain a promoter and
other regulatory ces (e.g., enhancers) that are operably linked to the
poiynucleotides encoding a Factor P-binding antibody chain or fragment. In some
embodiments, an inducible promoter is employed to prevent expression of ed
ces except under inducing conditions. inducible promoters include, 9.9.,
arabinose, lacZ, metallothionein promoter or a heat shock promoter. Cultures of
transformed organisms can be ed under ucing conditions without biasing
the population for coding sequences whose expression products are better tolerated by
the host cells. in addition to promoters, other regulatory elements may also be required
or desired for efficient expression of a Factor ing antibody chain or nt.
These elements typically include an ATG initiation codon and adjacent ribosome binding
site or other sequences. In addition, the efficiency of expression may be enhanced by
the inclusion of enhancers appropriate to the cell system in use (see, e.g., Scharf et at,
Results Probl. Cell Differ. 20:125, 1994; and Bittner et a/., Meth. Enzymoi., 153:516,
1987). For example, the SV4O enhancer or CMV er may be used to increase
expression in mammalian host cells.
The expression vectors may also provide a secretion signal sequence position to
form a fusion protein with ptides encoded by inserted Factor P-binding antibody
sequences. More often, the ed Factor P—binding antibody sequences are linked to
PCT/IBZOIZ/057394
1 08
a signal sequences before inclusion in the vector. Vectors to be used to receive
sequences encoding Factor P-binding antibody light and heavy chain variable domains
sometimes also encode constant regions or parts thereof. Such vectors allow
expression of the variable regions as fusion proteins with the constant regions thereby
leading to production of intact dies or fragments f. Typically, such constant
regions are human.
The host cells for harboring and sing the Factor P-binding antibody chains
can be either prokaryotic or eukaryotic. E. coli is one prokaryotic host useful for cloning
and expressing the polynucleotides of the present invention. Other microbial hosts
suitable for use include bacilli, such as Bacillus subtilis, and other enterobacteriaceae,
such as Salmonella, Serratia, and various Pseudomonas s. In these prokaryotic
hosts, one can also make expression vectors, which typically contain expression control
sequences compatible with the host cell (6.9., an origin of replication). In addition, any
number of a variety of well-known promoters will be present, such as the lactose
promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter
system, or a promoter system from phage lambda. The promoters typically control
expression, ally with an operator ce, and have ribosome binding site
sequences and the like, for initiating and completing transcription and translation. Other
microbes, such as yeast, can also be employed to express Factor P—binding polypeptides
of the invention. Insect cells in combination with baculovirus vectors can also be used.
In some preferred ments, ian host cells are used to express and
produce the Factor P —binding ptides of the present invention. For e, they
can be either a hybridoma cell line expressing endogenous globulin genes (e.g.,
the 1D6.C9 myeloma hybridoma clone as bed in the Examples) or a mammalian
cell line harboring an exogenous expression vector (e.g., the SP2/O myeloma cells
exemplified below). These include any normal mortal or normal or abnormal immortal
animal or human cell. For example, a number of suitable host cell lines capable of
secreting intact immunoglobulins have been developed including the CH0 cell lines,
various Cos cell lines, HeLa cells, myeloma cell lines, transformed B-cells and
omas. The use of mammalian tissue cell culture to express polypeptides is
discussed lly in, e.g., ker, FROM GENES TO CLONES, VCH Publishers,
N.Y., N.Y., 1987. Expression vectors for mammalian host cells can include sion
control sequences, such as an origin of replication, a promoter, and an enhancer (see,
9.9., Queen, at at, lmmunol. Rev. 89:49-68, 1986), and necessary sing
information sites, such as ribosome binding sites, RNA splice sites, polyadenylation
sites, and transcriptional terminator sequences. These expression vectors usually
PCT/[320121057394
1 09
contain promoters derived from mammalian genes or from mammalian viruses. Suitable
promoters may be constitutive, cell type-specific, stage—specific, and/or modulatable or
regulatable. Useful promoters include, but are not limited to, the metallothionein
promoter, the constitutive adenovirus major late promoter, the dexamethasone-inducible
MMTV promoter, the SV40 promoter, the MRP pollll promoter, the constitutive MPSV
er, the tetracycline-inducible CMV promoter (such as the human immediate-early
CMV promoter), the constitutive CMV promoter, and promoter-enhancer combinations
known in the art.
Methods for introducing expression vectors containing the polynucleotide
sequences of interest vary depending on the type of cellular host. For e, calcium
chloride transfection is commonly utilized for prokaryotic cells, whereas calcium
phosphate treatment or oporation may be used for other cellular hosts. (See
generally Sambrook, etai., . Other methods e, e.g., electroporation, calcium
phosphate treatment, liposome—mediated transformation, injection and microinjection,
ballistic methods, mes, liposomes, polycationmucleic acid conjugates,
naked DNA, artificial s, fusion to the herpes virus structural protein VP22 (Elliot and
O'Hare, Cell 88:223, 1997), agent-enhanced uptake of DNA, and ex vivo transduction.
For long-term, high-yield production of recombinant ns, stable expression will often
be desired. For e, cell lines which stably express Factor P ~binding dy
chains or binding fragments can be prepared using expression vectors of the invention
which contain viral origins of ation or endogenous expression elements and a
selectable marker gene. Following the introduction of the vector, cells may be allowed to
grow for 1—2 days in an enriched media before they are switched to ive media. The
purpose of the selectable marker is to confer resistance to selection, and its presence
allows growth of cells which successfully express the introduced sequences in selective
media. Resistant, stably transfected cells can be proliferated using tissue culture
techniques appropriate to the cell type.
Generation of monoclonal antibodies of the invention
onal antibodies (mAbs) can be produced by a variety of techniques,
including conventional monoclonal antibody methodology e.g., the rd somatic cell
hybridization technique of Kohler and Milstein, 1975 Nature 256: 495. Many techniques
for producing monoclonal antibody can be employed e.g., viral or oncogenic
transformation of B lymphocytes.
ZOIZ/057394
1 10
An animal systems for preparing hybridomas include the murine, rat and rabbit
systems. Hybridoma production in the mouse is a well established procedure.
Immunization protocols and techniques for isolation of immunized cytes for fusion
are known in the art. Fusion partners (e.g., murine myeloma cells) and fusion
procedures are also known.
Chimeric or humanized antibodies of the present ion can be prepared
based on the sequence of a murine monoclonal antibody prepared as described above.
DNA encoding the heavy and light chain immunoglobulins can be obtained from the
murine hybridoma of interest and engineered to contain rine (e.g.,. human)
immunoglobulin sequences using standard molecular biology techniques. For example,
to create a chimeric antibody, the murine variable regions can be linked to human
constant regions using methods known in the art (see e.g., U.S. Patent No. 4,816,567 to
Cabilly et al.). To create a humanized antibody, the murine CDR regions can be inserted
into a human framework using s known in the art. See e.g., US. Patent No.
5225539 to Winter, and US. Patent Nos. 5530101; 5585089; 2 and 6180370 to
Queen et al.
In a certain embodiment, the antibodies of the invention are human monoclonal
antibodies. Such human monoclonal antibodies directed against Factor P can be
generated using transgenic or transchromosomic mice carrying parts of the human
immune system rather than the mouse system. These transgenic and transchromosomic
mice include mice referred to herein as HuMAb mice and KM mice, respectively, and are
collectively referred to herein as "human lg mice."
The HuMAb mouse® (Medarex, lnc.) contains human immunoglobulin gene
miniloci that encode un-rearranged human heavy (u and v) and K light chain
immunoglobulin sequences, er with targeted mutations that inactivate the
nous u and K chain loci (see e.g., g, et al., 1994 Nature 368(6474): 856~
859). Accordingly, the mice exhibit reduced expression of mouse IgM or K, and in
response to immunization, the introduced human heavy and light chain transgenes
undergo class switching and somatic mutation to generate high affinity human lgGK
onal (Lonberg, N. et al., 1994 supra; reviewed in Lonberg, N., 1994 ok of
Experimental Pharmacology 113:49-101; Lonberg, N. and Huszar, D., 1995 . Rev.
lmmunol.13: 65—93, and Harding, F. and Lonberg, N., 1995 Ann. N. Y. Acad. Sci.
764:536-546). The preparation and use of HuMAb mice, and the genomic modifications
carried by such mice, is further bed in Taylor, L. et al., 1992 Nucleic Acids
Research 20:6287—6295; Chen, J. et at., 1993 lnternational immunology 5: 647-656;
PCT/IB2012J057394
1 11
Tuaillon et al., 1993 Proc. Natl. Acad. Sci. USA 0-3724; Choi et al., 1993 Nature
Genetics 42117—123; Chen, J. eta/., 1993 EMBO J. 12: 821-830; Tuaillon et al., 1994 J.
lmmunol. 152:2912-2920; Taylor, L. etal., 1994 international Immunology 1; and
Fishwild, D. etal., 1996 Nature Biotechnology 14: 845-851, the contents of all of which
are hereby specifically incorporated by reference in their entirety. See further, US.
Patent Nos. 5,545,806; 5,569,825; 126; 5,633,425; 5,789,650; 5,877,397;
,661,016; 5,814,318; 5,874,299; and 5,770,429; all to Lonberg and Kay; US. Patent
No. 5,545,807 to Surani et at; PCT Publication Nos. WO 92103918, WO 93112227, WO
94/25585, WO 97113852, WO 98/24884 and WO 62, all to Lonberg and Kay; and
PCT ation No. WO 01/14424 to Korman et a}.
in another embodiment, human antibodies of the invention can be raised using a
mouse that carries human immunoglobulin sequences on transgenes and
transchomosomes such as a mouse that carries a human heavy chain transgene and a
human light chain transchromosome. Such mice, referred to herein as “KM mice", are
described in detail in PCT Publication WO 02/43478 to lshida et al.
Still further, alternative transgenic animal systems expressing human
immunoglobulin genes are available in the art and can be used to raise Factor P -binding
antibodies of the invention. For example, an ative transgenic system referred to as
the Xenomouse (Abgenix, inc.) can be used. Such mice are bed in, 6.9., US.
Patent Nos. 5,939,598; 6,075,181; 6,114,598; 6, 150,584 and 6,162,963 to Kucherlapati
etal.
Moreover, alternative transchromosomic animal systems sing human
immunoglobulin genes are available in the art and can be used to raise Factor P ng
antibodies of the invention. For example, mice ng both a human heavy chain
transchromosome and a human light chain romosome, referred to as “TC mice"
can be used; such mice are described in Tomizuka et al., 2000 Proc. Natl. Acad. Sci.
USA 97:722-727. Furthermore, cows carrying human heavy and light chain
transchromosomes have been bed in the art (Kuroiwa et al., 2002 Nature
Biotechnology 20:889-894) and can be used to raise Factor P -binding antibodies of the
invention.
Human monoclonal antibodies of the invention can also be prepared using phage
display methods for screening libraries of human immunoglobulin genes. Such phage
display methods for isolating human antibodies are established in the art or described in
the examples below. See for example: US. Patent Nos. 5,223,409; 5,403,484; and
PCT/IBZOIZ/057394
1 12
,571,698 to Ladner et al.; US. Patent Nos. 5,427,908 and 5,580,717 to Dower et at;
US. Patent Nos. 5,969,108 and 6,172,197 to McCafferty et al.; and US. Patent Nos.
,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915 and 081 to Griffiths et al.
Human monoclonal dies of the invention can also be prepared using SCID
mice into which human immune cells have been reconstituted such that a human
antibody response can be generated upon immunization. Such mice are described in, for
example, US. Patent Nos. 996 and 5,698,767 to Wilson at al.
Framework or F0 engineering
Engineered antibodies of the invention include those in which modifications have
been made to framework residues within VH and/or VL, e.g. to e the properties of
the antibody. Typically such framework modifications are made to decrease the
immunogenicity of the antibody. For example, one approach is to "backmutate" one or
more framework residues to the corresponding germline sequence. More cally, an
antibody that has undergone somatic mutation may contain framework residues that
differ from the germline sequence from which the antibody is derived. Such residues can
be identified by comparing the dy framework ces to the ne
sequences from which the antibody is derived. To return the framework region
sequences to their germline configuration, the somatic ons can be "backmutated"
to the germline ce by, for example, site-directed mutagenesis. Such
"backmutated" antibodies are also intended to be encompassed by the invention.
Another type of ork modification involves mutating one or more residues
within the framework region, or even within one or more CDR regions, to remove T cell —
es to thereby reduce the potential immunogenicity of the antibody. This approach
is also referred to as "deimmunization" and is described in further detail in US. Patent
ation No. 20030153043 by Carr 91‘ al.
In addition or alternative to modifications made within the framework or CDR
regions, antibodies of the invention may be engineered to include modifications within
the Fc region, typically to alter one or more functional properties of the antibody, such as
serum half-life, ment fixation, Fc receptor binding, and/or antigen-dependent
cellular cytotoxicity. Furthermore, an antibody of the invention may be chemically
modified (e.g., one or more chemical moieties can be attached to the antibody) or be
modified to alter its glycosylation, again to alter one or more functional properties of the
dy. Each of these embodiments is described in further detail below. The numbering
of residues in the Fc region is that of the EU index of Kabat.
PCT/IBZOIZ/057394
1 13
In one embodiment, the hinge region of CH1 is modified such that the number of
cysteine residues in the hinge region is d, e.g., sed or decreased. This
approach is described r in US. Patent No. 5,677,425 by Bodmer et al. The
number of ne residues in the hinge region of CH1 is d to, for example,
tate assembly of the light and heavy chains or to increase or decrease the stability of
the antibody.
In another embodiment, the Fc hinge region of an antibody is mutated to
decrease the biological half—life of the antibody. More specifically, one or more amino
acid mutations are introduced into the CH2-CH3 domain interface region of the Fc-hinge
fragment such that the dy has impaired Staphylococcyl protein A (SpA) binding
relative to native Fc-hinge domain SpA binding. This approach is described in further
detail in US. Patent No. 6,165,745 by Ward et al.
In another embodiment, the antibody is modified to increase its biological half-life.
Various approaches are possible. For example, one or more of the following mutations
can be uced: T252L, T2548, T256F, as described in U.S. Patent No. 6,277,375 to
Ward. Alternatively, to increase the biological half life, the antibody can be altered within
the CH1 or CL region to contain a salvage receptor binding epitope taken from two loops
ofa CH2 domain of an Fc region of an lgG, as described in US. Patent Nos. 5,869,046
and 6,121,022 by Presta etal.
in yet other embodiments, the Fc region is altered by replacing at least one amino
acid residue with a different amino acid residue to alter the effector functions of the
antibody. For example, one or more amino acids can be replaced with a different amino
acid residue such that the antibody has an altered affinity for an effector ligand but
s the antigen-binding ability of the parent antibody. The effector ligand to which
affinity is altered can be, for example, an F0 or or the C1 component of
complement. This ch is described in further detail in U.S. Patent Nos. 5,624,821
and 5,648,260, both by Winter et al.
In another embodiment, one or more amino acids selected from amino acid
residues can be replaced with a different amino acid residue such that the antibody has
altered C1q binding and/or reduced or abolished complement dependent cytotoxicity
(CDC). This approach is bed in further detail in US. Patent Nos. 551 by
ldusogie et a].
PCT/[32012/057394
1 14
In another embodiment, one or more amino acid residues are altered to thereby
alter the ability of the antibody to fix ment. This approach is described further in
PCT Publication WO 94/29351 by Bodmer et al.
in yet another embodiment, the Fc region is modified to increase the ability of the
dy to mediate antibody dependent cellular cytotoxicity (ADCC) and/or to increase
the affinity of the antibody for an Fcy receptor by modifying one or more amino acids.
This ch is described further in PCT ation WO 00/42072 by .
Moreover, the binding sites on human igG1 for Fcle, FcyRiI, chRlll and FcRn have
been mapped and variants with improved binding have been described (see Shields,
R.L. eta/., 2001 J. Biol. Chen. 276:6591~6604).
in still another embodiment, the glycosylation of an dy is modified. For
example, an aglycoslated antibody can be made (i.e., the antibody lacks glycosylation).
Glycosylation can be altered to, for example, increase the affinity of the antibody for
"antigen'. Such carbohydrate modifications can be accomplished by, for example,
altering one or more sites of glycosylation within the antibody sequence. For example,
one or more amino acid substitutions can be made that result in elimination of one or
more variable region framework glycosylation sites to y eliminate glycosylation at
that site. Such aglycosylation may increase the affinity of the antibody for antigen. Such
an approach is described in r detail in US. Patent Nos. 5,714,350 and 6,350,861
by Co et al.
Additionally or alternatively, an antibody can be made that has an altered type of
glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl
residues or an antibody having increased bisecting GIcNac structures. Such altered
glycosylation patterns have been demonstrated to increase the ADCC ability of
dies. Such carbohydrate modifications can be accomplished by, for e,
expressing the antibody in a host cell with d glycosylation machinery. Cells with
altered glycosylation machinery have been described in the art and can be used as host
cells in which to express recombinant antibodies of the invention to thereby produce an
dy with altered glycosylation. For example, EP 1,176,195 by Hang eta]. bes
a cell line with a functionally disrupted FUT8 gene, which encodes a fucosyl transferase,
such that antibodies expressed in such a cell line exhibit hypofucosylation. PCT
Publication WO 03/035835 by Presta describes a variant CHO cell line, Lecl3 cells, with
reduced ability to attach fucose to Asn(297)—linked carbohydrates, also resulting in
hypofucosylation of dies expressed in that host cell (see also Shields, R.L. et al.,
2002 J. Biol. Chem. 277:26733—26740). PCT Publication WO 99/54342 by Umana et al.
’l 15
describes cell lines engineered to express rotein-modifying glycosyl transferases
(e.g., beta(1,4)—N acetylglucosaminyltransferase lll (GnTlll)) such that antibodies
expressed in the engineered cell lines t increased bisecting GlcNac structures
which results in increased ADCC activity of the antibodies (see also Umana et al., 1999
Nat. Biotech. 17:176-180).
Methods of ering Altered dies
As discussed above, the Factor P -binding antibodies having VH and VL
sequences or full length heavy and light chain ces shown herein can be used to
create new Factor P—binding antibodies by modifying full length heavy chain and/or light
chain sequences, VH and/or VL sequences, or the nt region(s) attached thereto.
Thus, in another aspect of the invention, the structural features of a Factor P-binding
antibody of the invention are used to create structurally related Factor P-binding
antibodies that retain at least one functional property of the antibodies of the ion,
such as binding to human Factor P and also inhibiting one or more functional properties
of Factor P (6.9., inhibiting MAC deposition in a MAC deposition assay, inhibit red blood
cell lysis in a hemolytic assay).
For example, one or more CDR regions of the dies of the present
invention, or mutations thereof, can be ed recombinantly with known framework
regions and/or other CDRs to create additional, recombinantly-engineered, Factor P —
binding antibodies of the invention, as discussed above. Other types of modifications
include those described in the previous section. The starting material for the engineering
method is one or more of the VH and/or VL sequences provided herein, or one or more
CDR regions thereof. To create the engineered antibody, it is not necessary to actually
prepare (i.e., express as a protein) an antibody having one or more of the VH and/or VL
sequences provided herein, or one or more CDR regions thereof. Rather, the
information contained in the ce(s) is used as the starting material to create a
"second tion" sequence(s) derived from the original sequence(s) and then the
"second generation" sequence(s) is prepared and expressed as a protein.
Accordingly, in another embodiment, the invention provides a method for
preparing a Factor P-binding antibody consisting of a heavy chain le region
antibody sequence having a CDR1 sequence selected from the group consisting of SEQ
ID NOs: 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239,
253, and 267, a CDR2 sequence ed from the group consisting of SEQ ID NOS: 2,
16, 30, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184, 198, 212, 226, 240, 254, and
1 16
268, and/or a CDR3 sequence ed from the group ting of SEQ ID NOs: 3, 17,
31, 45, 59, 73, 87, 101, 115, 129, 143, 157, 171, 185, 199, 213, 227, 241, 255, and 269;
and a light chain variable region antibody sequence having a CDR1 sequence ed
from the group consisting of SEQ ID NOs: 4, 18, 32, 46, 60, 74, 88, 102, 116, 130, 144,
158, 172, 186, 200, 214, 228, 242, 256, and 270, a CDR2 sequence selected from the
group consisting of SEQ ID NOs: 5, 19, 33, 47, 61, 75, 89, 103, 117, 131, 145, 159, 173,
187, 201, 215, 229, 243, 257, and 271, and/or a CDR3 sequence selected from the
group consisting of SEQ ID NOs: 6, 20, 34, 48, 62, 76, 90, 104, 118, 132, 146, 160, 174,
188, 202, 216, 230, 244, 258, and 272; altering at least one amino acid residue within the
heavy chain variable region antibody sequence and/or the light chain variable region
antibody sequence to create at least one altered antibody sequence; and expressing the
altered antibody sequence as a protein.
Accordingly, in another embodiment, the invention provides a method for
preparing a Factor ing dy consisting of a heavy chain le region
antibody sequence having a CDR1 sequence selected from the group ting of SEQ
ID NOs: 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341, 347, 353, 359, 365, 371,
377, 383, 389, and 395, a CDR2 sequence selected from the group consisting of SEQ ID
NOs: 282, 288, 294, 300, 306, 312, 318, 324, 330, 336, 342, 348, 354, 360, 366, 372,
378, 384, 390, and 396, and/or a CDR3 sequence selected from the group consisting of
SEQ ID NOs: 283, 289, 295, 301, 307, 313, 319, 325, 331, 337, 343, 349, 355, 361, 367,
373, 379, 385, 391, and 397; and a light chain variable region antibody sequence having
a CDR1 sequence selected from the group consisting of SEQ ID N08: 284, 290, 296,
302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 362, 368, 374, 380, 386, 392, and
398, a CDR2 sequence selected from the group consisting of SEQ ID N05: 285, 291,
297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393,
and 399, and/or a CDR3 sequence selected from the group consisting of SEQ ID NOs:
286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382,
388, 394, and 400; altering at least one amino acid residue within the heavy chain
variable region antibody sequence and/or the light chain variable region antibody
sequence to create at least one altered antibody sequence; and expressing the d
antibody sequence as a protein.
Accordingly, in another embodiment, the invention provides a method for
preparing a Factor P—binding antibody optimized for expression in a mammalian cell
consisting of: a full length heavy chain antibody ce having a sequence selected
from the group of SEQ ID NOs: 9, 23, 37, 51, 65, 79, 93, 107, 121, 135, 149, 163, 177,
191, 205, 219, 233, 247, 261 and 275; and a full length light chain dy sequence
WO 93762
1 17
having a sequence ed from the group of SEQ lD NOs: 10, 24, 38, 52, 66, 80, 94,
108, 122, 136, 150, 164, 178, 192, 206, 220, 234, 248, 262, and 276; altering at least
one amino acid residue within the full length heavy chain antibody ce and/or the
full length light chain antibody sequence to create at least one altered antibody
sequence; and expressing the altered antibody sequence as a protein. In one
embodiment, the alteration of the heavy or light chain is in the framework region of the
heavy or light chain.
The altered antibody sequence can also be prepared by screening antibody
libraries having fixed CDR3 sequences or minimal essential binding determinants as
bed in US20050255552 and diversity on CDR1 and CDR2 sequences. The
screening can be performed according to any ing technology appropriate for
screening antibodies from antibody libraries, such as phage display technology.
Standard molecular biology techniques can be used to prepare and express the
altered antibody sequence. The antibody encoded by the altered antibody sequence(s)
is one that retains one, some or all of the onal properties of the Factor P-binding
antibodies described herein, which functional properties include, but are not limited to,
specifically binding to human and/or cynomolgus Factor P; and the antibody inhibit red
blood cell lysis in a hemolytic assay.
In certain embodiments of the methods of engineering antibodies of the invention,
mutations can be introduced randomly or ively along all or part of an Factor P—
binding antibody coding sequence and the resulting modified Factor P-binding dies
can be screened for binding activity and/or other functional ties as described
herein. Mutational methods have been described in the art. For example, PCT
Publication WO 02/092780 by Short bes methods for creating and ing
antibody mutations using saturation mutagenesis, tic ligation assembly, or a
combination thereof. Alternatively, PCT Publication WO 679 by Lazar et al.
describes methods of using computational screening methods to optimize
physiochemical properties of antibodies.
1 18
In certain embodiments of the invention antibodies have been engineered to
remove sites of deamidation. Deamidation is known to cause structural and functional
changes in a peptide or protein. Deamindation can result in decreased bioactivity, as
well as alterations in pharmacokinetics and antigenicity of the protein pharmaceutical.
(Anal Chem. 2005 Mar 1:77(5):1432-9).
The functional properties of the d antibodies can be assessed using
standard assays available in the art and/or described herein, such as those set forth in
the Examples (e.g., ELlSAs).
Prophylactic and eutic Uses
Antibodies that binds Factor P as bed herein, can be used at a
therapeutically useful concentration for the treatment of a disease or disorder associated
with increased complement activity by administering to a subject in need thereof an
effective amount of the antibodies or antigen binding fragments of the invention. In a
specific embodiment, the t invention provides a method of treating age—related
macular degeneration (AMD) by administering to a subject in need f an effective
amount of the antibodies of the invention.
The dies of the invention can be used, inter alia, to prevent progression of
dry AMD to wet AMD, to slow and/or t progression of phic y, to treat
or prevent macular edema, to reduce the frequency of Lucentis ion and to improve
vision lost due to dry and wet AMD progression. it can also be used in combination with
anti—VEGF therapies for the ent of wet AMD patients.
Treatment and/or prevention of r disease such as AMD can be determined
by an ophthalmologist or health care professional using clinically relevant measurements
of visual function and/or retinal anatomy. Treatment of AMD means any action (e.g.,
administration of an anti—Factor P antibody described herein) contemplated to improve or
preserve visual function and/or retinal anatomy. in addition, prevention as it relates to
AMD means any action (e.g., administration of an anti-Factor P antibody described
herein) that prevents or slows a ing in visual function, retinal anatomy, and/or an
AMD disease parameter, as defined herein, in a patient at risk for said worsening.
Visual function may include, for example, visual acuity, visual acuity with low
illumination, visual field, central visual field, peripheral vision, contrast sensitivity, dark
adaptation, photostress recovery, color discrimination, reading speed, dependence on
assistive devices (e.g., large typeface, magnifying devices, telescopes), facial
1 19
ition, proficiency at operating a motor vehicle, ability to perform one or more
activities of daily , and/or patient—reported satisfaction related to visual function.
THus, treatment of AMD can be said to occur where a subject has an at least 10%
decrease or lack of a 10% or more se in time to a pre-specified degree of dark
adaptation. in addition, treatment of AMD can be said to occur where a subject exhibits
at least a 10% reduction or lack of a 10% or more se in total area of central visual
scotoma expressed as a visual angle determined by a qualified health care professional
(i.e., opthalmologist).
Exemplary measures of visual function include Snellen visual acuity, ETDRS
visual acuity, low—luminance visual acuity, Amsler grid, Goldmann visual field, Humphrey
visual field, microperimetry, Pelli-Robson charts, SKILL card, lshihara color plates,
Farnsworth D15 or D100 color test, and validated tests for reading speed, facial
recognition, g simulations, and patient reported satisfaction. Thus, ent of
AMD can be said to be achieved upon a gain of or failure to lose 2 or more lines (or 10
letters) of vision on an ETDRS scale. In on, treatment of AMD can be said to occur
where a subject exhibits at least a 10% an increase or lack of 10% decrease in reading
speed (words per minute). in addition, treamtne of AMD can be said to occur where a
subject exhibits at least a 20% increase or lack of a 20% decrease in the proportion of
correctly identified plates on an lshihara test or sequenced disks ona Farnsworth test.
Undesirable aspects of retinal anatomy that may be treated or prevented include,
for example, drusen, soft drusen, hard , cuticular drusen, basal laminar drusen,
confluent drusen, large drusen (e.g., greater than 125 s in er), RPE
atrophy, eceptor atrophy, geographic atrophy, choroidal neovascularization,
inal neovascularization, retinal neovascularization, classic choroidal
neovascularization, occult choroidal neovascularization, retinal atous proliferation,
chorioretinal anastomosis, an abnormality of choroidal anatomy, subretinal hemorrhage,
intraretinal hemorrhage, vitreous hemorrhage, macular scar, subretinal fibrosis, and
retinal fibrosis. Thus, treatment of, for example, geographic atrophy can be determined
by a 20% or more reduction in lesion growth rate as compared to control or previously
documented growth rate in the same subject in the same eye.
Exemplary means of assessing retinal anatomy include funduscopy, fundus
photography, fluorescein angiography, indocyanine green angiography, ocular
coherence tomography (OCT), spectral domain ocular coherence tomography, scanning
laser lmoscopy, confocal microscopy, adaptive optics, fundus orescence,
biopsy, sy, and immunohistochemistry. Thus, AMD can be said to be treated in a
PCT/IBZOlZ/057394
’l 20
subject upon a 10% reduction in the measurement of macular thickness as determined
by OCT, and/or a reduction of hyperfluorescence as determined by cein
angiography.
Exemplary measures of retinal y include drusen area, drusen volume,
geographic atrophy lesion area, geographic atrophy growth rate, and cular
membrane area.
In some embodiments, the present invention provides methods of treating a
complement related disease or er by administering to a t in need thereof an
ive amount of the antibodies of the invention. Examples of known complement
related diseases or disorders include: neurological ers, multiple sclerosis, ,
Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, disorders of
inappropriate or undesirable ment activation, alysis complications,
hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during lL—
2 y, inflammatory disorders, inflammation of autoimmune diseases, Crohn's
disease, adult respiratory distress syndrome, thermal injury including burns or frostbite,
post-ischemic reperfusion ions, myocardial infarction, balloon angioplasty, post-
pump syndrome in cardiopulmonary bypass or renal bypass, hemodialysis, renal
ischemia, mesenteric artery reperfusion after acrotic reconstruction, infectious disease or
sepsis, immune complex disorders and autoimmune diseases, rheumatoid tis,
systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, hemolytic
anemia, and myasthenia . in addition, other known complement related disease
are lung disease and ers such as dyspnea, hemoptysis, ARDS, asthma, c
obstructive pulmonary disease (COPD), ema, pulmonary embolisms and infarcts,
pneumonia, fibrogenic dust diseases, inert dusts and minerals (e.g., silicon, coal dust,
beryllium, and asbestos), pulmonary fibrosis, organic dust diseases, chemical injury (due
to irritant gasses and chemicals, e.g., chlorine, phosgene, sulfur dioxide, hydrogen
sulfide, nitrogen dioxide, ammonia, and hydrochloric acid), smoke injury, thermal injury
(e.g., burn, freeze), asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis,
parasitic diseases, Goodpasture’s Syndrome, pulmonary vasculitis, and immune
complex-associated inflammation.
In a specific embodiment, the present invention provides methods of treating a
complement related disease or er by stering to a subject in need thereof an
effective amount of the antibodies of the invention, wherein said disease or disorder is
asthma, arthritis (e.g., toid arthritis), autoimmune heart disease, multiple
sclerosis, inflammatory bowel disease, ischemia-reperfusion injuries, Barraquer—Simons
1 21
Syndrome, hemodialysis, systemic lupus, lupus erythematosus, psoriasis, multiple
sclerosis, transplantation, diseases of the central s system such as Alzheimer's
disease and other egenerative conditions, aHUS, glomerulonephritis, bullous
pemphigoid or MPGN II.
In a specific embodiment, the present invention provides methods of treating
glomerulonephritis by stering to a subject in need thereof an effective amount of a
composition comprising an antibody of the present invention. Symptoms of
glomerulonephritis include, but not limited to, proteinuria; reduced glomerular filtration
rate (GFR); serum electrolyte changes including azotemia (uremia, excessive blood urea
en--BUN) and salt retention, leading to water retention ing in hypertension
and edema; ria and abnormal urinary sediments including red cell casts;
hypoalbuminemia; hyperlipidemia; and lipiduria. in a specific embodiment, the present
invention provides methods of treating paroxysmal nocturnal hemoglobinuria (PNH) by
administering to a t in need f an effective amount of a composition
comprising an antibody of the present invention.
In a specific embodiment, the t invention es methods of reducing the
dysfunction of the immune and hemostatic systems associated with extracorporeal
circulation by administering to a subject in need thereof an effective amount of a
composition comprising an antibody of the present invention. The dies of the
present invention can be used in any procedure which involves ating the patient’s
blood from a blood vessel of the patient, through a conduit, and back to a blood vessel of
the patient, the conduit having a luminal surface comprising a material capable of
causing at least one of complement tion, platelet activation, leukocyte activation, or
platelet-leukocyte adhesion. Such procedures e, but are not d to, all forms of
ECG, as well as procedures involving the introduction of an artificial or foreign organ,
tissue, or vessel into the blood circuit of a patient.
Subjects to be treated with therapeutic agents of the present ion can also
be administered other therapeutic agents with know methods of treating conditions
associated with macular ration, such as antibiotic treatments as described in US
Pat. No. 6,218,368. In other treatments, immunosuppressive agents such as
cyclosporine, are agents capable of suppressing immune responses. These agents
include cytotoxic drugs, corticosteriods, nonsteroidal nflammatory drugs (NSAIDs),
specific T—lymphocyte immunosuppressants, and antibodies or fragments thereof (see
Physicians' Desk Reference, 53rd edition, Medical Economics Company lnc., Montvale,
N.J. (1999). Immunosuppressive treatment is typically continued at intervals for a period
012/057394
1 22
of a week, a month, three months, six months or a year. In some patients, ent is
administered for up to the rest of a patient's life.
When the therapeutic agents of the present invention are administered together
with another agent, the two can be stered tially in either order or
simultaneously. In some aspects, an antibody of the present invention is administered to
a subject who is also receiving therapy with a second agent (e.g., verteporfin). In other
aspects, the binding molecule is administered in conjunction with surgical treatments.
Suitable agents for combination treatment with Factor P binding antibodies
include agents known in the art that are able to modulate the activities of complement
components (see, e.g., US. Pat. No. 5,808,109). Other agents have been reported to
diminish complement-mediated activity. Such agents include: amino acids (Takada, Y.
etal. logy 1978, 34, 509); phosphonate esters (Becker, L. Biochem. Biophy. Acta
1967, 147, 289); polyanionic substances (Conrow, R. B. etal. J. Med. Chem. 1980, 23,
242); sulfonyl des h, C.; Yoshimoto, M. J. Med. Chem. 1974, 17, 1160, and
references cited therein); polynucleotides rcq, P. F. eta]. Biochem. Biophys. Res.
Commun. 1975, 67, 255); pimaric acids (Glovsky, M. M. etal. J. Immunol. 1969, 102, 1);
porphines (Lapidus, M. and Tomasco, J. Immunopharmacol. 1981, 3, 137); several
antiinflammatories (Burge, J. J. etal. J. Immunol. 1978, 120, 1625); phenols (Muller—
Eberhard, H. J. 1978, in lar Basis of Biological Degradative Processes, Berlin, R.
D. el‘ al., eds. ic Press, New York, p. 65); and idines (Vogt, W. eta/
Immunology 1979, 36, 138). Some of these agents function by general inhibition of
proteases and esterases. Others are not specific to any particular intermediate step in
the complement pathway, but, rather, inhibit more than one step of complement
activation. Examples of the latter compounds include the benzamidines, which block C1,
C4 and 03b utilization (see, e.g., Vogt et al. Immunol. 1979, 36, 138).
Additional agents known in the art that can t activity of complement
components include K-76, a fungal metabolite from Stachybotrys (Corey et al., J. Amer.
Chem. Soc. 104: 5551, 1982). Both K-76 and K~76 COOH have been shown to inhibit
complement mainly at the C3b step (Hong et al., J. Immunol. 122: 2418, 1979; Miyazaki
et al., iol. l. 24: 1091, 1980), and to prevent the generation ofa
chemotactic factor from normal human complement (Bumpers et al., Lab. Clinc. Med.
102: 421, 1983). At high concentrations of K-76 or K—76 COOH, some inhibition of the
reactions of 02, C3, C6, CT, and C9 with their respective preceding intermediaries is
exhibited. K—76 or K—76 COOH has also been reported to inhibit the 03b inactivator
system of complement (Hong et al., J. Immunol. 127: 104—108, 1981). Other suitable
1 23
agents for practicing methods of the present invention include griseofulvin (Weinberg, in
Principles of Medicinal Chemistry, 2d Ed., Foye, W. 0., ed., Lea & r, Philadelphia,
Pa., p. 813, 1981), isopannarin (Djura etal., Aust. J. Chem.36: 1057, 1983), and
metabolites of Siphonodictyon coralli-phagum (Sullivan et al., Tetrahedron 37: 979,
1981)
A combination therapy regimen may be additive, or it may produce synergistic
results (e.g., reductions in complement pathway activity more than ed for the
combined use of the two agents). in some embodiments, the present ion provide a
combination therapy for ting and/or treating AMD or another complement related
disease as described above with a Factor P binding antibody of the ion and an
anti-angiogenic, such as anti-VEGF agent, or r anti-complement antibody such as
an antibody or antigen binding fragment thereof that binds to complement factor 5 (C5).
ation of anti-complement antibodies
in one aspect, the invention provides combinations of any one or more of the anti-
Factor P with an additional antibody that binds to and ts the activity of a different
ent of the complement pathway. In particular, the invention includes any one or
more of the anti-Factor P antibodies or antigen binding fragments described herein in
combination with an antibody or antigen binding fragment that binds complement
component 5 (CS). Examples of antibodies or antigen binding fragments thereof that
bind to 05 and inhibit complement activation can be found, for example in US. Patent
8,241,628 (incorporated herein by reference). More specifically, antibodies or antigen
binding fragments thereof that bind to C5 and inhibit the complement pathway are shown
and described in Table 2. in one aspect the invention includes a combination of an anti-
Factor P antibody or antigen binding fragment thereof as shown and described in Table 1
with the anti-C5 antibody 8109 from Table 2. More specifically, one aspect of the
invention relates to a ation of antibody NV8962 from Table 1 (or an antigen
binding fragment thereof) with antibody 8109 from Table 2 (or an antigen binding
fragment thereof).
In one aspect the ations of anti-Factor P and anti-C5 antibodies described
herein demonstrate a syntergistic inhibition of the complement pathway, particularly the
alternative complement y. Such inhibition can be demonstrated, for example,
using the tic or poly-IC assays described in the Examples below. Synergy in the
inhibition of the alternative complement pathway, achieved using a combination of the
actor—P and anti—C5 antibodies described herein can be ined using methods
1 24
that are well known in the art. For example, a synergistic effect of the combination of
anti-Factor P antibody and anti-05 antibody can be determine relative to a merely
additive effect using specific software, such as a Chalice Analyzer.
Briefly, Chalice Analyzer (Lehar et al, Nature Biotechnology 2009, 7:659) software
can be used to determine whether the combination of complement inhibiting antibodies
(e.g., anti-Factor P and anti—C5) acted synergistically to block complement activation.
Combination effects can be characterized by comparing each data point’s inhibition to
that of a combination reference model that was derived from the single agent
curves , Bravo, Parsons . The search for synergy: a al review from a
response surface perspective. Pharmacol Rev 47(2): 331—85). in the Loewe
additivity model (Loewe . Die tativen Prob/eme der Pharmako/ogie. Ergebn.
Physiol. 27: 47-187), [Loewe(Cx,C\/) is the inhibition that satisfies (CXIICX) + (Cy/Icy) = 1,
and ICXIY are the effective concentrations at ILoewe for the fitted single agent
curves. Loewe vity is the generally ed reference for synergy (Greco et al.),
as it represents the combination response generated if X and Y are the same
compound.
Potency shifting is usually shown using an isobologram (Greco et al.) which shows
how much less drug is ed in combination to achieve a desired effect level, when
compared to the single agent doses needed to reach that effect. The choice of effect
level for the isobologram display and combination index calculations can either be
ly or tically selected in the Chalice Analyzer. The automatic iso—level
ion algorithm finds the observed [data with the the largest lam—(Loewe, excluding those
points with Idata exceeding the lesser single agent’s Imax. This exclusion is applied to
ensure that the isobologram reflects the best synergy at levels covered by both single
agents. Having selected an isobologram level ’cut, the isobologram is drawn by
identifying the locus of trations that correspond to crossing the chosen iso~
level. The isobologram shows the rd isobolographic analysis of synergy
compared to the Loewe dose-additive “drug-with—itself’ standard. For a specified
isobologram level, the ed iso-effect contour (e.g., curved line in Figure 3) is
displayed with the tical dose-additive contour (e.g., straight line in Figure 3), on an
lCeffect-normalized linear concentration scale for both substances in the combination. The
Dose-additive reference is always a line connecting the two lCefiect concentrations. The
lCefiect crossing points are found by interpolating the fitted sigmoidal dose response
curves.
Potency shifting is scored as the combination index (Chou, Talalay (1984).
Quantitative analysis of dose-effect onships: the combined effects of multiple drugs
or enzyme inhibitors. Adv Enzyme Regul 22: 27-55) Cl. For a chosen iso—effect level Icut,
Cl. = (Ox/ECX). + (CY/ECY)1, where (OX/ECX). for a particular data point is the ratio of the X
compound’s measured concentration to its effective concentration at the chosen
tion level. The Cl can be thought of as a rough estimate of how much drug was
needed in combination relative to the single agent doses ed to achieve the chosen
effect level, and a value of 0.1 means that only a tenth of equivalent amounts of the
single agents were needed for the combination to reach the same effect level. Cl values
in the range of 0.5-0.7 are typical for in vitro measurements of current clinical
combinations (Greco et al.). A CI value of 1.0 is indicative of an additive effect of a
combination of antibodies, while a Cl value of less than 0.5 is indiciative of a strong
synergistic effect ing from the antibody combination. in the Chalice Analyzer, the
best Cl is reported from the many combination index values calculated for each [cut
crossing concentration. Among all the measured CI values, the one with the t
signal-to-noise level is reported as the best combination index.
Combinations of anti-Factor P and anti-C5 antibodies as described herein can be
administered singly or as a single composition. In addition, the relative dose of an anti-
Factor P and anti-CS dy can be in a ratio of 1:1, or may be in a different ratio. The
specific dose of an anti-Factor P antibody relative to an 5 antibody may ultimately
be determined by a treating physician or health care professional to achieve
improvement in the pathological ion being treated. For example, when a
combination as described herein is used to treat AMD, a physician or health care
professional may taylor the relative doses of the actor P and 5 antibodies so
as to achive optimal therapeutic benefit as determined using the measurements and
criteria described herein.
Pharmaceutical Compositions
The invention provides pharmaceutical compositions comprising the Factor P—
binding antibodies (intact or binding fragments) formulated together with a
pharmaceutically acceptable carrier. The compositions can additionally n one or
more other therapeutic agents that are suitable for treating or preventing, for e,
pathological angiogeneis or tumor growth. Pharmaceutically acceptable carriers
e or stabilize the composition, or can be used to facilitate ation of the
composition. Pharmaceutically acceptable carriers e solvents, dispersion media,
1 26
coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents,
and the like that are physiologically compatible.
A ceutical composition of the present ion can be administered by a
variety of methods known in the art. The route and/or mode of administration vary
depending upon the desired results. it is preferred that administration be intravitreal,
intravenous, intramuscular, intraperitoneal, or subcutaneous, or administered proximal to
the site of the . The pharmaceutically acceptable carrier should be suitable for
intravitreal, intravenous, intramuscular, subcutaneous, eral, spinal or epidermal
administration (e.g., by injection or infusion). Depending on the route of administration,
the active compound, i.e., antibody, bispecific and multispecific molecule, may be coated
in a material to protect the compound from the action of acids and other natural
conditions that may inactivate the compound.
The ition should be e and fluid. Proper fluidity can be maintained, for
e, by use of coating such as lecithin, by maintenance of required particle size in
the case of dispersion and by use of surfactants. in many cases, it is preferable to
include isotonic agents, for e, sugars, polyalcohols such as mannitol or sorbitol,
and sodium chloride in the composition. Long—term absorption of the injectable
compositions can be brought about by including in the composition an agent which
delays tion, for example, aluminum monostearate or gelatin.
Pharmaceutical compositions of the invention can be prepared in accordance
with methods well known and routinely practiced in the art. See, e.g., Remington: The
Science and Practice of Pharmacy, Mack hing Co., 20th ed., 2000; and Sustained
and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc,
New York, 1978. ceutical compositions are preferably manufactured under GMP
ions. Typically, a therapeutically effective dose or efficacious dose of the Factor P-
binding antibody is employed in the pharmaceutical compositions of the invention. The
Factor P—binding antibodies are formulated into pharmaceutically acceptable dosage
forms by tional methods known to those of skill in the art. Dosage regimens are
adjusted to provide the optimum desired response (e.g., a therapeutic response). For
example, a single bolus may be administered, l divided doses may be
administered over time or the dose may be proportionally reduced or sed as
indicated by the exigencies of the therapeutic situation. It is especially advantageous to
formulate parenteral compositions in dosage unit form for ease of administration and
mity of dosage. Dosage unit form as used herein refers to physically discrete units
suited as unitary dosages for the ts to be treated; each unit contains a
1 27
predetermined quantity of active compound calculated to produce the desired therapeutic
effect in association with the required ceutical carrier.
Actual dosage levels of the active ingredients in the pharmaceutical compositions
of the present invention can be varied so as to obtain an amount of the active ient
which is effective to achieve the desired therapeutic response for a particular patient,
composition, and mode of administration, t being toxic to the patient. The selected
dosage level depends upon a variety of pharmacokinetic factors including the activity of
the particular compositions of the present invention ed, or the ester, salt or amide
thereof, the route of administration, the time of administration, the rate of excretion of the
particular compound being employed, the duration of the treatment, other drugs,
compounds and/or materials used in combination with the particular compositions
employed, the age, sex, weight, ion, general health and prior medical history of the
patient being treated, and like factors.
A physician or veterinarian can start doses of the antibodies of the ion
employed in the ceutical composition at levels lower than that required to achieve
the desired therapeutic effect and gradually increase the dosage until the desired effect
is achieved. In general, ive doses of the compositions of the present invention, for
the treatment of an allergic inflammatory disorder described herein vary depending upon
many ent factors, including means of administration, target site, physiological state
of the patient, r the patient is human or an , other medications
administered, and whether treatment is prophylactic or therapeutic. Treatment dosages
need to be titrated to optimize safety and efficacy. For systemic administration with an
antibody, the dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to
mg/kg, of the host body . For intravitreal administration with an antibody, the
dosage may range from 0.1 mg/eye to 5mg/eye. For example, 0.1 mg/ml, 0.2 mg/ml, 0.3
mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.6 mg/ml, 0.7 mg/ml, 0.8 mg/ml, 0.9 mg/ml, 1.0 mg/ml, 1.1
mg/ml, 1.2 mg/ml, 1.3 mg/ml, 1.4 mg/ml, 1.5 mg/ml, 1.6 mg/ml, 1.7 mg/ml, 1.8 mg/ml, 1.9
mg/ml, 2.0 mg/ml, 2.1 mg/ml, 2.2 mg/ml, 2.3 mg/ml, 2.4 mg/ml, 2.5 mg/ml, 2.6 mg/ml, 2.7
mg/ml, 2.8 mg/ml, 2.9 mg/ml, 3.0 mg/ml, 3.1 mg/ml, 3.2 mg/ml, 3.3 mg/ml, 3.4 mg/ml, 3.5
mg/ml, 3.6 mg/ml, 3.7 mg/ml, 3.8 mg/ml, 3.9 mg/ml, 4.0 mg/ml, 4.1 mg/ml, 4.2 mg/ml, 4.3
mg/ml, 4.4 mg/ml, 4.5 mg/ml, 4.6 mg/ml, 4.7 mg/ml, 4.8 mg/ml, 4.9 mg/ml, or 5.0 mg/ml.
An exemplary treatment regime entails systemic stration once per every two
weeks or once a month or once every 3 to 6 months. An exemplary treatment regime
entails systemic administration once per every two weeks or once a month or once every
3 to 6 months
PCT/IBZOI2/057394
1 28
dy is usually administered on multiple occasions. Intervals between single
dosages can be weekly, monthly or yearly. intervals can also be irregular as indicated
by measuring blood levels of Factor P-binding antibody in the patient. in addition
alternative dosing intervals can be determined by a physician and stered monthly
or as necessary to be cious. Efficacy is based on lesion growth, rate of is
rescue, retinal thinckness as determined by Spectral Domain-optical Optical nce
Tomography (SD-OCT), and secondary visual acuity. In some methods of systemic
administration, dosage is adjusted to achieve a plasma antibody concentration of 1—1000
pg/ml and in some methods 25—500 ug/ml. Alternatively, antibody can be administered
as a sustained release formulation, in which case less frequent administration is
required. Dosage and frequency vary depending on the half—life of the antibody in the
patient. in l, humanized antibodies show longer half life than that of chimeric
antibodies and nonhuman antibodies. The dosage and frequency of administration can
vary depending on whether the treatment is lactic or therapeutic. ln prophylactic
applications, a relatively low dosage is administered at relatively infrequent intervals over
a long period of time. Some patients ue to receive treatment for the rest of their
lives. in eutic applications, a relatively high dosage at relatively short als is
sometimes ed until progression of the disease is reduced or terminated, and
preferably until the patient shows partial or complete ration of symptoms of
disease. Thereafter, the patient can be administered a prophylactic regime.
The following examples are provided to further illustrate the invention but not to
limit its scope. Other ts of the invention will be readily apparent to one of ordinary
skill in the art and are encompassed by the appended claims.
Example 1: Generation of Affiniy d Factor P Antibodies
A fully human phage display library was used to generate the Factor P binding antibodies
described herein.
Biotinylated and non—biotinylated human and cynomolgus Factor P were used in solution
and solid phase pannings. Standard panning were performed as well as RapMAT
approaches (Prassler et al., (2009) lmmunotherapy 1(4):571—583). Following affinity
maturation (Knappik et al., (2000) J.Mol.Biol., 296:57~86) a set of 10 antibodies were
subsequently chosen for conversion to a disulfide-bridged Fab format. The resulting
PCT/IBZOIZ/057394
1 29
disulfide bridged Fabs are shown in Table 1 (NV8962, NV8963, NV8964, NV8965,
NV8966, NV8967).
Example 2: Further Antibody zation
The following example describes methods that may be used to further optimize
antibodies described herein.
Removal of Deamidation Sites
Deamindation sites were identified by peptide mapping and size exclusion
chromatography (SEC), run under ng conditions. The deamidated material has
decreased potency in a MAC deposition assay and decreased affinity for human and
cyno FP as measured by Biacore and SET. The extent of ation increased over
time (3 weeks), at higher temperatures (5 days at 37C), and under ng conditions.
Deamidation can be detected using an ion—exchange coiumn resultin multiple peaks and
observation of the additional, deamidated peak. Amino acid ces that are most
prone to deamidation are: SNG, LNG, LNN, ELN (Daugherty, A. and Mrsny, R. (2010)
Current Trends in Monoclonal Antibody Development and Manufacturing. Springer.
pips-129.). Accordingly, we engaged in a series of studies to remove the deamidation
sites and test the modified antibodies for ed on.
Two Fabs, NV8962 and NV8965, were re-engineered to replace a deamindation
site on the heavy chain, specifically occuring at an asparagine at position 30. The
ing new Fabs were generated to remove the deamindation site and corresponding
amino acid replacements shown in Table 2.
Table 2: Deamidated Fabs
Deaminadated Fab N30 replaced with: Modified Fab
NV8962
1 30
An additional Fab that was generated replaced serine 31 with an e in Fab ,
generating Fab NV8962-831A. The sequences of the modified Fabs is shown in Table
Removal of Cleavage Sites
Further optimization was conducted on NV8962-S and NV8965-S to remove a cleavage
site in the heavy chain CDRS. Specifically the heavy chain was cleaved at Y102S103.
The following table describes the amino acid substitutions that were made to destroy the
cleavage site. The sequences of the modified Fabs is shown in Table 1.
Table 3: Modified Fabs
NV8965-S NV8804
NV8805
Example 3: Characterization of Optimized Antibodies
The following example describes methods that may be used to measure antibody affinity.
These and other methods of measuring binding ty are known in the art.
Affinity Determination
Antibody affinity for Factor P was measured by surface plasmon resonance
(SPR) using a Biacore T200 (Biacore) and solution equilibrium ion (SET).
Explanations of each logy and ponding mean results for Factor P binding
are described below. Modelling assumptions take into account concentrations of Factor
P in the , kinetics of Factor P biosynthesis and half-life, as well as the desired
dosing schedule, and suggest that a Fab with an affinity of greater than 500 pM for
Factor P is ient to lower levels of free Factor P.
e Determination
The kinetics of an interaction, i.e. the rates of complex formation (ka) and
dissociation (kd), can be determined from the information in a sensorgram. if binding
occurs as sample passes over a prepared sensor surface, the response in the
sensorgram increases. if equilibrium is reached a constant signal will be seen.
Replacing sample with buffer causes the bound molecules to dissociate and the
response decreases. Biacore evaluation software generates the values of ka and kd by
fitting the data to interaction models (Table 4).
Biacore kinetic experiments were done with the BlAcore T100 (GE Healthcare)
using CM5 sensor chips (GE Healthcare, BR30) at 25°C. The running buffer was
HBS—EP(+) (GE Healthcare, BR—1001—88). Briefly, the following steps were carried out to
determine binding affinity.
Prepare anti-FP lgG immobilized sensor chip: Mouse anti—FP monnoclonal
antibody (Quidel, A235) (30ug/ml in acetate pH5.0 coupling buffer (GE
Healthcare, BR51)) was d to two ent flow cells (F01 and 2) on a
CM5 chip at 10ul/min flow rate for 600 seconds by using coupling
procedure according to the supplier’s instruction (GE Healthcare, BR50).
The final immobilized level will be >7000RU.
Capture FP on second flow cell: tug/ml of FP in running buffer was injected at
1OUl/min on second flow cell (Fc2) to reach capture level ~20 RU for Fab or ~7
RU for lgG kinetics analysis.
inject anti-FP Fab or lgG at different concentration on both flow cells: Inject anti-
FP solution (0.3125nM~10nM in running buffer; at 1:2 serial dilutions) on both
flow cells (F01 and 2) at 60u|lmin for 240 seconds.
Dissociation: Inject (+) running buffer at in on both flow cells to
monitor the dissociation between FP and anti-FP Fab/lgG. iation time was
set at 2400 seconds for 5nM and 2.5M Fab/lgG concentrations and at 300
seconds for all other concentrations including another 5nM Fab/lgG
concentration.
Regeneration: Regeneration was performed at the end of each cycle on both flow
cells with 10 mM Glycine-HCl pH1.7 ded by GE Healthcare)+ 0.05% P20
surfactant (GE Healthcare, BR54) at a flow rate of in for 15 seconds
twice.
Kinetics analysis: Kinetic rate constants was obtained by applying 1:1 binding
model with BlAevaluation 1.1 software, wherein the Rmax values were fit locally.
The results of the Biacore binding kinetics determination are shown in Table 4. As
shown the antibodies described herein exhibit high affinity binding to human Factor P,
with KD values typically less than or equal to 1 nM, and in many cases less than or equal
to 200 pM. These dies also show very high ty to cyno Factor P (binding
affinity less than 500 pM).
ZOIZ/057394
1 32
SET Determination
In contrast to kinetic assays using sensor surfaces, such as SPR, SET is a
method which determines affinities in solution. it is an equilibrium measurement that
does not deliver kinetic data.
In SET, a constant amount of antibody is ted with different concentrations
of antigen until equilibrium is reached. The concentration of free antibody in the
brated solution is determined by ng the solution on an antigen coated MSDTM
plate (Meso Scale DiscoveryTM) followed by incubation with an beled secondary
antibody and measurement of signal intensity. At low antigen concentrations, a strong
signal is achieved (high concentration of free antibody which binds to the antigen on the
plate) whereas for high antigen concentration, the antibody is completely antigen-
captured, resulting in a low signal. If a sufficient number of antigen concentrations in a
matching range are available, the titration curve allows for a reasonable determination of
the affinity, using the appropriate fit model. For a complete titration, antigen
trations of at least 10-fold higher than the anticipated KD have to be applied. The
constant concentration of antibody d in the assay should be in the range of, or
below, the KD (Table 4).
For KD determination by solution equilibrium titration (SET), monomer fractions of
antibody protein were used (at least 90% monomer content, analyzed by analytical SEC;
Superdex75 (Amersham Pharmacia) for Fab, or Tosoh GBOOOSWXL (Tosoh Bioscience)
for lgG, respectively).
y determination in solution was basically performed as described in the
literature (Friguet et al. 305-19). In order to improve the sensitivity and accuracy of the
SET method, it was transferred from classical ELISA to ECL based technology (Haenel
et al., 2005).
1 mg/ml goat-anti—human (Fab)2 fragment specific antibodies (Dianova) were
labeled with MSD Sulfo-TAGTM NHS—Ester (Meso Scale Discovery, Gaithersburg, MD,
USA) according to the manufacturer's ctions.
Human Factor P (Complement Technology cat#: A139) and Cyno Factor P
purified from cyno serum (protocol adapted from Nakano, et al., (1986) J Immunol
Methods 90:77—83) were coated on rd g MSD plates Scale
Discovery, 384-well: MSD cat#: L21XA, 96—well: MSD cat#: L15XA) at 0.2—0.3ug/ml in
25u| PBS and incubated overnight at 4°C. Factor P inhibitors were diluted to a fixed
concentration (1pM or 10pM) in incubation buffer (PBS with 2% BSA (Sigma cat#:
A4503) and 1% Tween20 and 1% Triton-X (Sigma cat#: )), and added to a serial
dilution of Factor P (human or cyno) in incubation buffer. Samples were allowed to reach
equilibrium by incubation at RT overnight. Plates were washed 3x in wash buffer (PBS
1 33
with 0.05% Tween20), and blocked with 100ul incubation buffer at RT for 2hrs. Plates
were washed 3x in wash buffer. Sample containing Factor P inhibitors and Factor P
titration were added to the plate (25M), and incubated at RT for 15min. Plates were
washed 3x in wash buffer. 25u| detection antibody was added (Anti-Human (Goat) Sulfo-
TAG, 111000 in incubation buffer, MSD cat#: R32AJ-1), and ted at RT for 60min.
Plates were washed 3X in wash buffer, and 50u| of 1X MSD Read buffer T was added
(with tant, MSD cat#: R92TC—1). Plates were read on a MSD Spector lmager 6000.
Data was analyzed using GraphPad Prism software v4, with background (an average of
wells containing no Fab) subtracted from each value. X-axis values (concentration of
Factor P in solution) were transformed into . KD values (KD) were fitted from the
following model:
Fab:
Y=(Top-((Top/(2xFab))><((((1O"x)+Fab)+KD)-(((((1OAx)+Fab)+KD)><(((1OAx)+Fab)+KD)) -
((4X(10AX))XFab))"0-5))))
Top= signal at antigen concentration = O
X: concentration of Factor P in solution
Fab: tration of applied lent analyte (Fab)
Table 4: Affinity Binding of Factor P Antibodies
Factor P Factor P Biacore K; Biacore Ka Biacore Kd
Antibody Species (W) (1/Ms) (1/s)
NV8962 Human 46 83 1.52 X 10' 1.25 x10'
47 182 1.53 X 10 2.79 x 10
-CynoNV8965 Human 36 16 2.65 x 10' 4.10 X 10'
14 28 2.24 x 10' 6.22 x10‘
NV8963 Human 55 _ 1x10 1x104
PCT/IBZOlZ/057394
1 34
NV8967 —
NV8962-Q _-_-l-
——__—
WO 93762
1 35
Example 4: Factor P Antibodies Inhibit the Alternative Complement Pathway
sr’s Assay
ln hemolytic techniques, all of the complement components must be present and
functional. Therefore hemolytic techniques can screen both functional integrity and
deficiencies of the complement system (van et al., 1980;Minh et al., 1983;Tanaka et al.,
1986). To measure the functional capacity of the classical pathway, sheep red blood
cells coated with hemolysin (rabbit 196 to sheep red blood cells) or chicken red blood
cells that are sensitized with rabbit anti-chicken antibodies are used as target cells
(sensitized cells). These Ag-Ab xes te the classical pathway and result in
lysis of the target cells when the components are functional and present in adequate
concentration. To determine the functional capacity of the alternative y in human
and cynomolgus sera, rabbit red blood cells are used as the target cell (see U.S. Pat. No.
6,087,120).
The hemolytic assay is a basic functional assay that tests for complement
activation and has been used to te the ability of anti—human FP mAbs and Fab
molecules to block lysis of red blood cells (RBCs) by complement pathways. In vitro and
in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human
C5 can be ed using a haemolytic assay (Thomas et al., 1996;Rinder et al.,
1995;Rinder et al., 1995) . Blockade of 05a and C5b—9 generation inhibits leukocyte and
platelet activation during extracorporeal circulation. Briefly, for classical pathway assays,
sensitized red blood cells (e.g., chicken RBCs) are used as targets for lysis by
complement proteins present in serum. The following assay is of interest for the
characterization and screening of Factor P dies for their inhibition of the alternative
complement pathway.
This procedure was adapted from (Rinder et al., 1995;Thomas et al., 1996).
0 Rabbit red blood cells (Rb RBCs) — Lampire, Cat# 7246408
. Human serum — Novartis Blood Research Program; or Cyno serum — Alpha
Genesis
. n veronal buffer (GVB) — Boston BioProducts, Cat# lBB—300
o EGTA — Boston BioProducts, Cat# BM-151
. MgCl2
. U-bottom 96—well plate — g, Cat# 3795
o Flat-bottom 96-well plate — Corning, Cat# 3370
o NP—40 — Sigma, Cat# 74385
PCT/[B2012/057394
1 36
Protocol:
Rabbit red blood cells (RBCs) were washed and adjusted to 8.33x107 cells/ml in
GVB/EGTA/Mg++. 50u| Fab diluted in GVB was added to wells in a 96-well round
bottom plate. 50u| serum diluted in GVB with EGTA and Mg++ was then added. Control
wells were prepared in the following manner: serum wihtout Fab (negative control) and
cells plus 0.1% NP-40 (100% lysis control), and NP-40 blank wells. Serum with and
without Fab and controls were incubated at room temperature for 30 minutes. At that
point, 30u| Rb RBCs were added to sample and control wells and 30ul of buffer was
added to the blank wells. The cells were generally incubated for 30 minutes at 37°C and
the plate centrifuged at m for 5min. The supernatant was harvested and
transferred to a flat-bottom plate. The absorbance of the supernatant was read at
OD415 and OD570. Percent hemolysis was calculated using the formula below.
(ODsampZe — ODserum .blank )— (OD ‘s —- ODbufler blank )
(y Hemol 731.30 Im.3
(OD100 %Zysz's - ODNP 40 blank )— (OD ‘s — ODbufler .biank )
Table 5 exemplifies of the ability of the Factor P antibodies and antigen binding
fragments to inhibit hemolysis in 10% human or 20% cynomolgus serum. Each of the
Factor P dies described herein inhibited hemolysis with an |C50 of less than or
equal to 50 nM.
In contrast, when the assay was performed using sensitized red blood cells in
order to examine activation of the classical complement pathway, the Factor P antibodies
bed herein were found not to inhibit the classical complement pathway (data not
shown).
03b Deposition Assay
One method of measuring the tor activity against the ment C3 in the
alternative pathway is to e its breakdown product, 03b, depositing on zymosan.
This ELISA based assay was performed according to the following steps: 25ul of 1mg/ml
Zymosan A (Sigma Z4250) in carbonate buffer, pH 9.6 (Pierce Cat# 28382) was coated
on Maxisorp 384—well ELISA plate (Nunc 464718) overnight at 4°C. On the following
day, the zymosan—coated plate was aspirated and blocked with 100ul per well of ELISA
blocking , Synblock (AbD Serotec BUF034C) for 2h at room ature. in a
separate on, the inhibitors, serially diluted in gelatin veronal buffer (Boston
Bioproducts ~10mM Barbital, 145mM NaCl, 0.1% Gelatin, 0.5mM MgClz, 10mM
EGTA) were added to 10% serum supplemented with MgClz and EGTA for a final total
reaction concentration of 1mM MgClz and 10mM EGTA. The positive control contained
PCT/IBZOIZ/057394
1 37
no inhibitor and negative control had 25mM EDTA. The mixture was allowed to reach
brium by incubating at room temperature for 30min. To remove the blocking buffer,
the buffer was aspirated and the plate was washed once with TBS/0.05% Tween-20.
25ul per well of the 10% serum containing the inhibitors or controls was added to the
plate and incubated at 37°C for 30min (previously determined by ourse to be within
the linear range of C3b deposition on zymosan.) After the 30min incubation, the plate
was washed three times with TBS/0.05% Tween-20. To detect 03b deposition on
zymosan, 25ul per well of chicken anti—human CB-HRP conjugated polyclonal antibody
(Immunology Consultants Laboratory, lnc. Cat# CC3-80P-1) diluted ing to
manufacturer in PBS with 2%BSA Fraction V (Fisher Cat# lCN 80), 0.1%
Tween20 (Sigma Cat# P1379), and 0.1% TritonX-100 (Sigma Cat# P234729) was added
to the plate and incubate at room temperature for 1h. Afterward, the plate was washed
three times with TBS/0.05% Tween-20 and then add 25ul of Ultra TMB Substrate
Solution (Pierce Cat#34028.) When the solution in the well turned blue, the reaction was
stoppedwith 15u| of 2N sulfuric acid. The plate was read at 450nm using the
Spectromax with correction for the plastic plate at 570nm (OD 450-57%,“ reading.) The
percentage of 03b deposition on zymosan was calculated using the following formula:
[(013 no inhibitor - OD 25mM EDTA)‘ (OD sample - OD 25mM EDTA)]
% 03b Deposition = 100 — 100 *
(OD no inhibitor ' OD 25mM EDTA)
Each of the antibodies tested were shown to inhibit C3b deposition with an ICSO
of at least less than or equal to 10 nM (Table 5).
MAC Deposition Assay
Another assay that was used to determine the ability of the Factor P antibodies to
inhibit the alternative ment pathway was to e the ability of the antibodies
to inhibit the generation of the ne attack complex (MAC), which is ream of
the CS convertase and the activity of Factor P. Briefly, Zymosan A (Sigma ) was coated
on a plate at 1mg/ml in carbonate buffer, pH 9.5, to activate the Alternative Pathway.
Fabs were pre—incubated with serum (20% serum, 5mM MgClg, 10mM EDTA), then
added to the plate and incubated overnight at room temperature. After g the plate
three times with TBST, MAC was ed by incubation with anti—C5b—9—ALP (Diatec) for
1h, followed by three washes with TBST, and incubation with ylumbelliferyl
phosphate (Fisher) supplemented with 2mM MgClz for 30 minutes. The reaction was
stopped with 0.2M EDTA, and the plate was read at ex=355nm , em=460nm. Inhibition
‘l 38
of MAC deposition was calculated for each sample relative to baseline (EDTA treated
human serum) and positive control (human serum), and used to generate the IC50 curve
with PRISM.
Table 5 shows data demonstrating the ability of the Factor P dies to inhibit
the deposition of MAC, thus indicating that the antibodies inhibited the alternative
complement pathway. Specifically, the antibodies inhibited MAC deposition with an lCSO
of less than or equal to 25nM.
03a Deposition Assay
Another method used to assess the ability of Factor P antibodies to inhibit the
alternative complement pathway is to measure the y of antibodies to inhibit the
generation of C3a following cleavage of CS by C3 tase. The assay was carried
out on zymosan—coated Maxisorp plates coated at 10 mg/ml and 10% and 20% human
serum pre-incubated with anti-properdin Fab diluted in a 2“ series. The serum was added
to the plates for 30 s at which time the serum was collected for assessment of
C3a generation.
Maxisorp plates were coated with anti-03a des-arg neo antibody (1 ug/ml)
overnight, washed three times, and blocked with diluent for two hours at room
temperature. ing aspiration of the diluent, serum was added for one hour. Plates
were washed three times and a 100 uL/well detection antibody Mouse anti—Human C3a—
Biotin 1:1000 diluted in diluent was added. Following an additional one hour incubation,
a streptavidin-HRP secondary dy d 1:5000 in diluent was added to the wells
for one hour at room temperature. Plates were washed four times before the addition of
TMB detection substrate. The reaction was stopped using rd stop solution and
absorbance was read at 450-570 nm.
In parallel to the addition of the serum, a standard curve was produced using
purified 03a des—arg d in serum. ng at 5ug/ml, 03a des-arg was serially
diluted 1:4 to generate a 7 point curve. The standard curve wells were treated, washed,
and read as above.
2012/057394
1 39
Table 5: Functional Analysis of Factor P Antibodies
Hemolytic Inhibition
Zymosan- of C33
MAC. assay
C3b [C50
_ generation,
Factor P Antibody Factor P SpeCIes_ DeP°S‘t'°“I
(nM) zooo
% Serum ’
% human
ECSO (nM)
serum
NV8962 Human 2.63 78.42
NVS965 Human 1.54 7.527 31.33
Cyno 22.17 6.36 13.20
NV8963 Human 2.34 65.08
Cyno ND 9.75 14 53 ND
NV8966 Human ND 1.66 41.11
Cyno ND 6.62 13 00. N D
NV8964 Human ND 1.54 42.18
Cyno
NV8967 Human 2.53 43.53
C noV ND 5.92 -14.01 N D
NVS962—Q Human 0.64 N D
NV8962-S Human 1.53 ND
Cyno 15.57 1.94 12 02 ND
NV8962-T Human 1.75
C noy - -5.42 3.10 12.54 ND
NV8962-G Human 1.18 ND
NV8962-S31A Human 1.15 ND
C noy - --7.86 3.12 11.61 ND
NV8965—T
1 4O
—-5.90 ND
ND: Not Determined
e 5: Species Cross Reactivity
in order to determine whether, in addition to human and cynomolgus, the anti-
Factor P antibodies described herein would bind to Factor P from other species, MAC
deposition and hemolytic assays were carried out as described above. BlAcore is,
or hemolytic assays were carried out as described above. The serum concentrations
used for each species were as follows: 10 and 20% rabbit, 10 and 20% lgus, and
and 20% human sera. Rat Factor P binding was assessed by BlAcore. As shown in
Table 6 below, the Factor P antibodies were able to cross react with several species,
including rabbit, rat and cynomolgus.
Table 6: Species cross-reactivity
----Rabbit Cyno
PCT/IBZOlZ/057394
NV8965-S II
ND: not determined
Example 6: Epitope Mapping
Factor P is comprised of several Thrombospondin repeat domains (TSR 0-6).
The TSRO domain is also referred to as the N terminal domain. Epitope mapping of the
Factor P Fabs was performed by creating mouse and human chimeras for each TSR.
us functional assays showed that the Fabs do not bind to mouse Factor P
(hemolytic assays), although each of the chimeras was functional in Factor P-depleted
serum. Using this method it was determined that all of the Fabs bind to TSR 5 (SEQ lD
NO: 406). Figure 10 shows the dies bind region B of TSR5. The commercially-
available antibody, A233, was shown not to bind in this region. Binding can be assessed
by ELISA or Biacore using standard s. For one Ab, NVS487, the data was not
conclusive due to cross reactivity to mouse Factor P. Sequence alignment between
mouse and human Factor P TSR5 domain shows the epitope es the amino acids of
SEQ ID NO: 408.
Example 7: In vivo inhibition of the Alternative Complement y
Experiments were performed in cynomolgus money with antibodies of the invention to
ine their ability to inhibit the alternative complement pathway.
The test item, , was administered at the dose levels shown in Table 7. The route
of administration was either intravitral (NT) or intravenous (lV).
Table 7: In Vivo Study Design
Dose volume Animals/group
number description (pL/injection)
PCT/IBZOIZ/057394
1 Control 0 (vehicle) 50llVT
injection
100/IV
injection
2 Low NT 1 mgleye 50/lVT
(2 injection
mg/mon key)
3 IV 10 100/lV
mg/monkey injection
4 High IVT 5 mg/eye 50/lVT
(1 0 injection
key)
The test item and vehicle solutions (vehicle: 10 mM His/His-HCl; 10% trehalose; 0.02%
Tween 20; pH 5.5) were administered itreally and intravenously on days 1, 15, and
29 of the study as indicated in Table 7.
Assessment of toxicity was based on mortality, clinical observations, body weights,
pharmacodynamics (hemolytic analysis), ophthalmic examinations, intraocular pressure
ements, electroretinography, hematology, clinical chemistry, organ weights, and
pathology.
There were no mortalities during the study and no test item related findings were seen
after evaluation of clinical signs, body weights, ophthalmic examinations, cular
pressure measurements, oretinography, hematology, clinical chemistry, organ
weights, and pathology.
Complement mediated hemolytic activity was ed using the hemolytic assay
described above (see Example 4). Analysis of the tic assay data showed that IV
administration of NV8962 led to a complete or nearly complete but short—lived, inhibition
of tic complement activity immediately after administration. When administered by
the IVT route at a dose of 1 mg/eye, the test item had little or no effect on serum
hemolytic complement activity. At 5 mg/eye and in 10% cynomolgus serum, a complete
or nearly complete inhibition of hemolytic complement activity was observed.
WO 93762
1 43
Example 8: istic inhibition of the Alternative Complement Pathway by Antibody
ations
Hemo/ysis Assay
Hemolytic assays using the Fab ns of the anti-CS antibody 8109 from Table
2 and anti—Factor P antibody NV8962 from Table 1 were performed as described in
Example 4.
Figure 2 ifies of the ability of the Factor P antibodies and antigen binding
fragments in combinations with anti-C5 antibodies and antigen binding fragments to
inhibit hemolysis in 20% human serum. 500nM actor P and 500nM anti—CS Fabs
individually demonstrate no inhibition of sis when incubated for 60 mins. In
contrast, the combination of anti-factor P and anti-C5 antibodies at the same
concentration and at concentrations as low as 167nM demonstrate near complete
inhibition of hemolysis. In addition, the near complete inhibition of hemolysis lasts for up
to 250 minutes.
Data from the hemolytic assay was used with Chalice Analyzer software to determine
r the combination of complement inhibiting antibodies acted synergistically to
block complement activation. Combination effects can be characterized by comparing
each data point’s inhibition to that of a combination nce model that was derived
from the single agent curves (Greco, Bravo, Parsons (1995). The search for synergy: a
critical review from a response surface perspective. Pharmacol Rev 47(2): 331-85). in
the Loewe additivity model (Loewe (1928). Die quantitativen Probieme der
Pharmako/ogie. Ergebn. Physiol. 27: 47—187), lLoewe(Cx,CY) is the inhibition that satisfies
X) + (Cy/ICY) = 1, and ley are the effective concentrations at [Loewe for the fitted
single agent curves. Loewe additivity is the generally accepted reference for
y (Greco et al.), as it represents the combination response generated if X and Y
are the same compound.
Potency shifting is usually shown using an isobologram (Greco et al.) which shows
how much less drug is required in combination to achieve a desired effect level, when
compared to the single agent doses needed to reach that effect. The choice of effect
level for the isobologram y and combination index calculations can either be
ly or automatically ed in the Chalice er. The automatic iso-level
selection algorithm finds the observed Idata with the the largest [data—[Loewe, excluding those
points with [data exceeding the lesser single agent’s Imax. This exclusion is applied to
ensure that the isobologram reflects the best synergy at levels covered by both single
PCT/IBZOIZ/057394
1 44
agents. Having selected an isobologram level tout, the ogram is drawn by
identifying the locus of concentrations that pond to crossing the chosen iso-
Ievel. The isobologram shows the standard isobolographic analysis of synergy
compared to the Loewe dose-additive “drug-with-itself' standard. For a specified
isobologram level, the observed iso-effect contour (e.g., curved line in Figure 3) is
displayed with the theoretical dose-additive contour (e.g., straight line in Figure 3), on an
ICefiect-normalized linear concentration scale for both substances in the combination. The
Dose—additive reference is always a line connecting the two ICefiect concentrations. The
lCefiect crossing points are found by interpolating the fitted sigmoidal dose response
CUl’VGS.
Potency shifting is scored as the combination index (Chou, Talalay (1984).
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs
or enzyme tors. Adv Enzyme Regul 22: 27—55) CI. For a chosen iso-effect level icut,
Cl. = (Ox/ECX). + (CY/ECY)|, where (Cx/ECX). for a particular data point is the ratio of the X
compound’s measured concentration to its effective concentration at the chosen
inhibition level. The Cl can be thought of as a rough estimate of how much drug was
needed in combination relative to the single agent doses required to achieve the chosen
effect level, and a value of 0.1 means that only a tenth of equivalent s of the
single agents were needed for the combination to reach the same effect level. CI values
in the range of 0.5—0.7 are typical for in vitro measurements of current clinical
combinations (Greco et al.). A Cl value of 1.0 is indicative of an additive effect of a
combination of antibodies, while a Cl value of less than 0.5 is indiciative of a synergistic
effect resulting from the antibody combination. In the Chalice Analyzer, the best Cl is
reported from the many combination index values calculated for each [cut crossing
concentration. Among all the measured CI , the one with the largest signal-to-
noise level is reported as the best combination index.
Data from the hemolytic assay were expressed as % inhibition and loaded into an
8x8 Excel table, in which the dies concentrations were sed as uM values.
The Excel te was uploaded to the Chalice re (Lehar et al. 2009) and the
combination index was generated by ng an isobologram curve using ICZO for each
antibody (Cl = Cx/ICX + Cy/le, where le and leare, tively, the concentrations
of anti-factor P antibody and anti-C5 antibody alone that result in a 20% inhibition effect
and Cx and Cy are the concentrations of each drug in the mixture that yield 20 %
tion). The combination index at 20% inhibition is 0.36, indicating synergy between
anti-factor P antibody and 5 antibody (Figure 3).
PCT/IBZOIZ/057394
1 45
Marcophage Infiltration
The effect of anti—fP and anti—C5 Fabs individually or in combination were
assessed in vivo using the poly-IC murine model of ocular ation. Mice were
injected iv. with tic dsRNA analog, poly |:C in 0.1ml PBS systemically into
CS7BL/6 mice along with anti-fP (antibody NV8962 from Table 1) and anti—CS antibodies
(antibody 8019 from Table 2) individually or in combination. Mice were euthanized at
indicated time points. Eyes and retinas were collected and protein extracts were
prepared for cytokine and chemokine analysis using a multiplex assay (Pierce). To
determine retinal leukocyte infiltration, eyes were fixed in 4% paraformaldehyde and
stained with Alexa Fluor—488 conjugated F4/80 antibody for hages. The retinas
were flat d with the retinal vasculature orientated superiorly onto a glass slide and
coversliped with a drop of Vectashield mounting medium (Vector Laboratories Inc,
game, CA). Fluorescent images of five (500um) regions on each retina were
captured using the Axiocam MR3 camera on a Axio.lmageM1 microscope ). The
number of neutrophils and macrophages was quantified with Axiovision software
(Version 4.5 Zeiss). Using optical coherence tomography (OCT), images of retinas were
obtained and analysed from mice treated with poly l:C. These results (Figure 4)
demonstrate that at the highest concentrations tested (20ug) no greater than 45%
inhibition of macrophage inhibition was observed. in contrast, combinations of the anti-
Factor P and CS antibodies at concentrations as low as 2 ug demonstrated 79%
inhibition and increasing the concentration achieved 100% inhibition (compared to only
13% and 32% inhibition respectively for the anti—CS and anti-Factor P antibodies
dually).
Data from in vivo poly—IC model (macrophage infiltration) described in the
preceding paragraph were expressed as % inhibition and loaded into a 4x4 Excel table,
in which the antibody doses were expressed as ug values. The Excel template was
ed to the Chalice analyzer (described above) and the combination index was
generated by creating an isobologram curve using lC50 for each antibody (CI = Cx/ICX +
Cy/le, where le and leare, respectively, the concentrations of anti-factor P dy
and 5 antibody alone that result in a 50% inhibition effect and CX and Cy are the
concentrations of each drug in the mixture that yield 50 % inhibition). The combination
index at 50% tion is 0.42 (See Figure 5), indicating synergy between anti-factor P
dy and anti—C5 antibody.
Claims (18)
1. An isolated antibody, or antigen binding fragment, that binds Factor P, said antibody or antigen binding fragment comprising: a) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs: 1, 2, and 3, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs: 4, 5, and 6, respectively; b) heavy chain le region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N05: 85, 86, and 87, respectively, and light chain variable region 1O LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs: 88, 89, and 90, respectively; 0) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N05: 99, 100, and 101, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 102, 103, and 104, 15 respectively; d) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N03: 113, 114, and 115, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N08: 116, 117, and 118, respectively; 20 e) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs: 169, 170, and 171, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N05: 172, 173, and 174, respectively; f) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ 25 ID N05: 183, 184, and 185, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 186, 187, and 188, respectively; 9) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N03: 197, 198, and 199, respectively, and light chain variable region 30 LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 200, 201, and 202, respectively; h) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N05: 211, 212, and 213, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N03: 214, 215, and 216, respectively; or i) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID N08: 225, 226, and 227, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID N08: 228, 229, and 230, respectively.
The isolated antibody, or antigen g fragment, of claim 1 comprising a 1O heavy chain variable region and a light chain variable region, wherein: (a) said heavy chain variable region (1) has an amino acid sequence at least 90% identical to SEQ lD NO:175, and (2) ses an HCDR1 having the sequence of SEQ ID NO: 169; an HCDR2 having the sequence of SEQ ID NO:170; and an HCDR3 having the sequence of SEQ ID NO: 171; and 15 (b) said light chain variable region (1) has an amino acid ce at least 90% identical to SEQ lD NO:176 and (2) comprises an LCDR1 having the sequence of SEQ ID NO: 172; an LCDR2 having the sequence of SEQ ID NO:173; and an LCDR3 having the sequence of SEQ ID NO: 174.
The isolated antibody, or antigen g fragment, of claim 1 which comprises 20 a heavy chain variable region comprising SEQ ID NO: 7, 91, 105, 119, 175, 189, 203, 217, or 231 and a light chain variable region, wherein said heavy chain le region and said light chain variable region combine to form an n binding site to Factor P.
The isolated antibody, or antigen binding fragment, of claim 1 which comprises 25 a light chain variable domain comprising SEQ ID NO: 8, 92, 106, 120, 176, 190, 204, 218, or 232 and a heavy chain variable domain, wherein the light chain variable domain and the heavy chain variable domain combine to form an antigen binding site to Factor P.
The isolated antibody, or antigen binding fragment, of claim 3 wherein said light 30 chain variable domain region comprises SEQ ID NO: 8, 92, 106, 120, 176, 190, 204, 218, or 232.
The ed antibody, or antigen binding fragment, of claim 1 which comprises a heavy chain of SEQ ID NO: 9, 93, 107, 121, 177, 191, 205, 219, or 233 and a light chain, wherein the heavy chain and the light chain combine to form an antigen binding site to Factor P.
The isolated antibody, or antigen binding fragment, of claim 1 which comprises a light chain of SEQ ID NO: 10, 94, 108, 122, 178, 192, 206, 220, or 234 and a heavy chain, wherein the light chain and the heavy chain combine to form an antigen binding site to Factor P.
The isolated antibody, or antigen g fragment, of claim 6 wherein said light 1O chain comprises SEQ ID NO: 10, 94, 108, 122, 178, 192, 206, 220, or 234.
The isolated antibody, or antigen binding fragment, of claim 2 n said isolated antibody, or antigen binding fragment, comprises a heavy chain and a light chain, said heavy chain: 15 (1) comprising said heavy chain variable ; and (2) having a sequence that is at least 90% ce identity to SEQ ID NO: 177; and said light chain: (1) comprising said light chain variable region; and 20 (2) having a sequence that is at least 90% sequence identity to SEQ ID NO: 178.
10. The antibody or antigen binding fragment of claim 1, wherein said antibody or antigen binding fragment is a human dy, a chimeric antibody, a 25 monoclonal antibody, a single chain antibody, Fab, Fab’, F(ab’)2, Fv or scFv.
11. The antibody or antigen binding fragment of claim 1, wherein said dy is an IgG isotype.
12. The isolated dy, or antigen binding fragment, of claim 1 comprising a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 each 30 having the sequence set forth in SEQ ID N03: 169, 170, and 171, respectively, and a light chain variable region comprising LCDR1, LCDR2, and LCDR3 each having the sequence set forth in SEQ ID NOs: 172, 173, and 174, respectively.
13. The antibody or antigen binding fragment of claim 12, wherein said dy or antigen binding fragment is a human antibody, a chimeric antibody, a monoclonal antibody, a single chain dy, Fab, Fab’, F(ab’)2, Fv, or scFv.
14. The antibody or antigen binding fragment of claim 12, wherein said antibody is an lgG e.
15. A composition comprising the antibody or antigen binding fragment of any one of the preceding claims and a pharmaceutically acceptable diluent or carrier.
16. The antibody or antigen binding nt of claim 1, substantially as herein described with reference to any one of the Examples and/or s thereof. 1O
17. The antibody or antigen binding fragment of any one of claims 1 to 14, substantially as herein described.
18. The composition of claim 15, substantially as herein described.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ721643A NZ721817B2 (en) | 2011-12-21 | 2012-12-17 | Compositions and methods for antibodies targeting Factor P |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161578458P | 2011-12-21 | 2011-12-21 | |
US61/578,458 | 2011-12-21 | ||
PCT/IB2012/057394 WO2013093762A1 (en) | 2011-12-21 | 2012-12-17 | Compositions and methods for antibodies targeting factor p |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ626296A NZ626296A (en) | 2016-12-23 |
NZ626296B2 true NZ626296B2 (en) | 2017-03-24 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10865237B2 (en) | Nucleic acids encoding anti-Factor P antibodies | |
AU2021201487B2 (en) | Compositions and methods for antibodies targeting EPO | |
NZ626296B2 (en) | Compositions and methods for antibodies targeting factor p | |
NZ721901A (en) | Electronic cheque-based payment system | |
BR112015011363B1 (en) | ANTI-EPO ANTIBODY, AND USES THEREOF |